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Abstract
The serotonin transporter (SERT), among the transporters for dopamine (DAT)
and norepinephrine (NET) member of the SLC6 gene family, is an integrated mem-
brane protein facilitating the rapid reuptake of previously released serotonin from
the synaptic cleft and thus the main mechanism of terminating the neurochemical
signal using an electrochemical sodium gradient. Involved in various diseases of
the central nervous system, such as depression, it is with NET the main target for
antidepressant therapy and together with DAT targeted by psychostimulants.1
Up to now, no crystal structure of a human neurotransmitter:sodium symporter
(NSS) is available. High resolution crystal structures of a bacterial homologue
leucine transporter (LeuT) were resolved.2 Similar in structure and function, it
shares a sequence identity of ∼45% with the NSS in the binding site.3 The de-
tailed molecular mechanisms of binding and inhibition of the transporters is still
a matter of discussion. To get insights into the molecular mechanisms of pro-
tein ligand interactions, in-vitro and in-silico methods are combined to
answer questions about interactions of tricyclic antidepressants (TCA)
with SERT at atomic level within the framework of the research project SFB35
(Spezialforschungsbereich 35, www.sfb35.at).
Starting with homology modelling4 of the human transporters based on the
‘open-to-out’ conformation of the template LeuT, subsequent docking experiments5
with selected inhibitors have been performed. A protocol was elaborated to avoid
bias from scoring functions in an early step, that uses primarily hierarchical clus-
tering and protein–ligand–interactions combined with experimental data. The
selection of the docking solutions was ﬁnally driven by the results of the pharma-
cological assays and ended up in a newly proposed binding mode for imipramine
in SERT.6
To further assess the docking complexes in explicit water, molecular dynamics
simulations7 were performed on the ﬁnally selected docking poses. In total, ≈ 60
simulations were carried out on the Vienna Scientiﬁc Cluster (www.vsc.ac.at).
The trajectories were analysed with respect to the stability of the ligand, speciﬁc
protein-ligand distances and hydrogen bond networks.
As ﬁnal part, pharmacophore modelling8 and virtual screening was applied.
A database of 300000 purchasable drug–like compounds (www.lifechemicals.
com) was used for screening against the validated model. The ﬁnally selected
compounds have been experimentally tested at the Institute of Pharmacology,
Medical University of Vienna. The experiments revealed active compounds with
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The human brain harbours billions of neurons ﬁring and communicating contin-
uously in a huge network to provide perception of the environment, to maintain
the vegetative functions of the individual living organism and to control humoral
eﬀects. During signal processing, each of the aﬀerent neurons collect informations
of the neighbouring neurons until the threshold towards the action potential is
succeeded, which is occurring in an ‘all-or-none’ manner. The eﬀerent neuron for-
wards the signal to the next one by translating the electrical impulse into chemical
entities - the neurotransmitters.9 Rapid changes in the membrane potential and
the subsequent changes of the ion concentrations within the cell cause the exo-
cytosis of neurotransmitter from intracellular vesicles into the synaptic cleft - the
neurotransmission.10 After activating the post-synaptic receptors, the termination
of the neurochemical signalling happens by removing the neurotransmitter from
the synaptic cleft via (i) thermodynamical diﬀusion, (ii) enzymatic degradation
or (iii) secondary active transport through the cell membrane using an electro-
chemical gradient.11 The latter mechanism is facilitated by the neurotransmit-
ter transporters, integrated membrane proteins which are removing their cognate
transmitter from the synaptic cleft. After the release of the transmitter, reuptake
is the primary and fastest mechanism to terminate neuronal transmission. Intra-
cellular, the transmitters are stored again in vesicles to provide the rapid reuse
during the next incoming action potential.12
A growing group of the adult population suﬀers from mental diseases, such
as depression or burnout syndrome, which is manifesting in a disturbed trans-
mitter concentration within the synaptic cleft. In these medical conditions, the
transporters are involved. The molecular mechanisms behind are still a matter of
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debate. To invent new therapeutics for the treatment of diseases of the central
nervous system, the detailed understanding of the physiological processes is neces-
sary. Proteins as the functional entities in physiological processes are major drug
targets in pharmacotherapy. The analysis of the interactions between proteins and
drugs at molecular level is of crucial importance for elaborating new therapeutic
agents.
1.1 Aim
The present work focuses on the elucidation of the molecular interactions between
substrates and inhibitors and the neurotransmitter:sodium symporter (NSS) for
serotonin (SERT). The protein–ligand–interactions are studied with (i) compu-
tational methods and (ii) pharmacological experiments in collaboration with the
groups of Michael Freissmuth and Harald H. Sitte within the framework of the
SFB35. The SFB35 – “Transmembrane Transporters in Health and Disease” is a
research project focusing on the understanding of the structure, the function and
the regulation of transmembrane transporters. Funded by the Austrian Science
Fund for seven years, the project uses a multidisciplinary approach to study (i) the
interactions between inhibitors and monoamine transporters and the underlying
thermodynamics at molecular level, (ii) the regulation of the surface expression
at cellular level, and (iii) how the levels of transporters change dynamically in
living brain. Several laboratories use their ﬁeld of expertise to increase the knowl-
edge on the role of transmembrane transporters implicated in various diseases
(www.sfb35.at).
The aims of the research focus within the collaboration are the creation of
validated homology models of the neurotransmitter transporters, which are used
for molecular docking to get insights in the atomic interactions between the trans-
porters and the ligands. Based on this data, site directed mutagenesis was per-
formed to test the selected compounds experimentally on the wild type and the
mutants at cellular level. A further aim is to study the behaviour of the obtained
complexes over time for getting explanations for the results of the experiments,
which was achieved by molecular dynamics (MD) simulations. The third aim is
to ﬁnd new compounds acting as inhibitors at the transporters by pharmacophore
modelling and virtual screening.
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1.2 Clinical Background
Regarding the high degree of organisation of the human brain, diseases of the
central nervous system are of very complex nature. Today, several diseases are
known to be related to a disturbed homoeostasis of neurotransmitter in the brain.
Often, the aetiology is multifactorial — a combination of genetic (single nucleotide
polymorphisms),13 social (stress) or environmental (toxins) factors.
1.2.1 Depression
Genetic, endocrinological, social, dietary and environmental factors combined with
psychological factors like stress can lead to manifest depression. The ICD-10 classi-
ﬁes depression as as aﬀective disease (F32: depressive episode, F33: major depres-
sive disorder).14 The symptoms are summarized in loss of concentration, pleasure,
appetite, libido and self–worth. People suﬀering on depression are punished by low
mood and feelings such as sorrow, anxiety, testiness and aggression. Depending
on the level of severity people have to live with many restrictions in vitality and
involve their near social environment as well. In developed countries, the World
Health Organisation (WHO) estimates the rate of depression among the popula-
tion at 10% with increasing trend. In 2020 it will be the second most common
disease after cardiovascular diseases with increasing costs regarding the status of
employees illness and prescribed antidepressants. Today, 6.27% of prescribed drugs
paid by the social insurance in Austria were psychoanaleptics, which is rank 3 after
cardiovascular agents (10.3%) and ulcer therapeutics (8.1%).15
At neurophysiological level, depression is the result of the deﬁciency of the
neurotransmitter concentration serotonin and norepinephrine in the brain. A re-
duced amount of neurotransmitter in the synaptic cleft is not able to occupy the
post-synaptic receptors suﬃciently, which leads to disturbed brain function. This
is also known as the monoamine hypothesis of depression.16 The lack of neuro-
transmitter leads further to a decrease of the density of the serotonin transporter.17
Medicamentous therapeutic approaches are derived from the mode of neuronal dys-
function (i) lowering the rate of degradation of neurotransmitter by inhibiting the
mono amino oxidase (MAO), (ii) stimulating the post-synaptic receptors or (iii)
inhibiting the reuptake into the emitting neuron.11 Regarding the multifactorial
nature of the disease, it is known today, that also cytokines, the hypothalamic–
pituitary–thyroid system, the brain-derived neuropathic factor and cyclic adeno-
sine monophosphate (cAMP) response element binding protein are involved in the
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aetiology of depression.18
1.2.2 Attention Deficit Hyperactivity Disorder
Attention deﬁcit hyperactivity disorder (ADHD) occurs between the age of three
and seven. The symptoms are inattention, impulsiveness, hyperactivity and the
disability of working concentrated on one single task (see ICD-10, F90).14 It
is diagnosed in 5% of the school-aged children worldwide, but the prevalence in
Europe is signiﬁcantly lower than in the United States. Boys are more often
aﬀected by the disease than girls. 30 to 50% of the patients still have symptoms
during adulthood and are often untreated.19
Similar to depression, the aetiology is multifactorial and still a matter of re-
search. It is assumed, that genetic, environmental, social and dietary factors con-
tribute to the disease. At neurochemical level, the disease is correlated with a lack
of dopamine and norepinephrine in the synaptic cleft.20 Besides psychotherapy,
methylphenidate is prescribed for treatment. Although classiﬁed as amphetamine,
it acts as inhibitor of the dopamine transporter with high aﬃnity, and in less extend
on the norepinephrine transporter, to restore the transmitter concentration.21,22
1.2.3 Drug Abuse
The use of mind altering drugs by mankind is very old. Source for these sub-
stances were plants or fungi. Socially integrated, these drugs were used ritually
by persons which were knowing about the harms and the potency (Lophophora
williamsii, Psilocype species), were used as medicine (Cannabis preparations, Pa-
paver somniferum) or as luxury food (alcohol, tobacco, khat).
In the early 20th century, single substances became popular. Cocaine was used
in lemonade (Coca Cola), heroine was introduced as antitussive medicine or am-
phetamine as β-sympathomimetic drug. The adverse eﬀects, especially addiction,
were soon recognised which led to a restrictive use resulting in prohibition. In the
mid of the 20th century, the use of hallucinogenic drugs was very prominent. LSD,
‘magic mushrooms’ and mescaline were used by many parts of the society before
it was prohibited.
Today, many of the mind altering drugs are illegal to prevent the society from
the potential adverse eﬀects of the unsupervised usage. The legal status not always
resembles the harm potential of several (ab)used drugs23
1.2. CLINICAL BACKGROUND 5
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Nicotine Nicotiana tabaccum N-ACh receptors toxine




Diazepam synthetic GABAa benzodiazepines
Flunitrazepam synthetic GABAa benzodiazepines
Diphenhydramine synthetic H antihistaminic
∆9 THC Cannabis sativa CB cannabinoid
Psychedelic LSD semisynthetic (Clavi-
ceps purpurea)
5HT, D, α, β lysergic acid
LSA Ololiuqui or Argyreia
nervosa
5HT, D, α, β lysergic acid
Meskalin Lophophora williamsii α, β, 5HT, D phenethylamine
Psilocybin Stropharia sp., Psilo-
cype sp.
5HT indole
DMT Ayahuasca, Bufo bufo 5HT indole
∆9 THC Cannabis sp. CB cannabinoid
Ibogaine Therebinthae iboga 5HT indole
MDMA synthetic 5HT, D, α, β amphetamine
Empathogene GHB synthetic GABA neurotransmitter
MDMA synthetic 5HT, α β amphetamine
Stimulants Cocaine Erythroxylum coca SERT, DAT, NET tropane
Speed, METH synthetic 5HT, D, α, β amphetamine
Cathin Catha edulis α, β, NE, D amphetamine
Ephedrine Ephedra sinica α, β, NE, D amphetamine
Mephedron synthetic α, β, NE, D amphetamine
Caffeine coffee, green and black
tea, Mate, guaraná
adenosine xanthine
Table 1.1: Categories of mind altering drugs and the sources.
1.2.3.1 Substances
Psychotropic drugs are passing the blood brain barrier and inﬂuence brain phys-
iology and subsequently the behaviour and the psyche. These compounds are
very important in science and basic research towards the understanding of brain
functions at molecular level, but also for mental sciences, where Stanislav Grof
called LSD as “microscope in psychiatry”. Table 1.1 shows a rough categorisation
of selected drugs.
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In the central nervous system, the neurons of serotonin, dopamine and nore-
pinephrine have their origin in distinct regions in the brain stem. The projections
of the neurons reach into upper regions of the brain. Studies on knock out mice
revealed strong interconnections between the systems of serotonin, dopamine and
norepinephrine.24,25
Transmitter Origin Projection innervation
Serotonin
raphe nuclei cortex dopamine neurons in
thalamus nigrostriatal and





substantia nigra striatum glutamatergic systems














Table 1.3: Projections of the monoamine transmitter containing neurons
The concentration of the free transmitter within the brain is very low and
strictly controlled, since they act on many diﬀerent receptors. Structurally neu-
rotransmitters can be divided into (i) amino acids: glutamate, aspartate, glycine,
GABA, (ii) biogenic amines: serotonin, epinephrine, norepinephrine, dopamine
and histamine, (iii) in small neuropeptides, and (iv) acetylcholine, one of the most
important neurotransmitters in the nervous system (reviewed in reference 26). The
synthesis of the monoamine neurotransmitters occurs in the cell soma from amino
acids.25 The biogenic amines serotonin, dopamine and norepinephrine are ubiq-
uitous in the animal kingdom. They are found in various tissues and acting on a
multitude of physiological pathways, as summarised in table 1.4.1,10,20,24,25,27–38
1 taken from http://brain.exp.univie.ac.at/23_vorlesung_ss04/hauptseite.htm on 17th of December
2012
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Transmitter Physiological Roles Pathophysiology
Serotonin cognition, learning and memory depression and major depression
mood and behaviour anxiety
emotions and aggression suicide
sexual behaviour schizophrenia
appetite autism
sleep and wakefulnes Asperger’s syndrome
motor activity impulsive aggressive behaviour
temperature obsessive-compulsive disorder
pain bipolar disorder
autonomic funcion Tourette’s Syndrome
hormon secretion eating disorders
platelet aggregation substance abuse and alcoholism






mood and behaviour bipolar disorder




Norepinephrine neuronal excitability depression and major depression
learning and memory post traumatic stress syndrome
vigilance affective disorders
stress reactions drug addiction
attention, alertness and arousal orthostatic hypotension
pain neurotoxicity
reward
blood pressure and heart rate
sympathetic functions
Table 1.4: The physiological and pathophysiological roles of neurotransmitters
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1.3.2 Synaptic Neurotransmission
Figure 1.3: Graphical depiction of nerve
cells with cropped synapse2.
Neurons are highly polarised cells with
complex dendritic branches located cen-
timetres to meters away from the cell bod-
ies.29 Neurotransmission is the translation
of an electric signal into chemical entities at
the synaptic cleft between neurons. Today,
the knowledge of synaptic transmission is
very detailed. It is known, that 99% of the
synapses use chemical transmission. The
type of transmission can be divided into
fast (∼1 ms, ion channels) and slow (10
ms to seconds, G-protein coupled receptors
(GPCRs)) neurons, and excitatory (gluta-
mate, Na+: hyperpolarising) and inhibitory
(GABA, Cl–: depolarising) synapses. The
majority of the neurons are of slow nature
acting on second messenger systems. About 150 compounds could be identiﬁed,
including hormones, which are communicating within up to meters, while synaptic
communication occurs in a gap of about 10 nm, playing in concert in the nervous
system.10 Until the 1950s, only little was known about neurotransmitters and it
was not clear, if the neuronal transmission is of electrical or chemical nature. From
the early 20th century major discoveries cleared the way towards the understanding
of the neurophysiological mechanisms of brain function.
Figure 1.4: Schematic
depiction of exocytosis3.
In 1921, Otto Loewi discovered the chemical neurotrans-
mission on the frog heart, eﬀected by acetylcholine. Later,
Birkmayer and Hornykiewicz found dopamine reduced in
the brain of patients suﬀering on Morbus Parkinson. They
could improve the symptoms by applying L-DOPA which
provided a ﬁrst indication of chemical neurotransmission.
Based on this work, Arvid Carlsson was able to show, that dopamine occurs nat-
urally in the brain. The discovery of serotonin and norepinephrine allowed him to
prove the occurrence of chemical neurotransmission.9
2 taken from http://en.wikipedia.org/wiki/Neuron on 17th of December 2012
3 taken from http://de.wikipedia.org/wiki/Membrantransport on 17th of December 2012
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Figure 1.5: SNARE complex initiating ex-
ocytosis4.
The mechanisms of exocytosis are ef-
fected by speciﬁc structural proteins bound
to the vesicle as well as the plasma mem-
brane. Syntaxin 1A (Protein Data Bank
(PDB)44 IDs 1BR0, 1HVV, 1JTH) is a CNS
speciﬁc structural proteins bound to the
vesicle membrane. These proteins coordi-
nate the docking of the plasma membrane
bound v(vesicular) to the t(plasma mem-
brane) SNARE complex: vesicular bound
synaptobrevin – SNAP25 – membrane bound syntaxin, see ﬁgure 1.5. SNAREs
form an ultrastable coiled-coil complex during the membrane fusion and exocyto-
sis.
Proteins involved in the vesicle fusion are
• NSF is a homotetrameric ATPase and required for vesicle transport
• SNAPs are proteins mediating the attachment of NSF to membranes
• Synaptotagmin is a vesicle protein binding Ca2+ as homo-oligomer linking
synaptic vesicle and presynaptic plasma membrane
• Synaptobrevin (VAMP) participates in vesicle docking and fusion, which is
located on the cytoplasmic surface of the vesicle
• SNAP25 is located on the plasma membrane and participates in neurotrans-
mitter release
• Syntaxins 1A/1B interact with vesicle proteins (synaptotagmin) and Ca2+
channels, but also with neurotransmitter transporters
The coordinating proteins form the 20S complex connecting the vesicular and
plasma membrane. An incoming action potential induces changes in the intracel-
lular ion concentrations through voltage gated Ca2+ channels. Ca2+ eﬄux from
the endoplasmic reticulum forces the fusion of vesicles with the membrane by using
the energy of ATP with subsequent release of the transmitter into the synaptic
gap.45,46
The work of Axelrod and Hertting on the metabolism of norepinephrine re-
vealed COMT as degrading enzyme outside of the cell, while MAO is active in
the cytoplasm.42 Further experimental evidence indicated the reuptake of nora-
drenaline and storage in active form as the major mechanism, which was blocked





1.3.4.1 Classification of Transmembrane Transporters
First insights into the architecture of transmembrane transporters was provided
by the crystallisation of LacY58 and GlpT.59 Both proteins are members of the
major facilitator superfamily, which are transporting their substrate by using the
energy of co-transported ions.
The genome of living organisms harbours more than 400 gene families coding
for transmembrane transport proteins.52 The solute carrier (SLC) gene family en-
compasses 350 transporters, see examples in table 1.5. The homology of the gene
sequence united the Na+ dependent monoamine transporter, the neurotransmit-
ter:sodium symporter (NSS), into the SLC6 gene family. This family is absent in
yeast, fungi and plants since these organisms are using a K+ gradient instead.30
Further transporters for neurotransmitters are found in the SLC18 family (VMAT)
using the H+ gradient as secondary driving force.1
Gene Family
SLC1 Excitatory Amino Acid Transporter GltPh 60,61
SLC5 SoluteSodiumSymporter vSGLT 62
SLC6 Neurotransmitter:sodium Symporter see section 2.2.1
SLC6A1 γ-Amino Butyric Acid Transporter (GAT) 1
SLC6A2 Norepinephrine Transporter (NET)
SLC6A3 Dopamine Transporter (SERT)
SLC6A4 Serotonin Transporter (DAT)
SLC7 Amino acid Polyamine organoCation AdiC, ApcT, GadC 63–65
SLC18 VesicularMonoAmineTransporter see section 1.3.4.2
SLC22 OrganicCationTransporter see section 1.3.4.2
Table 1.5: Selected solute carrier gene families transporting small molecules. Crystal structures
published are indicated with references. These transporters elicit similar fold and energy source.
Since the early 1990s, Saier and co-workers are building up a public available
database for transmembrane transporters (www.tcdb.org, transporter classiﬁca-
tion database, TCDB), with the service of topology prediction tools and alignment
tools including key references. The transporters or permeases are classiﬁed into
9 main categories based on transporter type (uniporters, symporters, antiporters)
and energy coupling (primary active, secondary active). Further divided into recog-
nizable families, deﬁned by the phylogenetic cluster and the substrate speciﬁcity,
known transport proteins are distinctly encoded, see examples in table 1.6. A
common characteristic of these proteins is the facilitation of membrane transport
of impermeable solutes (eg. sugars and amino acids) and a similar architecture
comprising 10 to 14 transmembrane domains (TMDs), functional monomers or
oligomers and similar function and transport mechanism.66
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Index Family
2 Electrochemical Potential Driven Porters
2.A Uni-, Sym-, Antiporters
2.A.1 Major Facilitator Superfamily (MFS)
2.A.1.19 Organic Cation Transporter (OCT)
2.A.1.22 Vesicular Neurotransmitter Transporter (VMAT)
2.A.3 Amino acid Polyamine organoCation superfamily (APC)
2.A.21 Solute:Sodium Symporter (SSS)
2.A.22 Neurotransmitter:Sodium Symporter (NSS)
2.A.22.1 Monoamine Transporter (MAT)
2.A.22.1.1 human Serotonin Transporter (SERT)
2.A.22.1.2 human Norepinephrine Transporter (NET)
2.A.22.1.3 human Dopamine Transporter (DAT)
Table 1.6: Selected families of the TCDB related to NSS. A complete list can be found in ref. 66
1.3.4.2 Neurotransmitter Transporter
Neurotransmitter transporter can be divided into (i) vesicular monoamine trans-
porters (VMAT) and (ii) neurotransmitter:sodium symporter (NSS).67 Besides the
primary uptake mechanism through the NSS, a newly identiﬁed plasma-membrane
monoamine transporter (PMAT) was shown to transport serotonin. The transport
mechanism was earlier called “uptake 2”11 and was shown to be a member of organic
cation transporter (OCT) transporting with low aﬃnity but high capacity.32,68
(a) Schematic architecture of the sodium dependent NSS.
EL2 is elongated and the glycosylation sites are indicated.
(b) C and N termini of VMATs are located in the cell
plasma. IL 1 is elongated similarly but is located within
the vesicle.
Figure 1.11: 2D depiction of NSS and VMAT. (Figures from ref. 69)
VMAT270 is part of Major Facilitator Superfamily (MFS) and is localised in
the central nervous system.71 It plays an important role in the recycling of the
neurotransmitters. They are multidrug facilitators of the intracellular, vesicular
uptake of serotonin, dopamine, norepinephrine, epinephrine and histamine72 with
high aﬃnity using H+ gradient built up by V-ATPase. Structurally, NSS and MFS
have 12 TMDs with a low sequence homology. Albeit the energetic driving force,
the helix packing and the loop regions are diﬀerent, the proteins share similar
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function. Both are targeted by amphetamines and MPP+, but with a diﬀerent
pharmacological drug–interaction proﬁle.67,69,73,74
1.3.5 Neurotransmitter:Sodium Symporter
The seminal discoveries of the termination of neurotransmission,12 the uptake of
norepinephrine by rat heart,75 and the discovery of Na+ gradient76 provided indica-
tions for selective and stereo-speciﬁc transport, which is saturable and blockable.36
Since the ﬁrst neurotransmitter transporter were sequenced by cloning techniques,
the homology between the rGAT77 and hNET78 facilitated the search for cDNAs
of related proteins,69 which made available the expression and cloning of DAT79
and SERT.80 Since then, neurotransmitter transporter have been made available
for intense research by mutagenesis studies and cysteine scanning experiments.
NSS are further used as markers of their cognate neurons in visualising tech-
niques due to their presence on dendrites, perikarya, axons and nerve endings: DAT
is co-localised with markers for tyrosine hydroxylase and D2 autoreceptors and
NET is co-localised with markers for syntaxin, synaptophysin and synaptosomal-
associated protein.25 SERT is expressed in neurons on extra-synaptic axonal mem-
branes and on astrocytes and cytoplasmic in cell bodies and dendrites. DAT and
NET exclusively localised in neurons, at the perisynaptic terminal.29,33 All three
transporters are also expressed in glial cells.81
1.3.5.1 Structure
Neurotransmitter transporter are integral membrane proteins with similar struc-
ture, function and energy source. Members of this protein class consist of 500 to
700 amino acids with a high sequence identity suggesting a structural conserva-
tion. Hydropathicity analysis revealed the tertiary structure of 12 transmembrane
domains3,81 with both the N and C terminus intracellular.56 The functional en-
tities occur as homo di- or tetramers.67,82,83 A more detailed information about
the topology of the transporters and important regions are described in section
2.4. Despite belonging to diﬀerent families with diﬀerent substrate speciﬁcities
and basically no sequence identity, the internal structural repeat as found in the
bacterial leucine transporter of Aquifex aeolicus (LeuT),84 was also found in other
families, see table1.7,85




SSS vSGLT, Mhp1, BetP, CaiT
APC AdiC, ApcT
Table 1.7: Transporters of different classes with similar fold
1.3.5.2 Function
The primary function of the neurotransmitter:sodium symporters is the reuptake
of the cognate transmitter from the synaptic cleft through the membrane into the
emitting cell.
Figure 1.12: Schematic alternating ac-
cess model, taken from ref. 56
The alternating access model was ﬁrst
proposed in the 50s86 and later, it was reﬁned
and accepted as a mechanistic model.87 The
structural inverted repeat of TM 1 to 5 and TM
6 to 10 of LeuT suggests the formation of two al-
ternative pathways of solvent access.84 Crystal
structures of diﬀerent transporters showed ba-
sically three conformational states during the
transport cycle: open only to one side of the
membrane per step, see table 1.8.53
conformation transporter
inward LeuT, LacY, vSGLT
occluded LeuT, GltPh
outward LeuT, GltPh, Mhp1
Table 1.8: Conformation of the crystal structures
Electrophysiological measurements conﬁrmed the alternating access model for
NSS.81 The transport mechanism proposed for SERT occurs as a ‘4-helix rocking
bundle’ between the two states. Conﬁrmed by cysteine reactive accessibility mea-
surements on rSERT it has been shown, that the transmembrane domains 1b, 3,
6a and 10 on the extracellular face accord to TM 6b, 8, 1a and 5 on the cyto-
plasmic site.88 Intense mutagenesis and functional studies showed, that cocaine
and ibogaine block SERT in outward89 and inward90 faced conformation, respec-
tively. Analogous, an endogenous Zn2+ binding site in hDAT shows to stabilize
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the transporter in outward faced conformation.91
The Transport is eﬀected on slow synapses with GPCRs. The timescale of
transport ranges up to 100 ms and show slow transport rates from 0.5 to 10 mole-
cules per second.17,92 The kinetics of transport follow the Michaelis-Menten model
of saturable enzymatic activity.1 According to the alternating access model sub-
strate and ions are bound through the extracellular gate more easily than through
the intracellular gate, since it is the thermodynamically more stable conforma-
tion.93 Starting from the ‘open–to-out’ conformation, structural changes comprise
an ‘occluded’ and an ‘inward–open’ conformation, while the return to the open-
to-out is the time limiting step.94 Besides the secondary active transport of neuro-
transmitters, NSS might switch to ligand gated ion channel mode that contributes
to membrane excitability. It is referred as ‘leak channel mode’, where the protein is
open to both sides of the membrane that can be blocked by inhibitors.17,29,56,95,96
This mode is also thought to be able to transport water, see section 4.5.3.
Ion dependency Since acting as secondary active transporters, the driving force
and an absolute prerequisite of transport is an existing Na+ gradient.97 Removing
Na+, generally decreases transport activity.96,98,99 Also alternations in pH (low
pH inward exchanges the counter transported ion from K+ to H+ in SERT100)
and diﬀerent ion concentrations (Cl– facilitates conformational changes important
for binding of ﬂuoxetine, Na+ stimulated binding for cocaine101) inﬂuences ligand
binding and ion transport.
The electrochemical potential across the cell membrane (∆ψ inside negative)
is maintained by Na+/K+-ATPase57 (Na+: out>in and K+ out<in). Additionally,
Cl– is needed for transport (Cl–: out>in)95 but not as energy source, rather for
structural reasons.98 In contrast to DAT and NET, SERT counter-transports
one K+ ion100 and depends on the intracellular K+ concentration.95 Regarding
the stoichiometry,69 SERT transports electro-neutrally,98 while DAT96 and NET99
transport a positive net charge inwards without antiport, see ﬁgure 1.13.
1.3.5.3 Regulation
Depending on the activity of the neurons and the amount of released neurotrans-
mitter, uptake is regulated by the level and density of expressed transporter on
the cell surface. Endocytotic traﬃcking into an intracellular transporter pool pro-
vides functional transporters for rapid mobilisation during high activity. After
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The secretory vesicles dock to the membrane at specialised lipid raft zones of
the plasma membrane through non covalent linkages between v and t SNAREs.29
Syntaxin 1A interacts directly with the N terminus of SERT.103,104 Also for DAT,
NET and GAT, direct interaction of syntaxin 1A is involved in traﬃcking and
activity.30,102
Drugs inﬂuence the regulating systems of the transporters as well. The cog-
nate substrates modulate PKC activity depending on transmitter concentration,
Amphetamines, imipramine and other TCAs, paroxetine and citalopram induce
internalisation and down regulation by activating transporter phosphorylation.
Cocaine, nisoxetine and mazindole inhibit the eﬀect.18,28,29,105,106 Table 1.9 sum-

























PKC activators or maintained phosphorylation of NSS and reduce surface density by internalisation
(down regulation)
Ca2+ concentration, Ca2+/calmodulin-dependent (CaM) PKC and cAMP-dependent PKA mod-
ulate uptake
tyrosin kinases and MAP-kinase modulate transporter function
Protein Interactions
syntaxin1A, synaptophysin gouverns SERT activity and psychostimulant-mediated eﬀects
a-synuclein, PICK1, Hic5 interact with the transporters
Leucine heptad repeat motifs as protein-protein interaction site for structural proteins or olig-
ormerisation
Glycosylation of EL2 N-X-S/T motif - removal or declycosylation leads to reduced uptake due to reduced surface ex-
pression
Receptors Adenosine receptors may increase SERT activity, D2 dopamine receptor increses DAT expression
Substrates can prevent transporter internalisation or induce upregulation
Drug interactions
chronic block by TCAs leads to down regulation of SERT surface expression
dopamine and amphetamines promote internalisation of DAT
methylphenidate and cocaine increase DAT surface expression
mRNA chronic SERT-inhibitor treatment decreases the amount of SERT mRNA
Arachidonic Acids inhibits DAT and GAT
pH lowering the pH decreases the aﬃnity for Na+ and lowers transport activity
Membrane Potential hyperpolarisation: increased transport, depolarisation: decreased transport
Table 1.9: Regulating proteins of NSS
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1.4 Pharmacological Background
The highly complex functions of the human brain are still topic of intense research
in a multitude of research areas. Regarding the physiological role of neurotrans-
mitters known today, dysfunction of these systems can be targeted on multiple
spots: by agonising or antagonising the postsynaptic receptors, inhibiting the re-
uptake of the transmitter into the presynaptic neuron or inﬂuencing the anabolism
or metabolism of the transmitter. Concerning the neurotransmitter transporters,
diﬀerent compounds act in diﬀerent manners at these membrane proteins. (i)
The entire ligands serotonin, dopamine and norepinephrine are co-transported as
substrates using the sodium gradient, (ii) amphetamines are transported into the
neuron as substrate in the ﬁrst step and cause reverse transportation of the sub-
strate into the synaptic cleft in a second step and (iii) a further mode of action is
blocking the transporter as exerted by cocaine or ibogaine as inhibitors in diﬀerent
conformations.
The following example shows the eﬀect of a synergistic combination of drugs
with diﬀerent modes of action: The eﬀects of psychostimulants are the result of
increased levels and prolonged neurotransmission of the endogenous neurotrans-
mitters serotonin, dopamine and norepinephrine.107 To achieve the maximum ef-
fect of psychostimulants, amphetamine has to be applied ﬁrst, causing an increase
of synaptic neurotransmitter concentration by competing with the substrate bind-
ing site at the NSS and causing substrate release through the transporter. To
keep the synaptic neurotransmitter concentration elevated, cocaine should be ap-
plied second, to block the reuptake and further prolongation of the transmitter
signalling.25
1.4.1 Drugs acting on Neurotransmitter Transporters
The NSS are targeted by a variety of compounds, such as amphetamines, tropane
alkaloids and neurotoxins. More selective compounds are targeting at least one of
the three transporters with higher selectivity, e.g. SSRIs (selective serotonin reup-
take inhibitors), SNRIs (selective norepinephrine reuptake inhibitors), or methyl-
phenidate (DAT selective).
The transporters also exert a stereo-selectivity on several compounds. It is
known, that enantiomers have diﬀerent potencies on the transporters and should be
characterised individually with regard to synergistic (mianserine) or antagonistic
(citalopram) eﬀects or the eﬀects of chiral metabolites (amitriptyline).108 Most
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of the new reuptake inhibitors have chiral centres, e.g. ﬂuoxetine, paroxetine,
sertraline, venlafaxine, reboxetine. An impressive example of diﬀerent potencies
between the enantiomers is the potency of citalopram on SERT, where the S-form
is more active, and the potency of talopram on NET, where the R-form is more
active.109 Regarding methylphenidate, a compound with two chiral centres, where
the R,R-form is more potent.110 The aﬃnities of selected inhibitors on SERT,
DAT and NET are shown in tables 1.10 and 1.11.
Compound hSERT hDAT hNET
Amitriptyline 4.30 ± 0.12 3250 ± 20 35 ± 2
Butriptyline 1360 ± 50 3940 ± 40 5100 ± 400
Citalopram 1.16 ± 0.01 28100 ± 700 4070 ± 80
Clomipramine 0.28 ± 0.01 2190 ± 40 38 ± 1
Desipramine 17.6 ± 0.7 3190 ± 40 0.83 ± 0.05
Desmethylcitalopram 3.6 ± 0.2 18300 ± 500 1820 ± 40
Desmethylsertraline 3.0 ± 0.2 129 ± 2 390 ± 10
Dothiepin 8.6 ± 0.4 5310 ± 30 46 ± 1
Doxepin 68 ± 1 12100 ± 400 29.5 ± 0.8
Fluoxetine 0.81 ± 0.02 3600 ± 100 240 ± 10
Fluvoxamine 2.2 ± 0.2 9200 ± 200 1300 ± 30
Imipramine 1.40 ± 0.03 8500 ± 100 37 ± 2
Lofepramine 70 ± 4 18000 ± 1000 5.4 ± 0.4
Maprotiline 5800 ± 200 1000 ± 20 11.1 ± 0.3
Mianserin 4000 ± 300 9400 ± 200 71 ± 2
Mirtazapine > 100000 > 100000 4600 ± 300
(+)-Mirtazapine > 100000 > 100000 2900 ± 200
(-)-Mirtazapine > 100000 > 100000 26000 ± 3000
Norfluoxetine 1.47 ± 0.06 420 ± 20 1426 ± 9
Nortriptyline 18 ± 1 1140 ± 30 4.37 ± 0.07
Paroxetine 0.13 ± 0.01 490 ± 20 40 ± 2
Protriptyline 19.6 ± 0.5 2100 ± 60 1.41 ± 0.02
Sertraline 0.29 ± 0.01 25 ± 2 420 ± 20
Tomoxetine 8.9 ± 0.3 1080 ± 50 2.03 ± 0.06
Trazodone 160 ± 20 7400 ± 300 8500 ± 300
Trimipramine 149 ± 6 3780 ± 10 2450 ± 30
Venlafaxine 8.9 ± 0.3 9300 ± 50 1060 ± 40
Zimelidine 152 ± 6 11700 ± 400 9400 ± 100
Table 1.10: KD values of selected antidepressants towards NSS, taken from ref. 22.
1.4.1.1 Substrates
Compounds, structurally related to the endogenous substrate are transported by
the polyspeciﬁc NSS as well. Their cognate substrate is transported with rel-
atively high aﬃnity, ranging from 320 nM to 930 µM . In the frontal cortex,
NET co-transports dopamine with similar aﬃnity as DAT. Also DAT transports
norepinephrine but with lower aﬃnity than dopamine.25,81,112 Both transporters
transport amphetamines as substrates. SERT transports similar compounds to
serotonin, such as gramine, dimethyltryptamine (DMT) or MDMA.30,113
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Compound SERT DAT NET
Phentermine 13,900 ± 510 1580 ± 80 244 ± 15
(+)-Amphetamine 3830 ± 170 34 ± 6 38.9 ± 1.8
(-)-Ephedrine >50,000 4398 ± 213 225 ± 36
Fenfluramine 269 ± 7 23,700 ± 1300 1987 ± 205
(+)-Fenfluramine 150 ± 5 22,000 ± 1100 1290 ± 152
(-)-Fenfluramine 714 ± 31 >20,000 7187 ± 559
Norfenfluramine 480 ± 35 4305 ± 156 242 ± 25
(+)-Norfenfluramine 214 ± 9 2312 ± 87 205 ± 19
(-)-Norfenfluramine 1175 ± 89 19,194 ± 1048 2052 ± 297
Chlorphentermine 338 ± 6 3940 ± 110 451 ± 66
(-)-Methamphetamine 14,000 ± 644 4840 ± 178 234 ± 14
(+)-Methamphetamine 2137 ± 98 114 ± 11 48.0 ± 5.1
MDMA 238 ± 13 1572 ± 59 462 ± 18
Tyramine 1556 ± 95 106 ± 6.0 72.5 ± 5.0
Norepinephrine >50,000 357 ± 27 63.9 ± 1.6
Dopamine 6489 ± 200 38.3 ± 1.6 40.3 ± 4.4
5HT 16.7 ± 0.9 2703 ± 79 3013 ± 266
Cocaine 304 ± 10 478 ± 25 779 ± 30
GBR12935 289 ± 29 4.90 ± 0.30 277 ± 23
GBR12909 73.2 ± 1.5 4.3 ± 0.3 79.2 ± 4.9
RTI-55 1.00 ± 0.03 0.83 ± 0.09 5.89 ± 0.53
RTI-229 362 ± 13 0.35 ± 0.02 19.5 ± 0.6
Mazindol 272 ± 11 25.9 ± 0.56 2.88 ± 0.17
Desipramine 350 ± 13 5946 ± 193 8.32 ± 1.19
Fluoxetine 9.58 ± 0.88 >5000 688 ± 39
Citalopram 2.40 ± 0.09 20,485 ± 923 4332 ± 295
Table 1.11: Ki values of ligands towards NSS, taken from ref. 111.
Amphetamines
Consisting of an aromatic ring with an N-methylated amino-ethyl sidechain am-
phetamines were ﬁrst synthesised in 1887 as pure synthetic drugs which are not
found in nature.68 As psychoactive drugs, amphetamines activate the CNS, en-
hance alertness, wakefulness, energy, well-being, self conﬁdence and induce eupho-
ria, but also increase the sympathomimetic functions as heart rate and respiration
and suppress appetite.107 Therapeutically, amphetamines are used for treatment
of ADHD (by paradoxically exerting an inhibitory eﬀect), narcolepsy and obesity
in low doses or short time periods.25,112 Therapeutic oral doses are between 5 and
30 mg with an onset of 20 to 60 minutes. A worldwide increasing problem is the
illicit use of amphetamines with severe personal and social injuries, due to the
unsupervised application in high doses. In contrast to the medical use, the desired
eﬀect when used illicitly is a “rush” which occurs when applying high doses (up to
60 mg) on-setting within minutes.114 Albeit amphetamines exert a high risk to-
wards addiction and neurotoxicity, responsible use of amphetamines for cognitive
enhancement by healthy people might be beneﬁcial.115
At neurophysiological level, amphetamines are transported preferentially by
DAT over NET over SERT into the presynaptic neuron, competing with the
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information about drug-target interactions, facilitating the optimisation and dis-
covery of drugs. The emerging techniques of biotechnology in the 20th century






















Figure 1.23: Flow chart of the main steps of the present work.
The use of information technology beginning in the late 20th century within
diﬀerent areas of natural and life sciences culminated in the availability of a vast
amount of chemical, pharmacological and structural data. New ﬁelds incorpo-
rating computer technology emerged from chemistry and biology to cheminfor-
matics and bioinformatics. Strongly related to these ﬁelds, P h a r m a c o
i n f o r m a t i c s can be referred as the retrieval, storage, analysis and
processing of drug related information utilised in drug development, basic re-
search in academia and industry, insights in understanding of health and disease
states, but also in providing drug information important for the public health
(see http://en.wikipedia.org/wiki/Pharmacoinformatics). This ﬁeld oﬀers
important techniques applicable and used in every step of the drug discovery and
development process today.142,143 Figure 1.22 shows main steps of the drug dis-
covery and development process, where the techniques ligand and structure based
drug design are implemented.
The computational approaches are divided in (i) ligand based methods, where
the 2D or 3D structures or the physico-chemical descriptors of drug like molecules
are used for QSAR studies and optimisation and (ii) structure based methods,
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where the Cartesian information of drugs and the targets is used for studying
protein ligand interactions as performed in docking.143 Improvement of the per-
formance of the techniques can be obtained by combining the results of both
approaches as multiple source of information.144 The present work uses structure
based computational methods to analyse the binding mode of TCAs in the binding
site of SERT. In a consecutive protocol, protein–ligand–interactions are analysed
using homology modelling, docking and molecular dynamics simulations. Based on
the data obtained pharmacophore modelling and virtual screening is used to elu-
cidate potential new ligands on the transporter. All steps have been accompanied
by experiments witin the SFB35, see ﬁgure 1.23.
1.5.1 Homology Modelling
Beginning in the mid 1970s, when the ﬁrst crystal structure was deposited in the
protein database (PDB), the amount of available crystal structures of proteins
increased in exponential order, since the technologies in protein puriﬁcation, crys-
tallisation and structure determination evolved. It is now a publicly available
archive and resource for biological macromolecular structural data and contains
coordinates and general information about the resolved proteins or DNA/RNA
fragments. Among the more than 80 000 (by March 2012) protein structures in
the PDB (www.rcsb.org),44 only a relatively small number of membrane proteins
are resolved.
25 - 30 % of the genome is encoding for membrane proteins.51 In 2000, proteins
and enzymes were targeted by about 75 % of drugs.141 Today, membrane proteins
are targeted by 5051 to 6054 % of marketed drugs. Revealing protein ligand inter-
actions is of crucial importance to understand the molecular mechanisms of drug
action and membrane transport mechanisms,145 but also for drug development.142
Homology modelling comes into place at this point, where no crystal structure
of the target in the research focus is present. It is a standard method in structure
based drug design and can be distinguished between de novo and comparative
modelling. The ﬁrst method aims to predict the correct fold of the protein based
only on the sequence.146 The latter method, applied also in the present work
used, builds a 3D model of an unknown protein structure using a template and an
alignment by applying the general steps of147
• fold assignment and template selection
• primary sequence alignment
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an identity between 30 and 50 % and ab-initio modelling should be performed at
lower sequence identities.142
1.5.1.3 Modelling
It is known, that the 3D structure of proteins is more conserved, than the primary
sequence among protein families.149 Good models can be obtained, if the TM re-
gions have more than 30 % of sequence identity.150 Having the template and the
alignment, the homology modelling can be performed, using diﬀerent methods.
The ﬁrst modelling programs the (i) rigid-body modelling from few core and loop
regions, where small numbers of rigid bodies were superposed on the template
based on the alignment. Later, modelling was performed by (ii) segment match-
ing from core atoms and calculating the side chains, where a subset of positions
obtained from the alignment where used to ﬁnd matching sequences in structural
databases. Modelling by (iii) satisfaction of spatial restraints is used by MOD-
ELLER, one of the most commonly used modelling programs. Here, the restraints
were derived from the template and the alignment with subsequent distance and
geometry optimisation techniques to minimise the violations. Speciﬁc algorithms
are optimised for modelling loops or side-chains.146–148 Membrane bound proteins
are embedded in the lipid bilayer of ∼ 30 Å. Within the bilayer, α-helices or β-
strands are formed to satisfy the hydrogen bond (Hbond) potential of the protein
backbone and further to anchor the protein by lipid–side chain interactions. Soft-
ware and database resources for the homology modelling of membrane proteins
including TM segment prediction, comparative and ab-initio modelling tools are
reviewed in reference 151.
1.5.1.4 Assessment
A crucial step in modelling is the assessment of the obtained model. Programs and
scoring functions for checking stereo-chemical properties, local and global energies
(see eq. 1.1, where E is the energy of the structure and σ is the standard deviation






Scoring functions can be divided into (i) physics based, where interactions
are described by quantum mechanical calculations or (ii) knowledge based, where
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energy functions are derived from known proteins (distances, pairwise potentials
of mean force, statistical potentials). Single scoring functions are not suitable for
assessing the general quality of a protein model.153 But also MD simulations can
be used for checking the quality of protein structures.154 The importance of visual
inspection and comparison to mutagenesis data, see section 2.2.2, can hardly be
performed by programs.
Within this study, the following software tools were used for assessing the model
quality by using the binary ﬁle locally or the swissmodel server (www.swissmodel.
org).155 The models were initially selected based on the scoring functions included
in modeller, the DOPE156 and the PDF score, and by visual inspection of the ro-
tamer of SERT-D98. Procheck157 was used to assess the stereo-chemical quality of
the model. DFIRE158 and DFIRE2159 are all-atom statistical potential which was
used to score the non-bonded atomic interactions of the models. QMEAN153,160
is a composite scoring function with three statistical potential terms (distance
dependent, solvation and torsion angle potential), one term for the agreement of
the predicted and observed secondary structure and the solvent accessibility. It
estimates the global as well as the local quality of the model.
Analysing structure and function of receptors, transporters and channels is
usually approached by site directed mutagenesis and subsequent pharmacological
experiments.126 Besides the computational methods for validating a homology
model, experimental data should be included as well.142 Hydrophobicity plots are
only 60 to 70 % accurate. Insights into the functional topology of the proteins
is achieved by activation of inactivation of cysteine substituted residues.161 The
Substituted Cysteine Accessibility Method (SCAM)162 is a standard technique to
map transmembrane protein topology. Here, cysteines are introduced on deﬁned
spots and tested against highly reactive thiosolfonates (MTS-reagents) targeting
them. These experiments are used for analysing structure, function and dynamics
of proteins by systematically map residues on the water-accessible surface.
The SCAM is of crucial importance for experiments on membrane proteins,
since the membrane lipid composition is critical for topology and function. The
puriﬁcation and crystallisation process is still a challenging task, that in the end
might deliver distorted structures, due to crystallisation forces and the lack of
natural environment, e.g. surrounding lipids of membrane proteins.51
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1.5.2 Docking Experiments
Interactions of small molecules with proteins is a key feature in molecular com-
munication. In the 1890s, Emil Fischer proposed the ‘key–lock–principle’ for drug
protein interaction. This principle was reﬁned with the ‘induced ﬁt theory’ by
Koshland in the 1960s, where both the key and the lock are mutually adapting
during the docking process.163 In computational chemistry, the terminus docking
is used for simulating binding orientations of small molecules within the deﬁned
binding site of a protein. Invented in the 1980s, docking simulations use the two
methods of (i) posing and (ii) scoring for predicting proper binding modes. Nowa-
days, it is the most commonly used method in structure based drug design.163
Docking studies are applied for predicting the binding mode of known active lig-
ands, as aimed in this work, identifying new ligands and lead optimisation or
estimating binding aﬃnities.164,165
Docking simulations aim to ﬁnd the correct binding orientation of the ligand
within the binding site of the protein. Deﬁning a narrow binding site in the protein
increases the docking eﬃciency.163 An assessment of diﬀerent docking programs
and scoring functions on the prediction of the protein-bound ligand conformation
of selected crystal structures showed, that the programs were able to generate
crystal conformation during redocking but none of the scoring functions was able to
identify the crystal conformation as top ranked pose. Further, no docking program
used performed well across all of the selected targets.166 It exists a broad range
of prediction accuracy measured by redocking the crystal bound ligand, where a
root mean square deviation (RMSD) of < 2 Å is assumed to be acceptable.165 The






((xi − xj) + (yi − yj) + (zi − zj))2 (1.2)
where x, y and z are the coordinates of atom i and j. It is a single value in
Ångstrøm (Å, 1 Å=0.1 nm), where the distances between two atoms or molecules
within the 3D space can be estimated.
1.5.2.1 Posing
Before the docking process starts, the binding site needs to be deﬁned within each
software used. This can be done by spheres, cubes or residues. The placement
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algorithms can be distinguished by the treatment of the ligand and the protein
during the simulation process. (i) In the beginning, the translation and orienta-
tion of the ligand was considered by keeping rigid both the ligand and the protein.
Geometrical and chemical matching algorithms are applied. Ligand ﬂexibility is
obtained by conformational databases. (ii) Later algorithms treated the ligand as
ﬂexible which was shown to be the optimum between accuracy and computational
time. To cross energy barriers of the ligand conformations, the posing methods
use systematic search, stochastic or random search or simulations methods. (iii)
Systematic incremental construction divides the ligand in fragments and is built
up in the binding site. Monte Carlo stochastic conformation search of the ligand
uses an energy based selection of the conformation. (iv) Within genetic algorithms,
the degrees of freedom of the ligand are deﬁned as genes and the docking pose as
chromosome. Random mutations within the genes result in a new ligand confor-
mation which is assessed by the scoring function. (v) Simulation methods apply
molecular dynamics simulations on the ligand. This method can not cross high
energy barriers, but is eﬃcient in local optimisation.
Including protein ﬂexibility is still a signiﬁcant challenge in docking and com-
putationally costly. Several approaches are available to treat the protein ﬂexible,
such as using rotamer libraries, ensemble docking after sampling the site by molec-
ular dynamics simulations, induced ﬁt docking or by soft-docking with overlapping
Van der Waals (VdW) radii.143,163–165 With the increasing computer power, more
and more software packages include the feature of ﬂexible side chains or protein
ﬂexibility.
1.5.2.2 Scoring
Forces contributing to protein ligand binding exerts numerous forces occurring in
the condensed phases in-vivo. As a consequence calculating the binding aﬃnities
is still diﬃcult in the docking setup due to the proper parametrisation of these










∆G = ∆H − T∆S
∆H = ∆E − (∆PV )
Binding aﬃnities can be predicted well with thermodynamic integration and
free energy perturbation methods, but these are computationally demanding. MM-
PB/SA or MM-GB/SA rescoring improves the accuracy of the binding aﬃnity
prediction. The selection of the obtained docking poses is performed by estimating
free energies of binding using scoring functions.
Scoring functions can discriminate between the near-native and misdocked con-
formations but often do not rank correctly. Scoring functions can be divided into
(i) forceﬁeld based, which calculate the sum of the non-bonded interactions de-
ﬁned by the Coulomb and Van der Waals potentials, hydrogen bonds (Hbonds),
solvation and entropy contribution, (ii) empirical scoring functions decompose the
binding potentials calculate a weighted sum of the the terms deﬁning Hbonds, ionic
and hydrophobic interactions and the entropy and (iii) knowledge based scoring
functions perform a statistical analysis of the protein ligand complexes deﬁned by
contact frequencies and atomic distances deriving the statistical potential of mean
force.152,163–165
Several methods to improve the quality of the docking and scoring results
are available. Consensus scoring of the docking poses,168 target speciﬁc scoring
functions, protein ligand interaction ﬁngerprints143 or cluster analysis are able to
enrich the docking results.169
The scoring functions used during the docking experiment were ‘London dG’
and ‘Alpha HB’ within the software suite Molecular Operating Environment (MOE).5
The ﬁrst one estimates the binding aﬃnity according to equation 1.3, where c is
the gain or loss of rotational and translational entropy, Eflex is the energy due to
the loss of ligand ﬂexibility, fHB/M describe geometrical imperfections of hydrogen
bonds and metal ligations, cHB/M is the ideal energy and D is the desolvation
energy of each atom.
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The second scoring function, applied after the reﬁnement step, is a linear com-
bination of two terms, where the ﬁrst term measures the geometric ﬁt of the ligand
to the binding site and the measures hydrogen bonding eﬀects.5
1.5.3 Molecular Dynamics Simulations
MD simulations is a computational technique, that solves Newton’s equations of
motion (F = m~a), see equation 1.5, by describing the movement of all atoms (i =
1 . . . N) with their mass (mi) along the coordinates (r) over time (t). The system is
described with relatively simple empirical potential functions (V ), that are deﬁned
in the forceﬁeld. The forces (F), the negative derivatives of the potential energies,
of all atoms in the simulation box are calculated and integrated in small time steps
resulting in a trajectory of atomic coordinates as a function of time.170
Fi = −






It was developed in the late 1950s and early 1960s and used to study the be-
haviour of liquids.171,172 In the late 1970s, MD simulations were ﬁrst applied on
macromolecules.173 One of the earliest membrane protein simulations in vacuum
was presented in 1991 followed by the simulation of bacterio-rhodopsin within a
membrane bilayer in 1995. Nowadays, it is an established computational simula-
tion technique used for energy minimisation of macromolecules, studying protein
folding or analysing protein ligand interactions.170 It is also used for assessing
the quality of membrane protein crystal structures or homology models, where a
simulation time of 20 ns is suﬃcient.154
Several software packages and forceﬁelds are available currently, see table 1.12.
Within the present study, the calculations were performed with the software pack-
age GROMACS 4.5.47 using the GROMOS 53a6 forceﬁeld.174
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Software Forcefield Notes
ACEMD AMBER, CHARMM calculates on GPUs
AMBER AMBER
CHARMM CHARMM
DESMOND OPLS MD-optimised CPU
GROMACS GROMOS, AMBER, CHARMM, OPLS
GROMACS MARTINI coarse grained molecules
GROMOS GROMOS
NAMD CHARMM, OPLS
Table 1.12: MD Applications and forcefields.
1.5.3.1 The GROMOS 53a6 Forcefield
The following section is reviewed from references 174, 175 and 176. In theory,
each molecular system can be described by quantum mechanics (QM). Practically,
there is the limitation of computational power to calculate the molecular orbitals
for macromolecules. Therefore, approximations are necessary, since the exact sol-
vation of Schrödinger’s equation (equation 1.6) for systems with more than 100
atoms is still not possible in a reasonable calculation time. In contrast to QM
calculations, forceﬁelds used by MD simulations treat atoms ‘hard’ spheres with




ψ(t) = Hˆψ(t) (1.6)
Energy functions are used to calculate the movement of atoms within a deﬁned
system. The energy of such a system is deﬁned by the Hamiltonian (H), eq. 1.7. It
is described by kinetic (K) and potential (V ) energy functions in terms of classical
mechanics.
H(p, r,m, s) = K(p;m) + V (r; s) (1.7)
Independent from the coordinates, the kinetic energy part (eq. 1.8) is a function














The potential energy (eq. 1.9) is described by the interaction energy between
all atoms within the cartesian coordinates (r) and the forceﬁeld parameters (s)
as the sum of physical and special interactions. The parameter sets included in
the forceﬁeld describe the bonded and the nonbonded interactions, which were
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obtained by crystallographic data, spectroscopic experiments and quantum me-
chanical calculations.
V (r; s) = V BONDED(r; s) + V NONBONDED(r; s) (1.9)
Bonded Interactions
V BONDED = V bond + V angle + V dihedral + V improper (1.10)
bn The bond stretching potential energy is calculated as the sum over all
bonds (Nb) connecting atoms within a molecule. The energy is depending on the
ideal bond length b0 in [nm] and the force constant Kb in [106 kJ ·mol−1 · nm−4].
Θn The angle bending energy is the sum over all bond angles (NΘ), depending
on the ideal angle (Θ0) in degree [◦] and the force constant KΘ in [kJ ·mol−1].
ϕn The proper torsional dihedral angle potential is the sum of all dihedrals
Nϕ calculated from the phase shift δn (restricted to 0 or π), the multiplicity mn
and the force constant Kϕ in [kJ/mol−1].
ξn The deﬁned improper dihedral angle keeps a set of three bonds in a certain
conﬁguration. It is calculated from atomic positions and summarised over all
impropers. The parameter set deﬁnes the force constants Kξ [kJ · mol−1 · mol ·
degree−2] and the ideal angle ξ0 [◦] for in planar groups, tetrahedral centres and
the hem iron.
Non Bonded Interactions
V NONBONDED = V LennardJones + V Coulomb (1.11)
Van der Waals interactions are described using a Lennard-Jones 12/6
interaction function, including a repulsion and a dispersion term of two particles.
It is calculated as the sum over all interacting atom pairs, and are switched to
0 between rvdw-switch = 1.0 and rvdw = 1.4 nm. Equation 1.12 shows the
general deﬁnition of the Lennard-Jones potential, but for eﬃciency, it is calculated
as given in equation 1.13.
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Coulomb interactions describe the electrostatic interactions between two
charged particles as sum of all interacting pairs deﬁned as the partial charges
(q) of each atom (eq. 1.14). The type for calculating the Coulomb interac-
tions used was coulombtype = PME (ParticleMeshEwald) and switched to 0 from
rcoulomb-switch = 0.8 to rcoulomb = 1.2 nm. The dielectric constant (ǫ) was
set to epsilon_r = 1, which used with explicit water.









The Particle Mesh Ewald method was used to calculate the long range electro-
statics. The potential at each grid point is interpolated in a cubic way at a grid
with a mesh size of 0.1 nm and Fourier transformed obtaining the reciprocal energy
by a single sum. The force of each atom is given by the inverse transformation of
the potential of each grid point using an interpolation factor.
r
E
(a) The Lennard-Jones potential.
r
E
(b) The Coulomb potential.
Figure 1.25: Non bonded interactions.
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Fi of each atomi is calculated as sum the potential energy V and the restraining
forces. Using this information, the potential and kinetic energies as well as the
pressure tensor of the system is calculated for the next step. The update frequency
was set to a timestep of dt = 0.002 ps and calculated for nsteps = 5000000
steps, resulting in 10 ns of simulation.
1.5.3.3 Physical Conditions
Canonical Ensemble A canonical ensemble is the collection of systems embed-
ded into a larger system to control energy (E), temperature (T), pressure (P) or
volumes (V). The number of particles in the system (N) remains constant. The
NVT ensemble keeps the number of particles, the volume and the temperature
constant. It was used during the equilibration of the system. For the production
run, the NPT ensemble was used. To avoid unwanted eﬀects during the simulation,
such as drifting or integration errors, it is necessary to control temperature and
pressure by external ‘baths’. This is eﬀected by using thermostats and barostats.
Kinetic Energy and Temperature The temperature (T ) was initially set to
ref_t = 310◦K. During the simulation it is calculated from the kinetic energy of













During the equilibration in the NVT ensemble, the tcoupl = V-rescale algo-
rithm was used for temperature control to avoid ﬂuctuations of the kinetic energy.
It is a modiﬁed Berendsen thermostat including a stochastic term for a correct
energy distribution. To enable the canonical ensemble during the production run,
as thermostat tcoupl = Nose-Hoover was selected. This thermostat extends the
system Hamiltonian by a friction term and a thermal reservoir into the particles’
equation of motion.
Pressure and Virial The scalar pressure of the system is calculated from the
trace of the pressure tensor (P = trace(P)/3). The tensor is calculated as the
diﬀerence of the kinetic energy (Ekin) minus the virial. The virial is deﬁned as










The pressure control was necessary during the production run in the NPT
ensemble and was set to Pcoupl = Parrinello-Rahman. Similar to the Nosé-
Hoover thermostat, the equation of motion are extended by the box vectors, on
which the equation for the atoms are coupled. The Pcoupltype = Isotropic
allows the box to change the size isotropically in x and y direction, but diﬀerent
in z direction.
Constraints were used to correct bond lengths and angles between heavy atoms
and hydrogens. After an unconstrained update, the bond lengths and angles are
adapted to the deﬁned, correct parameters. This is necessary due to the frequency
of bond and angle movement between heavy atoms and hydrogens. The algo-
rithm used was the default LINCS (LINear Constraint Solver), since it is more
stable and faster than the traditional SHAKE algorithm. During the equilibra-
tion, constraints = all-bonds were constrained, during the production run the
constraint was applied on Hbonds.
Restraints Position restraints were used to keep atoms in place during equili-
bration. This is used to minimize or to equilibrate only parts of the system to
adapt properly to each other. The restraints were applied on the whole system
except water in a ﬁrst step and were lowered to 0 in four steps.
1.5.3.4 Charge Groups
Neighbouring atoms in consecutive order within a moiety are combined into a
charge group. This is important, if a plain cutoﬀ in the Coulomb potential is
used. Artefacts might occur, when charged atoms move in and out of the cutoﬀ
distance, leading to jumps in the potential and forces. By setting the total charge
of the moieties to zero, these artefacts are reduced from the charge-charge to
the dipole-dipole level with a faster decay. The partial charges of ionized atoms
is distributed within the charge group. Although not necessary, when PME or
switching functions are used, they were deﬁned for the ligands as given under
section 4.1.1 and 4.4.
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1.5.3.5 United Atoms
Solving Newton’s equations of motion for a system of tens of thousand atoms needs
strong computational power. There are forceﬁelds, that simulate the systems with
explicit atoms, such as AMBER or Charmm. To increase the calculation speed,
carbon atoms with bound hydrogens in aliphatic chains (CHn) are treated as one
single atom, with an increased mass by 1 for each hydrogen atom. This concept is
extended by coarse grained MD simulations, where groups of atoms are combined
to one single sphere. The MARTINI forceﬁeld uses this method for functional
studies to calculate molecular systems for large time scales (µ seconds).
1.5.3.6 The Trajectory
Successfully performed MD simulations deliver several output ﬁles. As the veloci-
ties and the forces, the trajectory was stored every in an uncompressed ﬁle every
5000th step (≡ 10 ps). The ﬁles for logging, energy and the compressed trajectory,
which were used for analysis, were stored every ps. This resulted in ≈ 5 gigabyte
(GB) of data per run.
1.5.4 Structure Based Pharmacophore Modelling
The continuously increasing number of protein crystals revealed structural details
of protein ligand interactions,163 which are used for screening methods. Pharma-
cophore modelling evolved to an important and successful method in high through-
put virtual screening.8
1.5.4.1 Pharmacophore Modelling
The concept of pharmacophore was introduced by Paul Ehrlich in the beginning of
the 20th century. In the ﬁeld of pharmacoinformatics, it became one of the major
tools in drug discovery during the past decade. Pharmacophores are the abstract
description of molecular properties in a deﬁned spatial arrangement, considering
only spheres of molecular features. It can divided into ligand and structure based
pharmacophore modelling. The ﬁrst method superposes active molecules based on
important functional groups.177 The latter one, the 3D pharmacophore concept is
based on interaction types between protein and ligands. Hydrogen bonding, charge
transfer, electrostatic and hydrophobic features obtained from crystal- or NMR
structures or from docking experiments are aligned in the 3D space. Structurally
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diﬀerent compounds may carry a similar pharmacophore pattern, determining the
activity of the drug.8
1.5.4.2 Virtual Screening
The term ‘virtual screening’ was ﬁrst reported in 1997 and is the usage of a set
of ligand and structure based computer methods that analyses large databases
or compound selections to identify hit candidates. These methods are based on
the assumption, that similar structures have a greater–than–random chance for
similar activities.143 Initially ligand based methods were based on 2D descriptors,
which were compared by using similarity metrices, such as the Tanimoto coef-
ﬁcient. Later, 3D descriptors, the pharmacophore concept and shape similarity
methods were developed. Herein, a protein–ligand–complex available from dock-
ing is used for structure based pharmacophore modelling and calculating shape
similarity based on the bound ligand.178 Virtual screening is usually performed to
complement or to reduce the number of compounds for high throughput screening
in drug development,143,178 since it is more eﬃcient in costs and eﬀectivity.163 In
pharmaceutical industry, millions of compounds and more database are available
for the improvement of drugs.141 The evaluation of 3D virtual screening methods
can be performed by various methods, such as calculating enrichment factors or
using the Receiver Operating Characteristic (ROC curve), as descriptor of selec-
tivity and speciﬁcity.178 It is important to compare several factors to calculate the
enrichment, since even structure unaware descriptors combined with distance can
lead to good enrichment factors.179
1.5.5 Technical background
The basis of the work in-silico are computers — the faster, the better. To introduce
shortly the hardware and software used, few words will be placed.
The homology modeling with MODELLER and docking calculations within
MOE were performed on workstations with Intel processors (i7 QuadCore at 3.07
GHz, Xeon 5650 Dual HexaCore at 2.66 GHz) running a RedHat based Fedora
Linux operating system, kernel 2.6.34.9. Creating 250 homology models on a
single CPU using an Intel i7 at 3.07 GHz took up to 24 hrs. The docking of a
conformational database of 100 entries into one homology model within MOE took
up to 12 hrs using up to 4 CPUs, if the reﬁnement was performed instantly.
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To minimise the personal interventions on various steps within the calcula-
tions, the use of scripts was necessary. MOE provides an internal programming
and scripting language, called Scientiﬁc Vector Language (SVL), which allows to
extend the program by simple scripts or completely new functions, but also the
modiﬁcation of existing ones to optimise individual workﬂows. It was used for
the preparation and the evaluation of the docking experiments. The resulting ﬁg-
ures of the homology model and the dockin study were created with the rendering
engine implemented in MOE.
The molecular dynamics calculations were prepared locally and later performed
on the Vienna Scientiﬁc Cluster (VSC) 1 using up to 96 cores (12 nodes with Intel
Xeon Dual QuadCore 5550 at 2,66 GHz) running a RedHat based CentOS Linux
operating system. To calculate 10 ns of the membrane embedded system took up
to 7 hrs.
Each simulation of the protein ligand complex resulted in more than 5GB of
data. To access the data, scripts were written within the Bash, the default shell
on Linux based systems. The scripts made use of the programs within the GRO-
MACS suite and performed text ﬁle processing. To visualise the numerical data,
the output of the programs was prepared for the open source plotting program
XMGRACE. The representations of the systems was done with VMD using the
raytracing interpreters POVRAY and TACHYON. Within VMD, scripting lan-
guage Tcl was used.
2Homology Modelling
The ﬁrst step towards analysing protein–ligand–interactions of selected antidepres-
sants with the SERT was the creation of a homology model. The ingredients of a
good model is a valid homologous template with a high sequence identity and a
proper alignment. During each modelling run, the protocol as depicted in 2.1 was
applied on all of the monomeric transporters. An extended validation by compar-
ing with mutagenesis data published was performed only on the homology model
of SERT in ‘open–to–out’ conformation.6
2.1 Modelling Protocol
The homology modelling was performed in a stepwise workﬂow, starting from the
crystal structures PDB ID 3F3A2 and 2A6584 and the alignment from reference 3.
The following steps were executed consecutively:
1. Modiﬁcation of the alignment as published in reference 180 in EL4.
2. Deﬁning the the disulphide bond in EL2 between C200 and C209.
3. Running modelling using Modeller 9.4 (within Accelrys Discovery Studio181)
and 9.8 (standalone). During modelling, (i) leucine was kept in the pocket
with the COO– moiety removed and (ii) without leucine as spacer within the
S1 site
4. Selection based on the consensus scores of DOPE and PDF
5. Visual inspection regarding the rotamer of D98, separating the Na1 from the
S1 site.
6. Manual placement of Cl–, based on the references182–184
7. Addition of hydrogens within MOE using Protonate 3D.
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8. Stepwise minimisation, from ref. 185, which was only applied, if the binding




































Figure 2.1: Modelling protocol
2.2 The Template
In the ﬁrst step, the following crystal structures have been inspected visually:
PDB IDs 2A65,84 2Q72188 and 3F3A,2 where the latter one was assessed. Besides
the coordinates of the protein, the two sodium ions and the ligands, several water
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molecules and detergent molecules are present in the .pdb ﬁle, see table 2.2. 2A65
shows a Cl– atom on the extracellular site of the transporter. The protein is
resolved from residue 5 to 131/132 in EL 2 and from residue 134 to 511 in a
resolution of 1.65 (2A65) to 2.00 Å(3F3A).
2.2.1 The Leucine Transporter of Aquifex aeolicus
Figure 2.2: The crystal structure of LeuTAa as published in ‘open–to–out’ conformation, PDB
ID 3F3A
Up to now, no crystal structure of a human NSS was resolved due to insuﬃcient
pure stable protein.1 A breakthrough in the elucidation of structural properties
of NSS was achieved by resolving the ﬁrst high resolution crystal structure of a
member of the neurotransmitter:sodium symporters owing a new and unique fold
of the 12 TMDs: the Leucine Transporter of Aquifex aeolicus.84 Aquifex aeolicus
is a thermophilic bacterium living in hot springs up to a temperature of 95 ◦C, ﬁrst
sequenced in 1998.190 Since the ﬁrst publication of LeuT in 2005, it was proved to
be a valid template for homology modelling technique,191,192 despite the diﬀerences
in structure, as there are larger C and N termini, larger loop regions in eukaryotic


















PDB code Resolution[Å] Conformation Ligands Reference Notes
2A65 1.65 occluded leucine 84
2Q6H 1.85 occluded leucine, clomipramine 188
2Q72 1.70 occluded leucine, imipramine 188
2QB4 1.90 occluded leucine, desipramine 188
2QEI 1.85 occluded alanine, clomipramine 188
2QJU 2.90 occluded leucine, desipramine 123
3F3A 2.00 outward tryptophane 2
3F3C 2.10 occluded 4-fluoro-L-phenylalanine 2
3F3D 2.30 occluded L-methionine 2
3F3E 1.80 occluded L-leucine 2
3F48 1.90 occluded L-alanine 2
3F4I 1.95 occluded L-selenomethionine 2
3F4J 2.15 occluded glycine 2
3GJC 2.80 occluded leucine, octoglucopyranoside 201 E290S mutant
3GJD 2.00 occluded leucine, octoglucopyranoside 201
3GWU 2.14 occluded leucine, sertraline 187
3GWV 2.35 occluded leucine, R-fluoxetine 187
3GWW 2.46 occluded leucine, S-fluoxetine 187
3MPN 2.25 occluded TODO 202 F177R mutant
3MPQ 2.25 occluded TODO 202 I204R mutant
3QS4 2.63 outward L-tryptophane 203 F259V mutant
3QS5 2.60 occluded L-tryptophane 203 I359Q mutant
3QS6 2.80 outward L-tryptophane 203 F250V+I359Q mutant
3TT1 3.10 outward - 186 complexed with Fab
3TT3 3.22 inward - 186 complexed with Fab
3TU0 2.99 occluded alanine 186 T355V+S354A+K288A mutant
3USG 2.50 occluded leucine 192
3USI 3.11 occluded L-leucine 192
3USJ 3.50 occluded leucine 192
3USK 4.50 occluded L-leucine 192
3USL 2.71 occluded L-selenomethionine 192
3USM 3.01 occluded L-selenomethionine 192
3USO 4.50 occluded L-selenomethionine 192
3USP 2.10 occluded leucine, heptyl-beta-D-Selenoglucoside 192
4FXZ 2.10 occluded leucine 204 F253A mutant
4FY0 2.10 occluded selenomethionine 204 F253A mutant
Table 2.2: Available crystal structures of LeuT in the PDB.
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G63) for aminoacid transporters.3 A second residue in TM3 has been shown to be
important for binding. It is conserved over all NSS proteins: LeuT-Y108, SERT-
Y176, DAT-Y156, NET-Y152, GAT-Y140),3,84,186 occluding the binding pocket
and directly interacting with substrate. Mutagenesis studies on TnaT revealed the





















Table 2.3: Leucine interactions with LeuT and the corresponding residues in SERT.
Several crystal structures of LeuT, non competitively inhibited by antidepres-
sants, revealed a second binding site on the extracellular site of the transporter. An
important interaction was observed between D404 and the charged nitrogen of the
inhibitors, braking the salt-bridge between R30 and D404.123,187,188 Clomipramine,
as the most potent compound, additionally interacts with N34 over the Cl atom.
Compared to 2A65, the inhibitors are buried under EL4, and the methyl group of
A319 points toward extracellular space.188 The vestibule below the kinked EL4 is
part of the substrate entry or permeation pathway and is called S2 binding site.
Further, a halogen binding pocket was found within the extracellular vestibule,
that is also conserved in SERT and might act as selectivity ﬁlter for SSRIs, see
table 2.4.187
Transporter Residues
LeuT L25 G26 L29 R30 Y108 I111 F253
SERT L99 G100 W103 R104 Y176 I179 F335
Table 2.4: Halogen binding pocket
As depicted in table 2.2, LeuT transports a variety of amino acids besides
leucine. Experimentally, it has been shown, that alanine is transported with higher
aﬃnity than Leucine.84 MD simulations and free energy calculations determined
F253 as discriminating factor between the substrate molecules glycine, alanine and
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leucine. An increasing length of the substrate side chain can form more favourable
non-electrostatic interactions and therefore increased the aﬃnity.205
Ion Binding Sites LeuT shows Na+ binding sites devoid of water and precisely
in size and charge.84 Computational studies on the selectivity of ions showed a
high selectivity for Na+ over K+ due to electrostatic and spatial properties of Na2
site and the electrostatic nature of the ligand for the Na1.205 LeuT is also able
to bind Li+, but – as seen with K+ – it is more selective to Na+.206 In other
sodium dependent transporters a common Na+ binding motif was described61 and
is also present in LeuT. It consists of an amino acid pattern GxxxG accompanied
by a ‘helix–break–helix’ motiv, wich is conserved among NSS205 in TM1. Due to
the spatial proximity, the two Na+ ions stabilize the unwound regions of LeuT
and the binding site of leucine by partly direct interaction. Since LeuT is not
Cl– dependent, no binding site is present. The crystal structure shows one Cl– on
















Table 2.5: Interacting residues of Na1 and Na2 in LeuT and the corresponding residues in SERT.
2.2.1.4 Function
The inverted structural repeat84 suggests a transportation cycle according to the
alternating access model88 via the rocking bundle of TMDs 1, 2, 6 and 7.36 Exerting
the states outward (PDB ID 3F3A), occluded (PDB ID 2A65) and inward (PDB
ID 3TT3), LeuT transports leucine with a rate of 0.1 to 0.4 molecules/min,194 see
ﬁgure 2.8.
Substrate Transport The crystal structures revealed regions within the trans-
porter important for substrate translocation. The ‘open–to–out’ (ﬁgure 2.8a) con-
formation is energetically favoured to receive both, Na+ and the substrate.94 In
this conformation, the extracellular vestibule (S2) is accessible by water down to
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(a) PDB ID 2A65 (b) PDB ID 3F3A
Figure 2.7: LeuT crystal structures in occluded and ‘open–to–out’ conformation.
the central binding site (S1) in the centre of the protein. Na+ prepares the bind-
ing site for the substrate entrance, which on its part dehydrates the S1 site.207
Conformational changes protect the S1 site from extracellular medium and change
the transporter to the substrate occluded state194 (ﬁgure 2.8b), that also decreases
the accessibility of the S2 site for solvent probably forming a second low aﬃnity
binding site in the S2 site.207 The binding of a second leucine molecule in the
S2 site has been shown to trigger the intracellular release of the ﬁrst substrate
molecule together with Na1194 (ﬁgure 2.8c).
The topic of two binding sites present in LeuT is not yet resolved and currently
discussed. But there are indications for one high aﬃnity S1 site and a spatial
distinct low aﬃnity S2 site. Depending on the experimental setup diﬀerences in
transport stoichiometry and binding sites are discovered.208 LeuT crystallised with
n-dodecyl-β-D-maltopyranoside (DDM) detergent can bind 2 leucine molecules,
crystallisation with n-β-D-octyl-glucopyranoside (β-OG) detergent allows only 1
molecule. This might be due to the length of the aliphatic side chain.201 Isothermal
Titration Calorimetry could show, that LeuT possesses only one high aﬃnity bind-
ing site for leucine, Kd = 54.7nM, but the hypothesis of a weak substrate binding
site before trapping into the S1 site could not be excluded.209 Experiments with
bivalent ligands gave indirect support for S2 site, separated by 11–13Å.191
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(a) PDB ID 3F3A – outward (b) PDB ID 2A65 – occluded (c) PDB ID 3TT3 – inward
Figure 2.8: Schematic substrate translocation pathway depicted as clipped plane throug LeuT.
Computational studies on LeuT in the occluded and ‘open–to–out’ conforma-
tion showed the importance of TM1 and Na2 for substrate translocation and re-
lease into the intracellular medium.88,210,211 The crystal structure PDB ID 3TT3
showed that the release of the substrate is eﬀected by a tilt of TM1a by 45 ◦. This
conformational change opens the central binding site to the cytoplasm after the
release of Na2 and further allows substrate to diﬀuse. The inward–faced LeuT was
stabilised by a Fab–fragment and the mutation Y108F,186 which was previously
found to be important for binding.209
Ion dependency The driving force for substrate translocation in the NSS fam-
ily is a pre-existing Na+ gradient. Spin labelling experiments showed, that Na+
increases the accessibility of S2 and induces outward faced conformation to prepare
the binding of substrate.194,207 Na+ bound to the transporter shields the cavity
and induces the occluded conformation.186,194 Binding free energy calculations
showed, that removing Na1 elicits unfavourable binding free energies for leucine
binding.206 It is assumed, that Na2 is as structural cation needed for stabilizing
the binding pocket for Na1 and the substrate.205,206 Na2 was found to subse-
quently tighten the extracellular gate in the substrate bound occluded state and
to facilitate the opening to the intracellular space. This is mediated by the access
of water molecules from the cytoplasm.88,212 The crystal structure of the ‘inward-
open’ LeuT was achieved by weakening the site of Na2 by mutating T354V, S355A
and Y268A.186
In contrast to the mammalian neurotransmitter transporter, most of the bac-
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terial homologues are Cl–-independent.84,195–197 PKa calculations on LeuT and
a homology model of SERT based on the crystal structure of LeuT revealed a
glutamate residue, that serves a negative charge for Cl–-independent bacterial
transporters. The Cl– shell is conserved among the NSS,182 see table 2.7. Mu-
tating residues within the Cl– shell of GAT1 (S331E), renders the transporter
relatively Cl–-independent. Analogous, LeuT (E290S), Tyt1 (D259N/A263S) and
TnaT (D268S) were shown to be rendered Cl–-dependent.183,184
Transport Inhibition The crystal structures of LeuT show a variety of sub-
strates within the central binding site, see table 2.2, but also several non-competitive
inhibitors, binding in the extracellular vestibule. In contrast to competitive inhi-
bition in SERT,193 TCAs stabilise the occluded state of LeuT and block the con-
version into the inward faced conformation. Besides imipramine and desipramine,
clomipramine as most potent inhibitor showed an IC50 of 5µM , TCAs were able to
retard the diﬀusion of leucine by stabilising the extracellular gate.123,188 Also the
SSRIs sertraline, R and S ﬂuoxetine were found to block LeuT non-competitively
with low aﬃnity in a similar manner in the S2 site,187 stabilised by cation-π inter-
actions with R30 and F253.191
Tryptophan acts as competitive inhibitor on LeuT and traps the transporter in
‘open–to–out’ conformation. Two molecules of tryptophan have been found: one
in the central binding site and the second in the S2 site breaking the salt bridge of
the extracellular gate R30· · ·D404 by the amino acid moiety.2 A single mutation of
LeuT (I359Q) towards the homologous residue in TnaT, turned LeuT tryptophan
transportable. The S2 site harbours a second tryptophan molecule only, when the
transporter is inhibited.203
It was found, that also the β-OG detergent molecules used for crystallisation
act as inhibitor of LeuT.207,210 A crystal structure with co-crystallised amphiphilic
β-OG was found to occupy the S2 site with the hydrophilic head and the S1 site
with the lipophilic tail. This crystal structure suggests, that also the ﬁrst structure
released (PDB ID: 2A65) is inhibited by β-OG. It is stated, that functional data
should be used with care.201 Crystallised LeuT from β-OG micelles was shown to
be in a functional conformation, but β-OG displaces substrate from S2.192
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%, the substrate transport pathway elicits a high degree of conservation up to 45
% within the central binding site, see appendix A.1.
Molecular dynamics simulations of a homology model of the DAT, performed
by a cooperation partner, showed, that EL4 is losing the α-helical structure. The
reason for this was thought to be related to a small misalignment between the
sequences of LeuT and DAT or SERT. Hydrophilic residues were placed below
EL4 into a very lipophilic regions.
⇐





Figure 2.12: EL4: from reference 3.
Manual modiﬁcation of this region in the sequences of DAT and SERT improved
the orientation of the hydrophilic residues and the stability of EL4 in DAT.180 MD
simulations on SERT, see section 4 showed, that more reﬁnement is necessary for
stabilising the helical structures.
additional matches
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Figure 2.13: EL4: modified according to reference 180.
In a previous study, it was aimed to elucidate the diﬀerences in aﬃnity of
methylphenidate between SERT and DAT,26 putative mutation sites for selectivity
could be found by analysing the diﬀerences in the primary sequence, see appendix
2.3.
2.4 The Serotonin Transporter Model
As introduced in section 1.3.4.2, the SERT transports 5HT across the membrane
into the cytoplasm in a secondary active mechanism using a Na+ gradient to
terminate neuronal transmission. In the 1970s, SERT was ﬁrst characterised from
platelets213 and the mechanism of transporter inhibition was described.214 SERT
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shares many structural, functional and regulatory features with DAT and NET
at least due to the high degree of homology.3 A number of homology models
have been published in the recent years.88,101,126,140,150,215–220 All used LeuT as
validated template. However, it is the only structure with NSS fold in the PDB.
The alignment varies in the diﬀerent publications.221
2.4.1 Structure
After cloning the transporter in 1991,80,222 structural and functional studies have
been performed, eliciting the organisation of the primary sequence of 620 amino
acids to the secondary structure of predominantly 12 TMDs with N and C terminus
intracellular.27,223
Conformations According to the alternating access mechanism, the tertiary
structure of SERT undergoes basically three main conformational changes from
outward-open for receiving the substrate, over the substrate occluded state where
both gates are closed, to the inward-open conformation to release the substrate
to the intracellular medium. The quaternary structure and functional entity of
the transporter is a constitutive oligomer, a dimer or a tetramer,224,225 which
was veriﬁed also for DAT and GAT1. Oligomerisation might be important for
traﬃcking rather than transport.36 But it has been shown, that the subunits
are functionally interacting and might transporting independently.117,226,227 For
amphetamine action, at least dimeric organisation is necessary.140
Membrane Placement Hydropathicity plots predicted 12 TMDs the SERT.
Homology modelling based on LeuT revealed the domains 4,9,11 and 12 anchor
the transporter3 in the membrane bilayer, where TM 2 is in contact with the upper
and the TMs 7 and 10 are contact with the lower leaﬂet, respectively. NHS-S-S-
biotin and MTS experiments support the predicted placement of the transporter
in the membrane, and further showed, that the N and C terminus are located
intracellular, see table 2.6.228 The membrane placement calculated for the template
reactivity residues
biotinyl 111, 194, 243, 319, 399, 490, 571
MTS 109, 310, 406, 489, 564
Table 2.6: Residues located on extracellular side.
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LeuT is shown in ﬁgure 2.3. Based on this data, the homology model of SERT
was placed in the membrane during the MD simulations, see section 4.3.
2.4.2 Topology
Termini The N-terminus of SERT ranges from residue 1 to 84 and is freely
mobile. It contains interaction sites for regulatory and structural proteins, such as
syntaxines and protein kinases (PKC, Cam), and putative phosphorylation sites.
The mutation T81A leads to a loss of amphetamine induced reverse transport,
indicating the importance for regulating the transport cycle.140 The C-terminus
ranges from residue 602 to 620. In the crystal structures of the template, these
regions are substantially smaller. Since a template for the N and the C terminus
does not exist, both have been removed during modelling.
Transmembrane Domains As known from bacterial homologues, only 11 do-
mains are needed for transport.56,196 The domains 1,3,6 and 8 align the proposed
substrate permeation pathway, including the high aﬃnity S1 site. The upper half
of TM10 contributes to the extracellular vestibule. In the outward-open confor-
mation, TM5 is buried in the protein, but mutagenesis data revealed an increased
MTS reactivity with 5HT suggesting participating in the intracellular substrate
pathway.85 Several discontinuous contact sites for NSS are linked to the oligomeri-
sation of the transporters. TM2 shows a ‘leucine heptat repeat’,31 TM6 elicits a
glycophorin A-like motif in TM6 and segments of TM4 in DAT were found to form
a symmetrical dimeric interface.225 The contact sites in SERT might be diﬀerent.36
• TM1 is part of the substrate entry pathway. The aqueous accessibility
hSERT from external site was tested by SCAM. Cysteine substitutions from
the cytoplasmic face to G94 were unaﬀected by the treatment with extracel-
lular MTS reagents. Mutations of D98, G100, W103 and Y107 inactivated
the substrate transport.161
• TM2 is delimited by A116 and Y136 and does not appear to contribute
directly to the binding site. Mutations showed decreased activity due to a
low surface expression.229 It contains conserved ‘leucine heptad repeat’ and
is probably involved in oligomerisation.82,83
• TM3 is partitioning to the substrate entry path as well as to the central
binding site. I172, Y176 and I179 are in one face of the helix, where the ﬁrst
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two residues are in contact with the S1 site. Mutations on Y175 and Y176
lowered the transport activity.230
• TM5 ranges fromW271 to Y289 and contributes to the intracellular substrate
pathway.56 MTS reactivity experiments showed an increased reactivity at
G273, V274, S277, V280, V281 and T284 by 5HT, but it was decreased by
cocaine.89
• TM6 contains the residues from T323 to A348 and is part of the extracellular
vestibule and the central binding site. The SCAM and biotinylation were
used to probe the aqueous accessibility and elicited solvent access to the
extracellular half of TM6 in an α-helical pattern: T323, G324, I327, A331,
F334, F335, S336. The unwound region was inaccessible and the intracellular
part of TM6 showed limited water access. It was validated for F347.231
• TM7 contributes to the Cl– binding site. MTS reactivity showed, that V366C
and M370C decreased 5HT transport and altered Na+/Cl– dependence. The
interpretation of the results in context of a homology model suggests ﬂexi-
bility of TM7.219
Loop Regions A signiﬁcant diﬀerence of the loop regions between LeuT and
SERT is the length of EL2. In SERT, it contains 20 residues more, where no tem-
plate is existing. It is known, that it harbours N-linked glycosylation sites required
for traﬃcking and stability of SERT in the membrane, but does not aﬀect 5HT
binding or transport.28,232 Two cysteines C201 and C209 have been found to form
a disulphide bond.228 EL4 is located above the substrate binding pocket. It is
organised as kinked and V-shaped broken α-helix and acts as lid during substrate
recognition.233 It aligns the extracellular part of the extracellular vestibule and is
able to move during the substrate translocation, as seen in the inward–faced struc-
ture of LeuT.186 On the intracellular half of the transporter, IL5 has been found
to be in α-helical conformation and undergoes conformational changes during sub-
strate translocation.234 In DAT it was found, that IL3 participates in substrate
translocation.31
• IL2 ranges from W271 to I290 and appears to be in α–helical conformation
and contains sequences for interactions with cGMP dependent PK and PKC.
It does not participate directly in the transportation cycle but may fulﬁl a
conformationally active role in the catalytic cycle.235
• EL2 is enlarged by more than 20 residues compared to the template. The
mutation of cysteines on EC site of the transporter showed, that C109 had
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no eﬀect on expression or transport activity of SERT. In contrast, mutat-
ing C200S and C209S showed severe decrease in surface expression. MTS-
accessibility did not inactivate these residues, suggesting that these residues
are involved in a disulphide bond.236,237
• EL4 with the noticeable kinked structure is in α-helical conformation from
386 to 399 and from 409 to 421 separated by a hinge region from 402 to 405.
It is not involved in binding but undergoes conformational changes during
the transport cycle. Cysteine scanning revealed, that the mutation of M386,
R390, G402 and L405 are of structural and functional importance due to loss
of function. The mutation F407C aﬀects 5HT and βCIT aﬃnity.233
• EL5 was found to span the region starting at S483 and ending at P499.
Cysteine scanning experiments revealed, that this loop is not important for
ligand binding but might be involved in interactions required for transport
cycle.238
Substrate Binding Sites The focus of the present study is the elucidation of
the binding mode of substrates and inhibitors of SERT. In contrast to the amino
acid transporters LeuT, GAT1 and others, a striking diﬀerence is the position 98
in SERT. As found in GPCRs, a negatively charged aspartate is important for
the coordination of the positively charged substrate in the binding pocket.28,239,240
D98 is crucial for the binding of ligands to the transporter as general mechanism
of amine recognition239 by ‘ion–pairing’ of D–COO–· · · +NH3–R. It coordinates the
substrate on the one hand and the binding of Na1 on the other side by separating
the charges.1 The mutation of this residue leads to loss of function, except mutat-
ing to glutamate, which reduces the aﬃnity for the substrate and potent ligands,
such as cocaine, imipramine, citalopram and DMT. Interestingly, the aﬃnity for
gramine (short 5HT) was increased and unaﬀected for paroxetine and mazindol.240
The central binding site is occluded from the extracellular medium by Y176
and F335. It is of amphiphilic nature can be divided into a hydrophilic part near
D98 and a hydrophobic part with I172 on the opposite side.150 I172 was also found
to be crucial for substrate and inhibitor binding.161 Towards the intracellular part
of the S1 site, the bottom is formed by Y95, which is also important for ligand
recognition.6,161
Controversially debated is the importance of the extracellular vestibule, see
section 2.2.1. It is formed by the TMs 1,3,6,8 and 10 and covered by EL4.85 Site
directed mutagenesis and pH modulated currents indicate E493 (TM10) as part of
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the extracellular gate, salt bridged to R104 (TM1).241 Mutagenesis studies support
the existence of a Halogen Binding Pocket (HBP) important for the binding of
SSRIs located in the S2 site, see table 2.4.187 Further, it has been shown, that
TCAs partially occupy the S2 site when competing with the substrate.6 Recently,
it was found, that citalopram can be bound in the S2 site.242 AFM microscopy
studies with an cocaine like inhibitor (MFZ2-12) revealed the existence of two
binding sites.243
Regarding the energy landscape, it is likely, that S2 imposes a barrier on entry
of compounds into the S1 site. The S2 site contributes to the selective recognition
of several compounds.243 Regarding the high degree of sequence identity between
SERT and DAT, the diﬀerences in aﬃnity in orders of magnitude for inhibitors
like imipramine (SERT) and methylphenidate (DAT), the substrate recognition
might occur in the extracellular vestibule. The ‘open–to–out’ conformation of the
SERT homology model shows a cavity, accessible by extracellular medium to the
bottom of the S1 site, aligned by the extracellular halves of TM1, 3, 6, 8 and 10,
covered by EL4.
Ion Binding Sites SERT is strictly Na+ dependent in substrate binding and
transport. The binding sites are according to the template. SERT is able to bind
two Na+ ions, but only one is transported. The second Na+ is believed to serve
the structural conditions for binding Na1 and the ligands.56
In contrast to bacterial transporters, mammalian NSS are dependent on Cl–.
Therefore, the crystal structures of LeuT lack a Cl– ion in the core of the protein.
Several studies revealed the binding site for Cl– coordinated by Y121, S336, N368
and S372, see table 2.7.182–184
Transporter Residues
LeuT Y47 T254 N286 E290
SERT Y121 S336 N368 S372
DAT Y102 S321 N353 S357
GAT1 Y86 S295 N327 S331
Tyt1 Y47 S227 D259 A263
TnaT Y47 S232 N264 D268
Table 2.7: Cl– binding site in NSS.
Substrate translocation Pathway According to the alternating access model
SERT has to undergo at least three conformational states for the substrate translo-
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cation of 5HT. Cocaine is able to stabilise SERT in ‘open–to–out’ conformation,
while ibogaine stabilises the transporter to the inward faced conformation.90 Fig-
ure 2.8 illustrates the conformational states for LeuT. The translocation pathway
of SERT is extensively studied by mutagenesis and computational studies. It
is known, that the substrate enters the transporter in an aqueous pore formed
by TM1 (D98, G100, N101, W103) and TM3 (Y176, I179).216 Mutations on the
residues Y95 and I172 suggest, that the central binding site is accessible from both
sides of the membrane.161,244 When passing the S1 site, the TMDs 1, 5, 6 and 8
form the permeation pathway. According to the internal symmetry TM5 might
participate to an intracellular vestibule during substrate release.56,88 MD simula-
tions showed the importance of TM1 and TM6 for the opening to the intracellular
side. It was further shown, that Na2 is important for opening of TM1,211,245,246
after the penetration of water and the solvation of the binding site.88,212 This
mechanism was conﬁrmed by the crystal structure PDB ID 3TT3 published re-
cently.186
Cysteine scanning mutagenesis studies revealed important residues, interacting
with substrates and inhibitors, which are protected during binding:
Mutation Eﬀect to Reference
D98C protected by 5HT 161
G100C protected by 5HT and COC 161
N101C protected by 5HT and COC 161
Y107C protected by 5HT 161
M180C contributes to antidepressant binding 216
I172C protected by 5HT and COC 244
I172C protected by 5HT and COC 230
I179C accessible from EC side, but not protected 244
I179C protected by 5HT 85
I179C protected by COC, not by ibogaine or MTSEA alone 247
A116C protected by 5HT 85
G338C locks in outward conformation, restored by Y95F 231
Table 2.8: Cysteine scanning of the translocation pathway.
2.4.3 Validation
The homology model of SERT was created and selected according to the protocol
as described above. To evaluate the structure, it was structurally assessed on the
server www.swissmodel.org as LeuT. In a second step the structure was compared
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to the results of mutagenesis and SCAM studies published previously.
2.4.3.1 Structural Assessment
PROCHECK was used to check the geometry of the system. Generally, the stereo-
chemical check for the homology model is very well. For the ‘open–to–out’ model
of SERT-WT, the following output was generated:
+----------<<< P R O C H E C K S U M M A R Y >>>----------+
| |
| SERT_SC6A4_HUMAN.B99990206.pdb 2.0 529 residues |
| |
*| Ramachandran plot: 93.5% core 5.2% allow 0.4% gener 0.9% disall |
| |
+| All Ramachandrans: 10 labelled residues (out of 523) |
+| Chi1-chi2 plots: 9 labelled residues (out of 306) |
| Main-chain params: 6 better 0 inside 0 worse |
| Side-chain params: 5 better 0 inside 0 worse |
| |
*| Residue properties: Max.deviation: 7.8 Bad contacts: 11 |
*| Bond len/angle: 5.4 Morris et al class: 1 1 2 |
+| 1 cis-peptides |
| G-factors Dihedrals: 0.11 Covalent: -0.16 Overall: 0.00 |
| |
| M/c bond lengths: 99.1% within limits 0.9% highlighted |
| M/c bond angles: 94.0% within limits 6.0% highlighted |
| Planar groups: 100.0% within limits 0.0% highlighted |
| |
+----------------------------------------------------------------------------+
+ May be worth investigating further. * Worth investigating further.
The Ramachandran plot elicits 4 outliers in the homology model, located in dis-
allowed regions: M311, A323, V379 and Y492. None of these residues mentioned
are located within the binding site or the substrate entry path. Therefore an
optimisation was omitted.
Figure 2.14b shows the per residue QMEAN score for the homology model of
SERT. Compared to the scores for the template (see ﬁgure 2.10), more regions
reached only low accuracy (indicated in red). Fortunately, the S1 binding site and
most of the parts of the S2 site elicit good local scores (indicated in blue). The
total QMEAN score is 0.129 and the DFIRE energy is at -891.50.
2.4.3.2 Mutagenesis Data
Despite the fact, that LeuT is a valid, and up to now the only existing, template217
for homology modelling of NSS, the obtained structures have to be assessed with
experimental data published. There exist examples of discrepancies in SCAM
studies between LeuT and SERT indicating conformational changes, which can
not be detected from the crystal structure alone. L137C, located on TM2 buried
in the protein reacted with MTSEA suggesting access to aqueous medium. A441C,
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Residue Criterion Comment Reference
I179 located in S2, part of entrypath fulfilled
126
D400 located on EL4, no or slight effect on in-
hibitor binding
fulfilled, orientated towards EC space
S438 conserved residue in S1, important for ligand
binding
fulfilled
L486 in S2, no or slight effect on inhibitor binding fulfilled
V489 in S2, no or slight effect on inhibitor binding fulfilled
K490 in S2, no or slight effect on inhibitor binding group 3 shows cation-π interaction
D98 most important for function, ion-pairing
with ligands
fulfilled, separates NH+3 · · ·Na
+ 249
I172 MTS-accessible from IC and EC site and
protected by ligands
fulfilled, in hydrophobic part of S1
244
I179 protected by substrates, buried in hydropho-
bic environment in S2
partly fulfilled
T323 MTSEA-Biotin accessible fulfilled
231
G234 MTSEA-Biotin accessible fulfilled
I327 MTSEA-Biotin accessible fulfilled
A331 MTSEA-Biotin accessible fulfilled
I333 MTSEA-Biotin accessible, distinguishes be-
tween 5HT and MDMA
orientated towards TM2
F334 MTSEA-Biotin accessible fulfilled
F335 MTSEA-Biotin accessible fulfilled
S336 MTSEA-Biotin accessible fulfilled
G338 no transporter function, when mutated - do-
main movement
located in unwound region
G342 no transporter function, when mutated - do-
main movement
located in unwound region
F346 MTSEA-Biotin accessible below S1
Y95 accessible from both sides of the membrane not in ‘open-to-out’ model
88G442 not accessible and part of S1 fulfilled
L443 not accessible and part of S1 fulfilled
D98 accessible and protected by 5HT fulfilled
161
G100 accessible and protected by 5HT and cocaine fulfilled
N101 accessible and protected by 5HT and cocaine fulfilled
W103 not well accessible fulfilled
Y107 accessible and protected by 5HT fulfilled
I108 accessible fulfilled
Y95C/I172C too distant to form Cd+2 binding site fulfilled
216N101C/I179C involved in Cd
+
2 binding site too distant
I172 located in S1 and invovled in ligand binding fulfilled
I179 located in S2 indirectly involved in ligand
binding
fulfilled
V102C/D98 Zn2+ binding site residues are in proximity
217V102C/M180C inhibited by MTS-3-MTS, 5 to 6.5 Å distant fulfilled
V102C/A183C disulpide bond fulfilled
W103H/M180C sensitive for Zn2+ inhibition fulfilled
Distances
V102· · · I179 8.5 Å 13.3 Å
217
V102· · ·M180 8.6 Å 13.3 Å
V102· · ·A181 n.d., opposite side of the helix fulfilled
V102· · ·W182 9.9 Å 13.3 Å
V102· · ·V183 7.5 Å 13.3 Å
V102· · ·L184 n.d., opposite side of the helix fulfilled
0.7 Å backbone RMSD of our model compared to the model of reference 150
Table 2.9: Comparison of the SERT model with experimental data
Leu Number PDF DOPE GA341 DFIRE core allow gener disall
no SERT-122.pdb 1912.53284 -77560.17969 1.00000 -1497.22 95.1 4.7 0.2 0.0
yes SERT-140.pdb 1969.10388 -77473.06250 1.00000 -1500.61 94.6 4.9 0.0 0.4
Table 2.10: Scoring values of the two selected models of SERT.
3Docking Experiments
Despite the intense research and an amount of pharmacological and computational
data published up to now, the molecular interactions between NSS and their sub-
strates and inhibitors are still a matter of debate. Many research groups aim to
reveal the exact binding mode of the ligands within the binding pocket of the
transporters. The knowledge about the molecular interactions between the pro-
teins and the ligands provides useful information for the development of new drugs
with higher selectivity for the treatment of NSS related diseases. A focus of the
present work is the elucidation of the binding mode of TCAs, and most prominent
imipramine.
3.1 Docking Protocol
A docking experiment delivers a variety of results, which then are scored by es-
timating the binding free energy of the obtained complex. Depending on the
scoring function used, the top scored docking pose may diﬀer from the real bind-
ing mode.168 To obtain the true binding mode, various sources of information have
to be used. Results from in-silico and in-vitro studies have to be included. It has
been shown, that the binding conformation within the protein is not obligatory in
a minimum conformation, which makes the scoring more complex. The evaluation
of 150 crystal structures revealed diﬀerences in the strain energies of > 5 kcal/mol
for more than 40 % of the analysed crystal structures.250
To cover the chemical space within the binding pocket of the protein, the
docking experiment was forced to deliver a maximum amount of poses per run. The
protocol applied in the present study focuses on selecting docking poses based on
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the geometry of the poses within the pocket in the ﬁrst step and important protein
ligand interactions known from the literature in the second step to avoid bias due
to scoring functions. The docking experiment was performed within the ‘Molecular
Operating Environment’ (MOE) from the Chemical Computing Group, Montreal,
Canada.5 Clustering was performed within R251 using the package ‘clv’.252
3.1.1 Ligand Preparation
Similar ligands bind in a similar fashion on a similar target. Within the protein,
similar ligands bind to the same region of the binding pocket. In the literature it
is reported, that diﬀerences were detected due to water molecule architecture, side
chain ﬂexibility, but rarely due to backbone movements.253 The ligands docked
were selected based on the experimental setup of our collaboration partners and
further based on the scaﬀold of the compounds:
• Imipramine as high aﬃnity ligand on SERT and major exponent of the TCAs
• Desipramine as one of the metabolites of imipramine
• Clomipramine as exponent of second generation TCA
• Amitriptyline due to the double bonded tail
• Carbamazepine since the tail is missing and used in the assays to determine
the binding mode
• DH-Carbamazepine where the ethylene bridge is more ﬂexible
Ligands
Crystal Structures
Molecule Builder Initial Structure
define atom names and numbering,




based on the potential energy MD Simulation
conformational sampling by
MD simulation at 2000◦K
for 1 ps; snapshot every 5 fs
Energy Minimisation
selection of diverse poses
based on the RMSD
and the potential energy.
Selected Conformations
50 – 100 conformations
prepared for docking
Figure 3.1: Ligand Preparation protocol.
The input conformations of the docked ligand inﬂuence the docking result. Mul-
tiple starting conformations can improve the result. Since the ligand is treated
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rigidly during the docking process, the creation of a conformational database is
necessary to provide a virtual ligand ﬂexibility.254
As depicted in ﬁgure 3.1, the ligands were either extracted from crystal struc-
tures (PDB ID 2Q72, 2Q6H and 2QB4188) or were drawn by hand using the
Molecule Builder within MOE. The Merck Molecular Force Field, developed
by Halgren and co-workers, is parametrised for small organic molecules. The
MMFF94x used within MOE is not published.5 It was chosen during ligand prepa-
ration and the docking protocol. The solvation model used was ‘Born’, which en-
ables Esolv in the forceﬁeld equation and calculates the energy of implicit solvent
according to the Generalised Born solvation model (GB/VI) with a dielectric con-
stant (ǫ) = 1, according to vacuum. For calculation of the electrostatic energies
(Ecoul), the Coulomb form of the equations. The forceﬁeld equation is deﬁned as
E = Ebond+Eangle+Estretch/bend+Eimproper+Edihedral+Evdw+Ecoul+Esolv+Eres (3.1)
where each of the energies are weighted sums of bonded and non bonded energies
plus the restraints.
Prior the conformational sampling, the hydrogens were added using the Protonate 3D
function255 at a pH = 7.4, assigning a positive charge on basic nitrogens. A stochas-
tic search of ligand conformations rotates randomly all bonds of the molecule in-
cluding ring systems. To sample most of the local minima, the Stochastic Search
function was used to obtain a minimum starting structure for the subsequent MD
simulation.
MD simulations at high temperatures are used to step over energetical peaks
on the energetical surface. Adapted from reference 256, the MD simulation on the
ligands was performed for 1 ps at 2000◦K in vacuum within MOE. 2000 confor-
mations were obtained by taking snapshots every 5 fs which were written into a
database. The conformations were minimized with the steepest descent algorithm
to a gradient of 0.01kcal/mol.
The Diverse Subset function was applied to select the starting conformations
for docking. Based on both the RMSD of each conformation to the initial struc-
ture after superposition and the potential energy, 100 input conformations were
selected. Diverse Subset calculates the distance from the ﬁrst entry of the data-
base as reference set to the actual set and chooses the farthest entry. The obtained
rank order is written to the subset, which is used as input for docking.




Solvation Model = GB/IV
Dielectric Constant = 4
Ion Placement
manual placement of the Cl– ion.Protonate 3D
pH = 7.4
ǫ = 4.0 Minimisation
stepwise minimisation:
Hs, SC, BB, all
500 steps SD, 1000 steps CG
Site Finder
dummy atoms r > 9 Å from the
plane D98 – Y176 – F335 removed Binding Site Deﬁnition
residues within 4.5 Å
were selected as binding site
Figure 3.2: Protein Preparation protocol.
Prior the homology model was loaded, the dielectric constant was changed to
4 according to protein environment256 in the Potential Setup panel. The hydro-
gens were assigned using the Protonate 3D function again within the MMFF94x
forceﬁeld. The following parameters were modiﬁed: temperature = 310◦K, pH =
7.4 and the dielectric constant = 4. The Site Finder function was used to create
dummy atoms considering hydrophilic and lipophilic nature of the pocket. The
location of the dummy atoms is based on geometric properties without consider-
ing energetic models. The discrimination between hydrophilic and hydrophobic
spheres depends on the coarse classiﬁcation of the chemical type of surrounding
atoms, from which the 3D data points are calculated.5
Figure 3.3: Dummy atoms in
the binding site of SERT.
In the ‘open–to–out’ model, the entry path from
EL4 and TM10 to the bottom of the S1 site, Y95,
was considered as binding site. To reduce the spatial
extent of the site and to deﬁne the binding site more
exactly, dummy atoms in the S2 site with a distance
of more than 9 Å from the plane D98, Y176 and F335
were deleted manually. All residues within a radius
of 4.5 Å around the remaining dummy atoms were
selected as binding site, see ﬁgure 3.3. The selected
residues were shown to be analogous to the template
structure, see table 3.1.
































Table 3.1: The defined binding site of SERT (left) compared to LeuT (right). Differences are
marked with *.
3.1.3 Docking Run
As ligand input, the conformational databases were selected. The placement
method used was Alpha Triangle. The poses were scored with the London dG
scoring function. A molecular mechanics reﬁnement step within the MMFF94x
forceﬁeld using the default values has been applied. Charges are assigned to the
atoms and minimised within a cutoﬀ–radius of 6 Å. Subsequently the poses were
rescored using the Alpha HB scoring function. Up to 2300 docking poses per ligand
were obtained, covering the chemical space of the deﬁned binding site.
3.2 Pose Selection
Scoring functions estimate the binding energy of a given complex, see 1.5.2.2.
The top scored poses can diﬀer, depending on the scoring function used. On
the other hand, docking poses resembling the ‘real’ binding conformation might
obtain low scores. To overcome this problem, an evaluation protocol was elab-
orated, that uses (i) the geometrical information of the obtained coordinates by
hierarchical clustering, (ii) the protein ligand information applying the function
Protein Ligand Interaction Fingerprint (PLIF) to select interactions with
important residues and (iii) consensus scoring to select the ﬁnal pose. To re-
duce the bias by the experimentator during pose selection, the number of poses
is reduced in a semi-automated workﬂow using the functions described below, see
in appendix A.2. Figure 3.4 shows the protocol applied in the docking of imi-
pramine, desipramine, amitriptyline and carbamazepine into the homology model
of SERT-WT. For the docking of imipramine, trimipramine, cyproheptadine and
desloratadine into the WT and the mutants, the splitting of the databases was
omitted, with respect to eﬃciency.
3.2.1 Removing Duplicates
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Docking
Homology Model Ligand conformations
Removal of Duplicates
export of squared RMSD matrix
clustering within R using clv-package
complete linkage; cutoff = 1 Å
Protein Ligand Interaction Fingerprint
D98 Y95 I179 E493
Minimisation of the complexes with LigX
Clustering of the minimised poses at 4 Å
Extracting the cluster centroid and the top consensus scored pose
PLIF: ionic interaction with D98 and E493





Figure 3.4: Protocol of selecting the docking poses. Main fields without background were con-
sidered only during the evaluation of imipramine in WT.
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3.2.3 Minimisation
To consider the relaxation of the docking pose within the binding pocket with
slight adaptations of the protein, the function LigX - Minimize was applied on
the selected poses. This function performs a molecular mechanics minimisation
of the ligand in the binding pocket. Residues within 6 Å are relaxed and allowed
to adapt to the ligand. The movements of the ligand and residues changed the
interaction pattern of the PLIF for several poses.
3.2.4 Clustering and Consensus Scoring
Onto the minimisation, the steps (i) removing duplicates (threshold was set to 3 Å
during complete linkage clustering) and (ii) PLIF were repeated. The remaining
poses were rescored using the scoring functions available in MOE: London dG,
Alpha HB, Affinity dG and ASE for a consensus scoring of each cluster. Finally,
the top scored pose of each cluster and the centroid are assessed visually.
3.2.5 Visual Inspection
Up to 25 poses per ligand were obtained in after ﬁnal step of the protocol. The
visual assessment considers the spatial orientation of the ligand within the binding
pocket. Poses placed in the S2 site were omitted due to the fact, that imipramine
and serotonin bind mutually exclusive on SERT.6 Three groups of poses were man-
ually deﬁned regarding the location of the tricyclic ring system and the orientation
of the dimethyl aminopropyl side chain, see ﬁgure 3.11.
3.3 Experimentally Validated Docking Pose
The protocol described above was elaborated for the docking pose of imipramine,
desipramine, clomipramine, amitriptyline and carbamazepine in SERT, as pub-
lished in reference 6. It combines the information of the docking, experimental
data from the cooperation partners and literature data.
3.3.1 Common Scaffold Clustering
As an additional proof of the binding mode, a common scaﬀold clustering was
applied on the ﬁnal poses. To perform this calculation, the RMSD matrix and
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complete linkage clustering was applied on the group 3 poses. Therefore, atoms,
which are similar in all of the ligands have been considered. The overlay of the
poses shows diﬀerences within the cutoﬀ range of 1 Å, but generally the ligands
were found to bind in a similar binding mode with similar interactions. To visualise
the lipophilic and hydrophilic regions of the transporter, the surface was calculated
with MOE using the Surfaces and Maps function in MOE. As rendering mode,
Lipophilicity was selected, which colour codes lipophilic regions from yellow to
brown and hydrophilic regions from white to blue. It has to be mentioned at this
point, that also for group 1 and 2, common scaﬀold clusters have been found.
Figure 3.7: Common scaffold clustering of the final poses.
3.3.2 Diagnostic Mutation
Based on the ﬁnally selected docking pose of imipramine and the common scaﬀold
clustering, the interactions important for binding in the central binding site are
the known salt bridge between the charged nitrogen and D98. Figure 3.7 shows
an isolated hydrophilic sphere between D98 and Y95. An explanation of this
observation is a possible water binding site near D98, Y95 and the nitrogen of the
ligand. Since docking represents a static snapshot of the system, we hypothesised a
hydrogen bonding interaction between the ligand and Y95. Therefore, a diagnostic
mutation was performed by Subhodeep Sarker in the lab of Prof. Freissmuth,
where the hydroxyl group of Y95 was removed. This mutant was used to test the
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3.3.5 Summary and Result
The pharmacological experiments of our cooperation partners guided the selection
of the ﬁnal docking pose for imipramine, see section 3.5. Figure 3.11 shows the
ﬁnally obtained poses of imipramine in SERT.
(a) Group 1 (b) Group 2 (c) Group 3
Figure 3.11: Representative Pose of the final groups of imipramine docking poses.
The decision of the ﬁnally selected pose 3 is based on the following assumptions
from the experiments:
• The mutation Y95F reduces the binding aﬃnity of imipramine by 1.22 kcal·mol−1,
see eqation 3.2, according to a weak hydrogen bond. Pose 1 does not elicit a
hydrogen bond interaction with Y95 and this might not be possible without
rotation within the binding pocket.
• Carbamazepine and serotonin can be bound simultaneously to SERT. Fol-
lowing the hypothesis, that similar compounds bind in a similar manner at
the same target, carbamazepine and serotonin could not be bound simulta-
neously, if the tricyclic ring is placed in the S1 site, as seen in pose 2.
• Pose 3 is consistent the ﬁndings of the pharmacological experiments in (i)
the tricyclic ring is placed in the changeover of the S1 and S2 site, (ii) the
dimethyl aminopropyl moiety is located in the S1 site and (iii) the direction
of the charged nitrogen towards Y95 suggests possible hydrogen bonding in-
vitro. Since the distance between the side chain of Y95 and the charged N+
is too large to form a direct hydrogen bond, it might be mediated over a
water molecule. This assumption is indicated by (i) the rather low reduction
of the binding energy and (ii) the representation of the lipophilicity surface,
see ﬁgure 3.7, where an isolated hydrophilic sphere. Both the distance and
the angle and the distance of the sphere to the hydroxyl group of Y95 and
to the charged nitrogen of imipramine would allow for hydrogen bonding.
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3.4 Validation of the Binding Hypothesis
The study was extended to validate the binding mode by using three more lig-
ands, classiﬁed as antihistamines: trimipramine, cyproheptadine and deslorata-
dine. To support the binding hypothesis additionally to the Y95F mutation, the
I172A mutation and the double mutant Y95F+I172A were cloned. In parallel,
homology models of the mutants as described in section 2 were created and pre-
pared for running the docking experiment. The docking protocol was shortened
for eﬃciency: the separation of the database derived from the most populated
interactions recorded from the PLIF was omitted (see ﬁgure 3.4). The rational
background for the decision was the crucial importance of D98 as main interaction
partner of the positively charged ligands, see section 2.4.2
3.4.1 Modelling and Docking into the Mutants
The mutants SERT-Y95F, SERT-I172A and the double mutant were created using
the protocol introduced in section 2. Prior the modelling, the primary sequence has
been modiﬁed according to the mutated amino acid residue. For each mutant 250
models were created, where one was ﬁnally selected based on the criteria described
previously.
The four ligands imipramine, both enantiomers of trimipramine, cyprohepta-
dine and desloratadine were docked into the models of the mutant. Following the
docking and evaluation protocol, the poses were selected with regard to the vali-
dated binding mode of imipramine into the wild type, resulting in poses according





















Table 3.2: Amount of poses in the finally obtained group 3.
3.4.2 Selected Poses
On the following pages ﬁres of the ﬁnally selected docking pose(s) of group 3 and
the protein ligand interactions as printed fromMOE using the function Ligand Interactions.
If two docking poses are selected, the green pose accords to better consensus score
(marked within the lines of the tables). To test the stability of the poses, at least
3.4. VALIDATION OF THE BINDING HYPOTHESIS 93
one pose of each docking run was was chosen for performing MD simulations. In
total, 29 complexes were selected.
The tables contain the consensus scoring of the three groups. The consensus
scoring was performed in a minimal manner. The poses are ranked according to
the scoring function and numbered. The ﬁnal consensus score is the sum of all
rankings. In the last column, the distance of the nitrogen to the side chain of Y95
is given.
3.4.2.1 Imipramine
Each of the docking results shows a similar interaction pattern. The main interact-
ion is the ionic interaction between D98 and the charged nitrogen. The nitrogen
interacts via cation-π with Y176 or F335. Inhibiting the direct interaction between
Y175 and D98 is reported to be one of the inhibition mechanisms as reported in
reference 139. Further, the tricyclic ring system is placed in the extracellular
vestibule and avoids the closure of the external gate, the direct interaction of
R104 and E493. The following ﬁgures show the binding site of hSERT with the
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3.4.2.2 Trimipramine
The common scaﬀold of imipramine and trimipramine suggests a similar binding
mode for trimipramine as observed for imipramine, desipramine, clomipramine
and amitriptyline. Considering this binding mode, a mutation of I172, which is
known to be important for ligand binding, might show an eﬀect in the binding.
Experiments showed a slight increase of trimipramine aﬃnity in the SERT-I172A
mutant. Regarding the placement of trimipramine, the removal of the isoleucine
side chain might free the space for the additional methyl group on the aliphatic
tail and allow more aﬃne binding of trimipramine to that mutant.
The ﬁnal group 3 of trimipramine elicited two diﬀerent orientations regarding
the additional methyl group. In the ﬁrst case, it is turned towards I172 the other
pose was orientated from 90 to 180 degrees away from the residue. This observation
is similar in all clusters, but only the docking poses of R-trimipramine in the I172A
mutant and S-trimipramine in the double mutant ranked the pose where the methyl
group is orientated towards the mutation on the ﬁrst place. Since the template
was in ‘open–to–out’ conformation, in the binding site of the models is enough
space near I172A and the wild type so that the docking algorithm was able to
place the sidechain of the ligand into S1 without steric hindrance. The following
ﬁgures show the two highest ranked poses of group three (green: the top ranked
pose, yellow: the highest ranked pose, where the methyl points to the opposite
direction), which were selected for MD simulations.
R-trimipramine
The interaction pattern is similar to imipramine according to the common scaﬀold
cluster and the experimentally validated binding mode. Between the external gate,
the tricyclic ring system is placed. In the double mutant a π-cation interaction is
present and the main interactions in the S1 site are the ionic interaction between
the charged nitrogen and D98. Further π-cation interactions are observed between
the ligand and Y176 and F335. The top scored pose in the double mutant elicits
a π-cation-interaction with R104. The second pose in the double mutant shows a
π-π-interaction R104 and further an interaction between the nitrogen and S438.
It can be summarised, that the docking experiments can not explain the diﬀerence
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3.4.2.3 Cyproheptadine
The structural diﬀerence between cyproheptadine and imipramine is quite high: a
nitrogen is changed by a carbon at position 14, the bridge between the benzene
rings is double bonded as in carbamazepine. The N-methyl-piperidine ring is
connected via a double bond to the tricyclic ring system, further reducing the
degrees of freedom. Applying the docking protocol, none of the ﬁnal poses of this
compound in the showed a charged interaction between the nitrogen and D98.
The top scored pose is stabilized via π-cation interaction between R104 and the
tricyclic ring system and between the nitrogen and F335. This observation accords
to the low aﬃnity to SERT-WT. The aﬃnity increase in Y95F can not be explained
with the ﬁnally selected docking pose in this mutant. The distance between the
N-piperidine ring and F95 is to high to form a direct interaction. The poses of
cyproheptadine in I172A and Y95F+I172A are placed deeper in binding site 1
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3.5 Pharmacological Experiments
The competition binding experiments and the site directed mutagenesis were per-
formed by Subhodeep Sarker in the lab of Prof. Freissmuth within the cooperation
of the SFB35. The results will be reviewed shortly on the following pages.
EC50 WT I172A Y95F
imipramine 0.120 0.030 0.220
trimipramine 1.666 0.343 2.977
trimipramine 1.321 0.293 2.234
cyproheptadine 57.56 3.883 54.47
desloratadine 3.215 0.856 7.987
Table 3.23: Derived EC50 values
3.5.1 Mutations
To test the binding hypothesis of TCAs in hSERT in-vitro, additional to the mu-
tant SERT-Y95F, the point mutation I172A and the double mutant Y95F+I172A
have been created. The binding aﬃnity of trimipramine is about 600× lower than
that of imipramine, even though the structural diﬀerence is one methyl group
attached on the aminopropyl side chain. According to the binding mode, it is
hypothesized that this additional methyl group of trimipramine elicits a steric
clashes during the binding to SERT. For further testing, the assays were per-
formed on more rigid compounds: cyproheptadine and desloratadine (both used
as H1-antihistamines).
3.5.2 Assays
The methods applied for the experiments are described in detail in the references
6 and 140. The obtained aﬃnities for the compounds are given in ﬁgure 3.61.
3.5.2.1 Imipramine
As written above, the mutation of Y95F showed an aﬃnity decrease according to
the loss of a weak Hbond. As reported in reference 6, it was hypothesized that
water mediates the interaction between the ligand and Y95F. In the I172A mutant,
an aﬃnity increase of about three times compared to the WT was detected. The
double mutant exhibited an aﬃnity between the WT and I172A. In this case, the
increase of aﬃnity might be due to the characteristic of alanine to form α-helices.
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Figure 3.61: Summary of the derived IC50 values
A better adaptation of the protein to the side chain of imipramine might enhance
the aﬃnity, see ﬁgure 3.62.
Figure 3.62: 5HT uptake inhibition by imipram-
ine
Figure 3.63: 5HT uptake inhibition by trim-
ipramine
3.5.2.2 Trimipramine
As depicted in ﬁgure 3.63, trimipramine showed similar aﬃnities in the Y95F
mutant and WT. There might be a steric hindrance that avoids direct interaction
with Y95. Mutating I172A shows an aﬃnity increase of about 10 times. We
hypothesised that the removal of the bulk of I172 allows trimipramine to get deeper
into the binding site and is more stabilised by the better adaptation of TM3 to the
ligand. In this mutant, direct interaction with Y95 might be possible. The double
mutant shows a slight diﬀerence in the aﬃnity compared to the I172A mutant.
This suggests a possible interaction with Y95 only in the I172A mutant.
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Figure 3.64: 5HT uptake inhibition by cypro-
heptadine
Figure 3.65: 5HT uptake inhibition by deslorata-
dine
3.5.2.3 Cyproheptadine
The antihistamine cyproheptadine is a low aﬃnity ligand to SERT, 6000 to 7000×
lower than imipramine. The mutation of Y95F doubles the aﬃnity compared
to the wild type. A reason for this observation might be the more hydrophobic
environment in the binding site. The mutant I172A and the double mutant exhibit
similar aﬃnities (30 times higher than in WT). As seen in the experimental data
of trimipramine, also the binding of cyproheptadine can be bound stronger due to
reduced steric hindrance. The hydrogen bond between this compound and Y95
might be not established or not important for binding, since there was no diﬀerence
in aﬃnity between I172A and I172A+Y95F.
Regarding the geometry of the tricyclic ring system is more rigid due to an ad-
ditional double bond. As seen in the docking results, there might be a substantial
diﬀerence in the binding mode of cyproheptadine to SERT compared to imipram-
ine regarding the table of measured binding aﬃnities. In the docking poses, no
interaction between Y95 and CYP was observed in contrast to the experiments,
where the aﬃnity was increased by a factor of 2 compared to the wild type. Due
to its compact structure, cyproheptadine might be bound directly in the central
binding site.
3.5.2.4 Desloratadine
The second generation desloratadine exhibits a similar behaviour as trimipramine
concerning the aﬃnities in the WT and the mutants. Y95F reduces the aﬃnity to
one half compared to the WT. This observation suggests a direct or water mediated
interaction between the ligand and Y95. The I172A mutant increases the aﬃnity
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ring. The charged nitrogen instead is placed at the plane D98, F176 and F335
without any contact to residues, located in the S1 site, eg. Y95.
Regarding the measured aﬃnities, I172 is a key residue that increases the the
aﬃnity of all compounds measured. Since the piperidine ring is not in spatial
proximity of this residue, a substantially diﬀerent binding mode for cyproheptadine
and desloratadine has to be hypothesised.
3.7 Discussion
TCAs and SSRIs are displaced by 5HT in a concentration dependent manner, in-
dicating a competitive antidepressant site (near or at substrate site), that is mutu-
ally exclusive with the substrate binding site.126 Radioligand competition binding
experiments can be ﬁtted with the Cheng-Prusoﬀ relationship to competitive inhi-
bition for antidepressants and cocaine derivatives.6,258 Inhibition by SSRIs, TCAs
and cocaine derivatives traps the transporter in outward-occluded state, where
imipramine stabilises more open than ﬂuoxetine.1 Therefore, the homology model
of SERT in ‘open–to–out’ conformation, based on the crystal structure PDB ID
3F3A as template, was used for docking inhibitors. The resolved crystal struc-
tures of LeuT inhibited by TCAs can not be directly used to study TCA binding
on SERT, due to non competitive inhibition.188
Important residues for inhibitor recognition and binding known from in-vitro
and in-silico studies located in S1 site are Y95, D98, A169, I172, A173, M180,
F335, S438 and T439.126 As most important interaction, the salt bridge between
D98 and the nitrogen of TCAs is obligatory.122 But also Y176 and F335 are
supposed to prevent the closure of the S1, during the binding of inhibitors259 by π–
π interactions, stabilising the transporter in a blocked state. Cation–π interactions
of R104 with one of the aromatic moieties of TCAs contributes to the disruption
of the extracellular gate, which is preventing the transporter to close.
A mutation of the conserved residue S438T showed a direct interaction with
the dimethyl amino moiety of SSRIs and S438. The nor-derivative of citalopram
elicited a considerably higher aﬃnity on the mutant suggesting, that it is a key
residue for binding and selectivity at SERT-WT. The eﬀect was also observed
for TCAs, but with lower extent.125 The binding mode proposed in this study is
consistent with these ﬁndings. Although the ligand is placed in a diﬀerent binding
mode, the distance between the methyl group of imipramine and S438 is within a
range where steric hindrance might be possible.
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Using transporters from diﬀerent species elicited several residues responsible for
the diﬀerence in aﬃnity. A chimera of r and hSERT revealed F586 as determinant
for TCA recognition. In contrast, SSRIs, cocaine, amphetamines or 5HT were not
aﬀected.260
For SERT was reported, that F586 is important for TCA selectivity.69 In the
present model, F586 is located on TM12 and - based on the template LeuT - on
the dimer interface of SERT. SERT from zebraﬁsh showed higher aﬃnity towards
imipramine and desipramine, but lower aﬃnity to cocaine compared to hSERT.
the diﬀerences were tracked down to A505, L506 and especially I507, where the
aﬃnity of TCAs in the mutant I507L was reduced. This indicates a contribution
of the S2 site to the binding of imipramine.
Mutations in TM3 (Y163F, F170L, L182F, and F186S) also aﬀected imipramine
binding. S174S in the chimeric construct restored the aﬃnity.261 The residues
M180 and F513 were found to be responsible for the higher aﬃnity of ﬂuoxetine
and imipramine on hSERT compared to bSERT.92
The binding of imipramine was validated to be placed in the S1 site with
the diagnostic mutants F335F, A173M, and the double mutant.127 Using these
mutants, the testing of 10 derivatives of imipramine could show, that the aromatic
rings of imipramine are placed within the S1 site: 7 position near F335 and 3
position near A173 and T439.122 Compared to our study, only one of these two
locations is consistent with docking pose 3. The 7 position is also near to F335.
Since the binding mode diﬀers essentially, A173 and T439 are not in proximity of
the tricyclic ring, but near the dimethyl aminopropyl tail.
Intense research revealed a detailed picture of ligand and inhibitor binding
towards SERT. The results depend on the experimental setup and diﬀer, when
membrane preparations or living cells are used,262 that makes the interpretation of
the results diﬃcult.191 Single and multiple point mutations spread over the trans-
porter aﬀect the aﬃnity of TCAs. Several mutagenesis studies showed, that mutat-
ing residues far from the ligand binding site inﬂuence the binding and inhibition of
substrates and inhibitors. Mutation of the cysteines at position 147, 200, 369 and
540 caused loss in 5HT transport and imipramine or citalopram binding.263 The
mutation of S545 alters the cation dependence and reduces IMI aﬃnity without
aﬀecting citalopram binding.237 T178A and F263C increased transport rates, de-
creased potency of inhibitors, such as imipramine and cocaine.262 A triple mutant
of D209A+V212I+I262F increases desipramine and short imipramine aﬃnity.264
Despite competitive inhibition occurs in the substrate binding site, literature data
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suggests multiple action sites of drugs on NSS as also reported for DAT265 for DAT.
SERT, DAT and NET share 75 % total sequence identity and up to 90 % in the
binding site, diﬀerences in aﬃnity of TCAs or MPD are remarkably, suggesting a
‘recognition site’ located on the entry path of the transporters.56
There is still an ongoing discussion about the location of inhibitors of SERT.
As described previously, there are indications towards the binding of imipramine in
the S1 site. Mutations in an allosteric (low aﬃnity) site showed, that the binding
of inhibitors inﬂuences SERT as following: high aﬃnity blocks transport and the
low aﬃnity increases the dissociation of inhibitors.266,267 Recently, it has been
shown, that the binding of a second molecule of citalopram is possible in SERT.242
Taken together all these ﬁndings, it can be suggested, that at least two inter-
mediate binding orientations might be possible during the inhibition of SERT by
TCAs in the substrate entry path. Further experiments on the eﬀect of muta-
tion sites distant from both, the S1 and S2 site, have to be considered to draw a
complete picture of the inhibition of SERT by TCAs.
4Molecular Dynamics Simulations
To get deeper insights in the behaviour of the ligands within the binding pocket of
SERT, molecular dynamics simulations on the protein ligand complexes selected
from the docking experiment were performed. Docking shows a single snapshot,
but ligand binding is a dynamic process.
During the docking experiment, no water molecules were considered. To verify
the hypothesis of a water mediated hydrogen bond between Y95 and the charged
nitrogen of the ligand, the simulation within a simulation box ﬁlled with explicit
water molecules was necessary.
4.1 Preparation
The results of the docking and the pharmacological experiments indicated a bind-
ing mode of TCAs within the changeover of the S1 and the S2 site. Since the
MD simulations are very CPU intensive and the evaluation of many simulations is
time consuming, only the ﬁnally selected pose of group 3 of each compound was
simulated.
4.1.1 Ligand Parameterisation
The GROMOS96 forceﬁeld is parametrised for proteins. Due to the structural
diversity of small drug like molecules, the parameters have to be deﬁned manually
and derived from the forceﬁeld.268 Starting with imipramine, the parameters were
deﬁned by using the automated topology builder (ATB)269 to obtain an initial
topology. Imipramine was extracted from the docking pose in the wild type and
submitted to the ATB server. The GAUSSIAN09270 installed on the VSC was
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1. Water: 100 steps SD
2. Lipids: 500 steps SD
3. Sidechains+Ligand: 500 steps SD
4. Backbone: 500 steps SD
5. Water Equilibration for 10ps
6. Complete System: 100 steps SD
Equilibration Protocol:
1. 50ps Water free
2. 200ps + Lipids free
3. 250ps Prot.+Lig.: 500kcal·mol−1
4. 250ps Prot.+Lig.: 250kcal·mol−1
5. 250ps Prot.+Lig.: 100kcal·mol−1
bilayer waterbox
Figure 4.1: Protocol of the MD simulation.
used to optimise the geometry of the molecule. The co-crystallised imipramine
from the crystal structure of LeuT PDB ID 2Q72188 was analysed regarding the
geometry. The information about bond lengths, angles and partial charges ob-
tained were compared with the parameters of the GROMOS forceﬁeld and applied
to the structure of imipramine. The parameters of the ligand were ﬁnalised man-
ually. To validate the parameters for the four ligands, short MD simulations of
within a water box were performed. The parameter ﬁle for imipramine can be
found in appendix A.3. The graphical representation with the parameters used
and the charge groups deﬁned can be found in the corresponding subsection.
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4.1.2 Import into GROMACS
The protein ligand complexes were exported as a .pdb ﬁle containing the coor-
dinates of all heavy atoms and hydrogens. Only the protein was imported into
gromacs by using the pdb2gmx function. The ligand information was added to
the .gro and the .top ﬁle, which are used within GROMACS as structure and
topology ﬁles, respectively. Having the complex imported, the simulation box was
ﬁlled with water, using the function genbox.
4.2 Simulation in a Water Box
In a ﬁrst step, the protein ligand complexes were simulated within a water box, in
order to save calculation time of the 29 simulations. To avoid protein movements,
the backbone beyond 12 Å around the ligand was restrained In a ﬁrst attempt,
the simulation setup did not contain a membrane bilayer and was prepared in a
very minimalistic manner. After a steepest descent minimisation of 5000 steps,
the system was simulated for 15 ns (timestep 2 ns) without equilibration steps.
4.2.1 Evaluation
Analysing these simulations showed, that several artefacts occurred, that made
the interpretation of the results diﬃcult. Unphysiological behaviour, such as the
water access through the TMDs was observed.
The analysis of the simulations was performed with regard to the deviations of
the protein–backbone and the ligand, and further based on distances and Hbonds
between residue 95 and the nitrogen of the ligand. Severe failures were observed in
several simulations. As a main bottleneck, the access of water molecules through
the transmembrane domains into the S1 site was observed. As a consequence, the
ligand was pushed out of the binding site. Further, the solvation of the Cl– ion
occurred, which moved into the simulation box:
• The distance between the binding site and the membrane interface of the
protein ranges from 12 to 16 Å. Solvating the protein led to water ﬁlled
cavities of the protein membrane interface, where the distance of the water
molecules and the binding site is between 8 and 12 Å, which is within the
cutoﬀ set for the Van der Waals and Coulomb interactions. As consequence,
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in more than 50 % of the simulations water access from the transmembrane
region into the S1 site was possible.
• The binding site was solvated with 6 to 10 water molecules. Na1 moved from
its binding site into the S1 site.
• Adding the counterions resulted in the placement of a Cl- ion in the S1 site.
• During one simulation, the Cl- ion was solvated by bulk water and was
subsequently removed into the waterbox.
4.2.2 Results
Despite the simulation artefacts in most of the simulations, some of them revealed
surprising data. The simulation of imipramine in the mutant I172A established
a stable water bridged hydrogen bond after 12 ns between the ligand nitrogen
and the Y95-OH. This mediating water molecule was further interacting with a
vicinal water molecule, that for itself connected Y95-BB with Y176-OH. In the
simulations, which were stable and had little or no water access through the TMDs,
we observed several water spots in the hydrophilic region of the S1 site, near the
plane D98, Y95, Y176, S438. Regarding the evaluation artefacts, it was decided
to run the simulations in a full membrane embedded system. The discussion of
the results from the simulations within the water box is following below.
4.3 Simulation in a Lipid Bilayer
It is known, that NSS are located within lipid raft microdomains.1,29,33 Further, it
has been shown, that the depletion of membrane cholesterol resulted in a decrease
of SERT activity due to a loss of substrate aﬃnity and reduced Vmax. These
results suggest a modulation of functional properties by cholesterol, which might
be able to stabilise SERT in an optimally active form within the bilayer.271
The constraints on the backbone atoms applied in the ﬁrst simulation within
the water box avoided the adaptation of the protein to the ligand. This circum-
stance allowed the ligands to move. To overcome the problems of the simulation
in the water box alone, a lipid bilayer was prepared for the simulations.
4.3.1 Membrane Preparation
The lipophilic environment of a membrane protein is of essential importance dur-
ing MD simulations. A simpliﬁed membrane system to increase the speed of the
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calculations can be applied.272 For the present study, the lipophilic environment
for the TMDs of SERT was provided by a lipid bilayer. The lipids for the mem-
brane used for simulations of neuronal membrane proteins is 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphocholine (POPC).194 Despite the importance of cholesterol for
transporter function,243,271 it was not considered for the simulations, since the
scope of the study is analysis of the protein ligand interactions rather than protein
function. Using the Membrane Generator function of VMD, a bilayer of 9.5 nm2
was created and solvated. The structure was imported into GROMACS, using
the parameter ﬁle from the group of Prof. Tieleman, downloaded from http:
//moose.bio.ucalgary.ca/index.php?page=Structures_and_Topologies and
attached in the appendix. The lipophilic tails are treated as united atoms. Af-
ter minimisation, the system was simulated for 1ns within the NVT ensemble. It
has been shown, that the self aggregation of lipids into a bilayer occurs within 20
ns.273 For the present study, the timescale for the membrane equilibration was set
to this value. Checking the thickness of the membrane with GridMat274 elicited
that the thickness is little higher, than observed in experiments. But it is known,
that within lipid rafts, the membrane has an increased thickness. It was further
checked the area per lipid ranging from 51 to 57 Å2 on the lower leaﬂet and 54 to
60 Å2 on the upper leaﬂet, which is lower than 65.8 Å2 for POPC molecules.275
4.3.2 Embedding
The protein ligand complexes were initially solvated in water to allow the place-
ment of water molecules in the S1 site, if possible. Water molecules within 4.5
Å around the ligand were retained within the complex resulting in 2 to 6 water
molecules present in the S1 site. These complexes were embedded into the mem-
brane using the g_membed program.276 The embedded complex was subsequently
solvated within the ﬁnal simulation box and simulated for 1 ns within the NVT en-
semble by keeping the membrane and the complex ﬁxed to allow the reorientation
of the water molecules.
4.3.3 Minimisation
A stepwise minimisation protocol was applied on the system, adapted from refer-
ence 185 in consecutive order:
• water (50 steps SD)
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• membrane (100 steps SD)
• protein Hs (100 steps SD)
• protein Side chains and ligand (100 steps SD)
• protein backbone (100 steps SD)
4.3.4 Equilibration
The system equilibration started with a simulation of 50 ps in the NVT ensemble
by keeping the protein ligand complex and the membrane ﬁxed to allow the water
molecules to reorientate. Subsequently, the lipid bilayer was equilibrated for 200
ps, still with position restraints on the protein ligand complex. Finally, the release
of the system was performed by lowering the constraints on the atoms of the
complex from 1000 kcal/mol · nm2 to 500, 250 and 100, which resulted in 3 times
250 ps MD simulation within the NVT ensemble. The structure, obtained at the
end of the equilibration was used as starting structure for the production run. In
appendix A.3, the settings for the ﬁnal equilibration step are attached.
4.3.5 Production
The computationally most expensive step was the production run of the equili-
brated system. The simulation was performed for 10 ns in the NPT ensemble,
using a timestep of 2 fs. In appendix A.3, the simulation parameters can be
viewed. The access to the VSC allowed us, to calculate all the simulations within
a reasonable timescale. One simulation took about 7 hours on 96 CPUs, where up
to 6 simulations were calculated simultaneously. To perform 29 simulations on a
single computer with 12 CPUs would have taken ≈ 2,5 months of calculation time.
4.4 Evaluation
The simulations are evaluated regarding diﬀerent geometrical and energetical pa-
rameters. To draw a detailed picture of the simulations in 2D, several parameters
were evaluated and described below.
Descritpion of the figures
In order to thet an overview of each simulation, the evaluation of all (and for
trimipramine selected) simulations are given on the following pages.
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The trajectories are illustrated in four ﬁgures from the binding site and the
domains aligning the substrate translocation pathway right after a short verbal
description of the trajectory:
a The endpoint of the simulation after 10 ns of production. The orientation of
residues aligning the binding site are colour coded according to the TMDs
(light red TM1, dark red TM3, orange TM6, brown TM8, cyan TM10 and
yellow EL4), shown in ‘line’ representation. The ligand is shown in ‘licorice’
representation in the core of the protein.
b Movement of the ligand during the simulation. The colour code corresponds
to the timestep from blue (begin at 0) over white to red (end at 10000).
Every 10th frame was considered in the ﬁgure
c Movements of important side chains of TM1 (Y95, D98, R104), TM3 (I172,
Y175, Y176), TM6 (F335, F341), TM8 (S438) and TM10 (E493) are shown
and colour coded similarly to (b).
d Stable water molecules and their motions are depicted as described in (a).
The Simulation overview gives a general impression of the simulation:
Protein movements of the trajectory are shown in subﬁgure (a). This il-
lustrates domain movements an generally the stability of the protein. The protein
is represented as ‘cylinders’ and ‘tubes’ interpreted as α-helices and loops respec-
tively. Each 100th frame is printed. The hydrophilic headgroups of the membrane
are represented as VdW surface and the lipid tails are depicted as sticks. Also
here, every 100th frame was printed. In the core of the ﬁgure, the ligand can be
found. Every 10th frame was used for depiction. The colour code illustrates the
time step from blue (begin) over white (mid) to red (end) of the simulation.
Protein ligand interactions as depicted in subﬁgure (b) are calculated
from the distance of the ligand to the protein. Atoms within a residue of 6 Å
are considered. The colour code of the ﬁgure is going from red (atoms, that are
frequently within 4.5 Å of the ligand) over white to blue (no interaction). This
ﬁgure gives an impression of the localisation of the ligand within the protein.
The membrane thickness was evaluated from the endpoint of the simula-
tion. It was one parameter to validate the lipid bilayer. The ﬁgures were created
using GridMAT274 and GNUPLOT. The colour scale is depicted on the right side
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of the ﬁgure and depicts the membrane thickness. At the end of the simulation it
reached the experimentally determined value of ∼ 30 Å.
Deviations are shown on the next page:
RMSF was calculated from each Cα atom. The graph shows the movements
of these atoms from the initial position. TM1, 3, 6, 8 and 10 are marked, as well
as EL2 and 4.
RMSD of the backbone is an important parameter to check the stability
of the protein during the simulation. The plot starts from the equilibration, at
t = −1000, which is separated from the production run, (0 < t < 10000), by a
vertical line. The timestep (t) is counted in picoseconds. Additionally the RMSD
of the ligand is included in the plot as violet graph.
The following parameters of the simulation are depicted as a function of t:
Plots on the bottom left
Volume (V) in [nm3]
Pressure (P) in [bar]
Density (ρ) in [ kg
m3
]
Plots on the bottom right
Box size (BS) in [nm]. The semi-isotropic pressure coupling is isotropic for
the x and y direction, but diﬀerent in the z direction. The length of the x/y (gray)
and the z (black) axis is shown.
Temperature (T) in [◦K]
Total energy (Etot) in [kcalmol ]
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Distances are calculated from the nitrogen of the ligand to three residues of
special interest ((a)Y176, (b)D98 and (d)Y/F95) and from a central carbon of the
ligand’s side chain (IMI-C17, RTR-C18, CYP/DES-C16) to Cα of I172 (c). These
graphs also include the RMSD of the ligand for clarity. These graphs should give
an impression of the ligand movement within the pocket, as main focus of interest
for the present study.
Waters seem to be present during inhibitor binding. To ﬁgure out interactions
with the oxygen of stable water molecules, the distances to (a) Y176, (b) D98, (c)
the nitrogen of the ligand and (d) Y/F95 have been calculated as well as the RMSD.
Water molecules for the calculation were considered, if they were interacting at
least for more than 10 % of the trajectory with the selected atoms. In case of many
water molecules – as seen in the simulations of cyproheptadine and desloratadine
– the threshold was increased up to 50 %
Experimental data The simulations have been further analysed with regard
to the experimental data in section 3.5. It is aimed to explain the ﬁndings of the
assays with the simulations.
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4.4.1.1 Imipramine, Wild Type, Pose 1
Trajectories
In the beginning, large protein movements were observed after the reduction of the
restraints. The ligand was ﬂuctuating in the beginning, but moved deeper into S1,
where it is stabilised after 2 ns. The aromatic rings of the ligand are stabilised over
T-stacking interactions with Y176 and Y175 and a cation–π interaction with R104.
A water bridged Hbond between the IMI-NH+3 and Y95-OH occurs between 5.7 and
7.2 ns. This bridge is more stable with the Y95-BB carbonyl. A Hbond–network
with 3 water molecules can be observed in the S1 site. Water sites are present near
Y95-OH and between D98 and Y95, see section 4.5.3. Since imipramine is a high
aﬃnity ligand, the stability of the pose during the simulation is in accordance to
the experimental data.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.3: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3



















Figure 4.4: Simulation overview.
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4.4.1.2 Imipramine, Wild Type, Pose 2
Trajectories
Compared to the ﬁrst simulation of imipramine in the WT, only slight domain
movements were observed in the beginning of the ligand. The ligand is located
deep in S1 site, shows ﬂuctuations between 2 and 6 ns of the simulation and is
stabilised for the rest of the remaining simulation time. The RMSD from the
starting structure is about 1.5 Å. Y175 undergoes a rotation and leaves space to
allow movements of the tricyclic ring system. The nitrogen of the ligand is bound
very stable to D98, over both a Hbond and electrostatically. The general trend
of the simulation shows, that the pose moves towards a conformation as found in
group 2 poses.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.9: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3




























4.4.1.3 Imipramine, Y95F Mutant
Trajectories
Slight movements of the system were observed in the beginning of the simulation.
The pose is tightly bound to D98 via Hbond and ionic interaction. The tricyclic
ring is unstable and rotates within between two conformations in the changeover of
the S1 and the S2 site. Y176 and F335 are interacting with the aromatic rings. The
ligand tends to move towards a placement similar to group 2. Two water molecules
are present in the binding site over whole simulation. Three water molecules are
moving into the binding site during the simulation, but are not stable. Although
the protein is quite stable over the simulation, the loss in aﬃnity can not be
explained.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.15: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3
























Figure 4.16: Simulation overview.
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4.4.1.4 Imipramine, I172A Mutant
Trajectories
Contrary to the expectation, that I172A leaves space for the ligand to converge
to pose 2, imipramine is kept in place with the tricyclic ring system in the S2 site
and the side chain pointing into the binding site. Y175 and W103 stabilise the
aromatic rings in the S2 site and a stable Hbond with IMI-NH+3 and D98 is present
over the trajectory with few interactions with Y176. 3 water molecules in the S1
site are forming networks with Y95SC, Y95BB, Y176SC, S438SC and Y175SC.
This pose is very stable and therefore is in agreement with the experimental data
with respect to the stability of the ligand in the binding pocket.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.21: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3























4.4.1.5 Imipramine, Y95F+I172A Mutant
Trajectories
The pose is stable over the simulation, even if the conformation of the ligand seems
not to be relaxed. From the starting point in the S2 site, the tricyclic ring moves
more downwards to Y176 at 3.15 ns after a rotation of Y175 which allowed the
movement of the ligand. T-stacking interactions are found between Y176 and F335
and the aromatic rings. Two water moleucules in the S1 site are networking. The
disassembly of TM3 and TM1 indicates, that the homology model is not stable.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.27: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3






























The ligand is placed according the proposed binding mode for TCAs. It is stable in
the changeover of the S2 site (tricyclic ring below EL4) and the S1 site (aliphatic
chain) but ﬂuctuates during the simulation. After 3 ns, a stable Hbond between the
charged nitrogen and D98 is established which is alternating to Y176. The tricyclic
ring is π-stacking with Y175, F335 communicates via a cation–π interaction with
the charged nitrogen. Two water molecules are present in the S1 site from the
beginning. After 4 ns, two further water molecules access the S1 site and establish
networks between Y95 and D98 and the other molecules. Regarding the protein,
EL4 is disassembling during the simulation, indicating an unstable model.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.34: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3



















Figure 4.35: Simulation overview.
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4.4.2.2 S-Trimipramine, WT
Trajectories
The simulation was started from the pose, where the methyl group of the aliphatic
chain is orientated towards I172. Within the ﬁrst 500 ps, the tail of trimipramine
rotates to the opposite direction allowing a stable Hbond to D98, which is present
over the rest of the simulation. Generally, the pose converges to group 2 and stays
very stable. Near I172 and T497 there is space for one aromatic ring, while the
other aromatic moiety is placed between R104 and E493. This simulation is not
in agreement with our proposed binding mode of the TCAs in SERT. Also the
experimental data can not be explained with this simulation, since trimipramine
binds with low aﬃnity. As seen in the simulation of R-trimipramine, EL4 is also
disassembling in the present simulation.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.40: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3






























The tricyclic ring system is located in S2, interacting with Y176 and F335. The
nitrogen interacts stable with D98 for 8ns. After this point, the nitrogen group
rotates towards the water molecules and takes part in the ﬂuctuating Hbond net-
work. The conformational change of F335 allows the ligand trap deeper into the
S1 site. The endpoint of the simulation shows, that the aliphatic chain of the
ligand is jolted, which indicates high conformational energy. Generally the simula-
tion is in aggreement with the proposed binding mode and the experimental data.
Regarding the conformational energy of the ligand, further reﬁnement might be
necessary.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.46: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3
























Figure 4.47: Simulation overview.
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4.4.2.4 S-Trimipramine, I172A
Trajectories
The tricyclic ring is located in S2, the methyl group points towards the intracellular
side and the proton on the nitrogen is orientated towards D98 allowing a direct
Hbond. A rotation of the dimethyl amine group allows the orientation of the
proton on the nitrogen towards Y95-OH, where a Hbond with Y95-OH over a
water molecule is established. According to the binding hypothesis, this simulation
is consistent with the experimental data of than increased aﬃnity compared to the
wild type. As seen in previous simulations, also here EL4 is disassembling. The
unwound region of TM1 in this model is not stable and starts disassembling the
extracellular part TM1.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.52: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3

























From the beginning of the simulation, a stable Hbond from the protonated ni-
trogen to D98 is established. The methyl group of the aliphatic side chain of
R-trimipramine points in the same direction, since it is energetically favoured.
Both the Hbond and the ionic interaction stabilises the aliphatic tail. The tri-
cyclic moiety shows minor ﬂuctuations and is interacting by T- and π-stacking
with Y176 and F335. The S1 site contains 2 water molecules, where one is perma-
nent bridging D98 and Y176, the other water bridges F95-BB and S438-SC. The
ligand is stable in a conformation according to the binding hypothesis. Regarding
the methyl group, no steric interaction is observed with I172. This simulation does
not explain the changes in aﬃnity, since the ligand is bound very stable.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.58: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3



















Figure 4.59: Simulation overview.
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4.4.2.6 S-Trimipramine, Y95F
Trajectories
The ligand is placed in the changeover of the S1 and the S2 site according to the
binding hypothesis. The nitrogen is kept in place in the plane Y176 and D98,
which allows a stable Hbond between nitrogen and Y176-OH. The methyl group
of the side chain of the ligand is orientated into the same direction. A cation-π
interaction with the ligand and R104, and hydrophobic interactions with I179 hold
the tricyclic ring system in place. Generally the ligand stays very stable over the
simulation. 2 water molecules connect Y95-BB and Y176-SC, but form also a
ﬂuctuating Hbond network with the nitrogen of the ligand and D98. Regarding
the RMSD of the backbone, which is increasing over the trajectory, there are
indications, that the homology model is not stable.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.64: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3






























Starting from a pose, which is placed deep in the S1 site, the tricyclic ring system
shows large movements between 2 and 3 ns. A rotation by 90◦ can be observed.
The interacting residues Y176, F335 allow large movements of the ligand by con-
formational changes. The additional proton of the nitrogen is orientated towards
D98, which is also true for the additional methyl group on the side chain of the
ligand. The ligand establishes a stable Hbond with D98 and stays in place. Only
1 stable water molecule is observed, interacting with Y95-BB and bridges interac-
tions with Y176 and the nitrogen of the ligand. This simulation does not conﬁrm
our binding hypothesis.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.70: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3



















Figure 4.71: Simulation overview.
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4.4.2.8 S-Trimipramine, Y95F+I172A
Trajectories
Heavy conformational changes of the ligand during the simulations are observed.
Starting in the S2 site with the methyl group pointing towards TM1, the ligand
moves deeper into the S1 and ﬁlls the place of I172A with the methyl group
within the ﬁrst ns. A network of Hbonds with water molecules located in the S1
site is established and of good stability. Y95F partly interacts with the aromatic
hydrogens. The tricyclic moiety is stabilised by π-π stacking interactions with
Y176 on the one and T-stacking with F335 on the other side of the seven–membered
ring. EL4 and TM3 on the intracellular face of the domain are very unstable and
start disassembling at the end of the simulation. The increasing RMSD of the
protein backbone indicates an unstable protein.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.76: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3
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4.4.3.1 Cyproheptadine, Wild Type
Trajectories
The pose is located below EL4 far in the S2 site. No part of the molecule is located
near or interacting with residues in the S1 site. Interactions can be observed with
the nitrogen and Y176 or D98. In general, the system is very unstable, although
the ligand is kept in place over the simulation time. The S1 site contains several
water molecules, where the hydrophobic part is devoid of water. Since it is known
from the experiments, that mutations on Y95 and I172 inﬂuence the binding, the
pose of cyproheptadine selected by the protocol is not correct. The binding mode
might diﬀer substantially from that of imipramine and trimipramine, as mentioned
previously. The experiments can therefore not be explained by this simulation.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.83: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3






























Similar observations as in the simulation of the WT were done here, too. The
ligand is placed in the S1 site without any interaction with residues in the S1 site.
Regarding the backbone RMSD, the simulation seems to be more unstable than
that of the WT, but can not explain the experimental aﬃnity data as well. As in
the simulation of the WT, the distance of the nitrogen to Y95 or I172 is very high.
Several water molecules are ﬂuctuating in the central binding site, but do not form
stable Hbonds. During the simulation, the ligand does not move towards the S1
site although the mutation I172A has an eﬀect on the aﬃnity in the experiment.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.89: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3
























Figure 4.90: Simulation overview.
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4.4.3.3 Cyproheptadine, Y95F
Trajectories
As observed in both simulations previously described, the ligand is very stable in
S2 site below EL4 and the plane D98, Y176 and F335. The tricyclic ring is located
near W103 and I179, surrounded by bulk water. Since no ligand is present, Na1
is trapping into the S1 site, solvated by several water molecules. Regarding the
simulations of cyproheptadine so far, mutations of residues in the central binding
site should not have any eﬀect on the aﬃnity of the ligand. The docking poses
used as starting point for the simulations are not correct for cyproheptadine.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.95: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3






























In contrast to the previous simulations, the starting conformation of the ligand is
in the changeover of S1 and S2. After 3.5 ns, cyproheptadine traps deeper into S1
site and rotates by almost 180◦, which allows Hbonding with D98. The placement
of the ligand converges towards group 2 and seems to be squeezed. Also here,
the experimental data can not be explained by the simulations. Regarding the
simulations and docking experiments so far, the binding might occur directly in
the S1 site.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.101: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3
























4.4.4.1 Desloratadine, Wild Type
Trajectories
Starting from the docking pose in the cangeover of S1 and S2 site, the pose shows
a very stable behaviour over the whole simulation after a ﬁrst movement. The
nitrogen of the piperidine ring is placed near D98 and the tricyclic moiety is kept
in place by aromatic interactions with Y175, Y176 and F335. Two water molecules
establish a Hbond network in the S1 site surrounded by Y95-SC, D98-SC, S438-
SC, Y176-SC and the nitrogen of the ligand. Compared to the simulations of
cyproheptadine, ﬁts more into the binding hypothesis. Generally, the simulation
is very stable over the simulation time.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.108: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3
























Figure 4.109: Simulation overview.
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4.4.4.2 Desloratadine, I172A
Trajectories
The ligand starts from a similar position as observed in theWT. Desloratadine soon
traps into S1 site and converges towards group 2. Compared to trimipramine, the
more compact structure might be bound easier in the S1 site, where one aromatic
ring is located in the changeover of the S1 and S2 site. In the beginning of the
simulation, the nitrogen interacts directly with Y95-OH and shifts during the
simulation to Y95-BB and S438-SC. The aromatic moiety, which is carrying the
chlorine atom is orientated towards the halogen binding pocket. Generally, it can
be observed, that the binding mode, as obtained from the docking is not correct.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.114: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3

























The starting point of the simulation is similar to the simulation of the I172A
mutant. The diﬀerence is the location of the Cl atom, which is placed near TM10.
In an early step of the simulation, the ligand is placed according to group 2 by
a slight movement towards S1. Important interactions are observed between the
nitrogen of the ligand and S438, but also with a water molecule and F95-BB. In
contrast to the previous simulation, the Cl atom is placed deep in S1. Regarding
the binding aﬃnity, the ligand is relatively stable, which is not in agreement with
the aﬃnity data measured.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.120: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3
























Figure 4.121: Simulation overview.
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4.4.4.4 Desloratadine, Y95F+I172A
Trajectories
The starting point of the docking pose of desloratadine in the double mutant
Y95F+I172A is more like the poses of cyproheptadine. Located more in the S2
site, the ligand moves further towards the extracellular space during the simula-
tion. Stable Hbonding is observed with D98-SC and F335-BB. in the end 5 water
molecules are located in the S1 site and are weakly networking. Interactions of
the water molecules were found with S438-SC, F335-BB, F95-BB. Experimentally,
the diﬀerence in aﬃnity of desloratadine to SERT-I172A and SERT-Y95F+I172A
compared to the WT is similar. This observation can not be explained with this
simulation.
(a) Endpoint (b) Ligand (c) Sidechains (d) Solutes
Figure 4.126: Detailed representations of the trajectories.
(a) Protein movement
(b) Protein ligand interactions
’50x50_average_pbc_gnuplot.dat’ matrix using (1+$1):(1+$2):3
























Figure 4.127: Simulation overview.
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4.5 Results and Discussion
The SERT, but also DAT and NET, are studied extensively in-vitro and in-silico.
Simulations give insights into the molecular behaviour of small organic compounds
to macromolecules. The timescale of transport for SERT is between 0.1 and 10
seconds. Compared to the timescale of MD simulations, where 10 nano- to few
microseconds can be calculated,1 it is obvious, that only a snapshot can be anal-
ysed. In this light, simulations in greater time scales might be necessary. But as
seen in the simulations presented here, an important factor of a successful simu-
lation, that explains experiments in detail, begins with a good starting structure.
The simulations are important for further reﬁnement of the model as well as for
reﬁning the binding hypothesis. Some simulations with respect to the experiments
suggest a binding mode, where the bulky aromatic residues Y175, Y176, F335 and
F341 stabilise the tricyclic ring in the S2 site, while the aliphatic or cyclic moiety
is bound in the S1 site by forming interactions with D98, Y95, I172, S438 and pu-
tative water molecules. For cyproheptadine and also for desloratadine, a diﬀerent
binding mode seems to be present during the binding to SERT.
4.5.1 Validation of the Docking Poses
MD simulations are used to describe dynamic properties of protein–ligand–interactions.194
The result depends on the selection of part of the system, which is in the focus of
the study. In the present study, MD simulations were used to validate the stability
of the obtained docking poses and further to analyse the behaviour of the ligand.
This was done by supervision of the deviations of the ligand and the protein, and
the distances between selected atoms of the ligand and the protein. Most of the
simulations revealed, that the ligand behaves relatively stable in the docked pose,
regardless of the aﬃnity.
The simulations could show, that the docking poses of cyproheptadine are not
conﬁrm with the experimental data, even if the binding hypothesis is fulﬁlled. The
simulation in the double mutant shows interactions with residues in the S1 site.
The simulations and the experimental data suggest, that cyproheptadine is bound
directly in the S1 site, similar to group 2, where the tricyclic ring occupies the
changeover of the S1 and the S2 site.
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4.5.2 Reduced flexibility of side chain
Trimipramine showed an interesting behaviour, regarding the aliphatic side chain.
As mentioned previously, the additional methyl group reduces the binding aﬃnity
by orders of magnitude. The simulations showed, that the methylated dimethyl
aminopropyl side chain is very restricted in ﬂexibility. This prevents the charged
nitrogen to form interactions with diﬀerent residues in the binding site. The pro-
tonated nitrogen is allowed to form directed Hbonds dependent on the direction
of the methyl group.131 In the simulations of S-trimipramine in the I172A mutant,
the methyl group is able to occupy the space near A172, where a water bridged
Hbond with Y95F is possible. It has been shown, that the minimum conformation
of trimipramine forces an explicit direction of the charged nitrogen towards the
methyl group.131 Rotations are possible over the ﬁrst bond between N14 and C16.
If trimipramine binds according to the proposed binding mode, a Hbond is estab-
lished towards D98, In that case, the methyl group is orientated into the same
direction. This might explain the low eﬀective mutation of SERT-Y95F. In con-
trast, the I172A mutant is hypothesised to leave space for the methyl group. Then,
a direct interaction with Y95 might be possible, as observed in the simulation of
S-trimipramine in the I172A mutant.
4.5.3 The Role of Water
Concerning the explicit water molecules, it could have been shown, that both the
stability and bridged interactions are possible. Water interactions during protein
ligand binding gains more and more interest in drug design. These interactions are
of crucial importance of the binding and recognition, especially in enzymes, where
often water bridges the hydrogen bonds between the ligand and the protein and
therefore contributes to the binding.277 In-silico studies on CYP-2D6 showed an
increase in the reliability of the prediction of the active site.278 Water is ubiquitous
in living cells. But also in crystal structures, water might be present, even if it
is not detected due to a high B-factor. 3 to 4 water molecules can be involved in
ligand binding acting as hydrogen bond donor and acceptor, but also for bridging
interactions.279 The crystal structure of LeuT PDB ID 2A65 is devoid of water
in the S1 site. One water molecule was detected in the unwound region of TM6,
near the substrate binding site.84 The stable water molecule in this region was
present in most of the simulations. The ‘open-to-out’ conformation, inhibited
by tryptophan, revealed 4 water molecules within the S1 site,2 indicating water
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mediated inhibition.
Water transport in the brain is important for the homoeostasis, cell volume and
the dimensions of extracellular space. It is transported through water channels/-
porines, or co-transported with organic and inorganic ions.280 It is also discussed,
if the water transport in neurons and glial cells occurs through Na+ dependent
transport proteins during reuptake of neurotransmitter or the removal of metabo-
lites.281 In case of EAAT1, GAT1 and SGLT, water transport was measured of
an amount of ∼ 175 to 200 molecules per cycle. The co-transport arises from
the coupling between water and the substrate in the pocket, where the transport
capacity depends on the substrate size. These transporter also might function as
passive water channels, maybe during the ‘leak–channel–mode’.282,283
The indication of a putative water molecule within the binding pocket of SERT
gave the docking pose of imipramine accompanied with the calculation of ∆G
between the WT and the Y95F mutant. The representation of the surface within
the binding pocket gave a further hint. One of the aims of the MD simulations
was to detect, if there might be stable water molecules. We observed in several
simulations, that 2 to 4 water molecules are bound very stable, several over more
than 75 % of the trajectory. These ﬁndings indicate, that water might play an
important role in – at least – inhibitor binding to SERT, see ﬁgure 4.132, 4.134a,
4.133a and 4.134b.
Figure 4.132 shows the occurrence of a hydrogen bond for the last 2 ns of a 15
ns simulation of imipramine in the SERT-I172A only in a water box. Both water
molecules have been present from the beginning. The depiction of the abidance of
the water molecules shows, that it moves within spheres, see ﬁgure 4.133a. This
indicates, that water access and occurrence within the S1 site of SERT might be
possible during ligand binding.
In the simulation of imipramine in the wild type embedded in the membrane,
the hydrogen bond bridge between the nitrogen and Y95 was detected for 1/2 ns.
This indicates, that the binding of imipramine in the S1 site might be mediated
by water, see ﬁgures 4.134a and 4.134b. The structural information out of this
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Figure 4.135: Example of a bulk water molecule, accessing the central binding site through TMD
region.
TM10, it was observed that the membrane spanning helix was kinked. As these
structures are highly stable, the focus during modelling has to be drawn on the
correct orientations of the hydrogen bonding of the backbone.
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Table 5.1: Number of resulting docking poses.
side chain) with similar conformation. Based on the experiments presented here,
it is probable, that the butterﬂy ‘sits’ in the S2 site having its trunk in the S1
site. The existence of the HBP187 in the S2 site supports the hypothesis, since the
‘wings’ of SSRIs carry halogens.
5.1.2 Docking into SERT containg structural water
The similar geometry of TCAs and some SSRIs suggest a similar binding mode. To
validate the binding hypothesis including the structural water molecule bridging a
hydrogen bond from the nitrogen of the ligand to the side chain of Y95 in-silico,
the sapshot of the simulation of imipramine in the I172A mutant at 1409 ps was
used. The snapshot was prepared for docking as following:
• Using the Rotamer Explorer in MOE to remutate A172 back to I172.
• Correct the elements of the ions (C to Cl– and N to Na+ by moving the
abbreviation into the respective column of the .pdb ﬁle)
• Assign charges with the function Fix Charges in MOE
• Adding hydrogens with the Protonate 3D function
• Stepwise minimisation using the minimisation script, shown in appendix A.2.
The docking protocol as written in section 3.1 was applied on imipramine,
paroxetine, R- and S-ﬂuoxetine and S-citalopram. Because of the water molecule
near Y95, the space in the S1 site is more limited. Group 1 and 2 as presented above
were not possible. The selection of the docking poses of imipramine revealed only
placements similar to group 3, which was experimentally validated. The poses
of the SSRIs docked were ﬁnally selected with respect to the binding mode of
imipramine. The number of poses obtained is depicted in table 5.1. Figure 5.2
shows the results of the docking experiment with regard to the common geometry
and depicted as an overlay of the exported snapshot.
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More recently, crystal structures of LeuT with bound ﬂuoxetine and sertraline were
published.187 The location of these SSRIs is in the S2 site, as found in the crystal
structures of LeuT with bound imipramine.123,188 Mutations within the S2 site of
hSERT revealed the existence of a HBP, see section 2.4. Residues I179 and Y175
decreased the aﬃnity of SSRIs without eﬀect on TCA binding and residues K490
and A401 dramatically decrease sertraline aﬃnity. Fluoxetine is not aﬀected of
these mutations and might bind more deeply.187 Most recently, it has been shown,
that two molecules of citalopram can be bound to SERT: one in the S1 site and
the second in an allosteric site near EL4.242 As discussed previously, modifying
the entry path of substrates or inhibitors will have an eﬀect on the aﬃnity. Taken
together, it can be assumed, that during the ligand entry, multiple intermediate
states might be possible.
5.2 Pharmacophore Modelling
The overlay of the minimized structure of ﬂuoxetine and S-citalopram with imi-
pramine showed a geometrical similarity. Even if the chemical class is diﬀerent,
these compounds share similar pharmacophore features, while imipramine lacks
halogens in the structure. Regarding the 3D structures of imipramine, citalopram
and ﬂuoxetine the following features might be extracted:
1 two bulky/aromatic residues connected by a chain of 1 to 2 atoms
2 attached Hbond-acceptors (not obligatory)
3 the connection of 1 should contain a Hbond acceptor (selectivity? - Y175/R104)
4 steric restrictions below the bulky/aromatic residues (Y175, Y176, F341)
5 an aliphatic chain within a range of of 3 to 5 atoms (might be bulky near
the nitrogen)
6 a charged Nitrogen at the end of the chain (charge to D98/Hbond-donor to
Y95)
Figure 5.3 shows simple representations of most prominent SSRIs and imipram-
ine. The color code is according to the pharmacophore features, explained in the
caption.
The pharmacophore model was created using Ligandscout8 based on (i) the
docking pose of imipramine, (ii) the re-mutated snapshot of the MD simulation
of imipramine in the I172A mutant with the water bridged hydrogen bond and
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5.3 Virtual Screening
Based on the pharmacophore model new potentially active compounds on SERT
are aimed to be elucidated. The database selected for screening was from the com-
pany ‘Life chemicals, Ltd’ (www.lifechem.com). It contains > 300 000 purchasable
and drug like molecules and oﬀer them on stock.
5.3.1 Database Preparation
In a ﬁrst step, the database (as .sdf ﬁle) was imported into a MOE database.
The function Wash Database was used to remove additional molecules, such as
counterions, and to assign the protonation state and total charge at a pH of 7.4.
The function Database Minimize was used to convert the structures into a min-
imum 3D conformation. The ﬁnally prepared database was saved as .sdf ﬁle.
Ligandscout was forced to import 500 conformations per ligand using ‘Omega’
from OpenEye by using the command:
idbgen -i input.sdf \
-o output.ldb \
-t omega-best \ # 500 conformation per ligand
--multi-conf # auto-sense conformations in
# SDF files by name comparison
The import of the at maximum 500 conformers into Ligandscout took 5 days on
a workstation with 12 CPUs at 2.66 GHz. After the import of the conformations,
the screening was started with the command:
iscreen -q [Ph4.pmz] \
-d [database.ldb] \
-o [output.sdf] \
-s \ # all matching conformations are considered
-a 3 \ # maximum number of features to omit
-l log.file
The software superposes the conformations of the database with the deﬁned
pharmacophore model. To each compound a scoring value was assigned, as a sum
of the molecule ﬁtting on the model. Higher values are ranked top.
5.3.2 Compound selection
To further check the validity of the pharmacophore model, the similarity between
imipramine and the compounds screened were calculated to ensure to get a hetero-
geneous result. The following ﬁngerprints were calculated within MOE: (i) MACCS
212 5. STRUCTURE BASED PHARMACOPHORE MODELLING
(substructure searching), (ii) GpiDAPH3 (three point pharmacophore), (iii) TAD
(3D atom type and distance based.) and (iv) TGD (atom type and distance based).
The ﬁngerprints were calculated for the life–chemical and the actives database.
To calculate the ‘shape based similarity’, Phase from Schrödinger Inc. was used.
Starting with importing the structure of imipramine from the snapshot into, a
conformational database was calculated using the function ConfGen - Standard.
Having the reference conformation of imipramine, the job was started by the com-
mand:
$SCHRODINGER/phase_shape \ # call the program
-screen lifechem500_imported-structures.sdf \ # lifechem database
-shape imipramine_conformations_maestro.sdf \ # reference ’shape’
-JOB lifechem_screen \ # job title
-flex \ # create conformations on the fly
-best \ # report only the highest similarity
-HOST localhost:12 \ # use all CPUs on the machine
-split \ # needed for conformer generation on multicores
-CHECKPOINT ~/LIFECHEM_SCREEN/ # if anything bad happens
The values from the pharmacophore screen, the ﬁngerprint calculations and
the shape screen, the selection of the compounds started with merging the actives
(655 compounds) and the life–chemicals (305 797 compounds) database. Now, the
compounds are merged and ranked according to the respective score to calculate
the enrichment rate (ER), see table 5.2. Within the top N % of the ranked list,
the number of active compounds is counted. Out of this numbers, the enrichment








while Ah is the number of found actives among Th, the selection out of the total
amount of compounds T containing the known actives A. The following table
shows the enrichment rates for the pharmacophore ﬁt score. ERmax is the ER,
when all actives (A) are found within the selection (Th)
All enrichment factors, for the pharmacophore ﬁt score as well as for the ﬁn-
gerprints and the shape similarity, are shown in ﬁgure 5.6.
The 20 top scored molecules of each of the ﬁngerprints, the shape similarity and
the pharmacophore ﬁt scrore were analysed visually. Out of the 80 compounds 13
were selected manually with respect of structural diversity and potential activity
regarding functional groups. Table 5.7 depicts the compound which were ordered
for experimental testing.
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Figure 5.7: Selected compounds to purchase.
5.5 Discussion
Only few data is available on pharmacophore modelling on NSS. The few reports in
the literature are substantially diﬀerent from ours. The pharmacophore model of
reference 287 was created ligand based. The query molecule were tropane deriva-
tives. The two structure based pharmacophore models, one on DAT288 and one
on SERT220 were both targeting the S2 site. The aﬃnities are comparable to our
ﬁndings, but the placement diﬀers. Since the low aﬃnity binding site is located
in the S2 site, high aﬃnity ligands might be bound in the S1 site or even occupy
both, as found for DAT, where bivalent ligands are bound.289 But it was also
hypthesised, that the S2 site might act as energetical barrier for S1 site.243 Future
research on SERT will reveal the detailed molecular interactions.
The work presented here shows a combination of structure based in-silico meth-
ods and in-vitro experiments to elucidate new active compounds on SERT. The
docking poses were experimentally validated and basis of the subsequent pharma-
cophore model, which showed to be predictive in screens.
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EC50 [nM] log EC50 Code Numbering
4615 664 F3314-0220 compound12
5294 724 F1386-0288 compound4
5782 762 F1345-0056 compound3
9979 999 F1021-0165 compound1
11660 1067 F1243-0192 compound2
12330 1091 F1986-0016 compound7
12990 1113 F3318-0667 compound13
25030 1398 F2880-3091 compound10
46640 1669 F2672-0070 compound9
55480 1744 F1768-0070 compound6
143800 2158 F1723-0134 compound5
728200 2862 F2392-1339 compound8
728300 2862 F3023-0458 compound11
Table 5.3: EC50 values of the tested compounds

6Final Remarks
Within the present study, the binding mode of selected TCAs was assessed using
homology modelling and docking, including the information from pharmacological
experiments. We could experimentally validate the binding hypothesis of imi-
pramine in the binding site of hSERT by the mutation Y95F.6 This binding mode
has not been reported in the literature previously. A further proof of the binding
hypothesis delivered the binding of trimipramine in the I172A mutant of SERT.
Proceeding with MD simulations of the docking poses, we were able to de-
termine stable water molecules in the central binding site. The possibility of
water molecules within the S1 site of SERT during inhibitor binding has not been
discussed in the literature, so far. Out of this result, a pharmacophore model
including the hydrogen bond feature and the exclusion sphere between D98 and
Y95F was created. The virtual screening of a drug–like ligand database revealed
4 compounds with an aﬃnity in the low µM range.
6.1 Discussion and Outlook
A multitude of experiments focusing on this topic can be found in the literature.
The interpretation of the results often is quite diﬃcult. A very detailed picture of
the molecular mechanisms between ligands of SERT within the binding pocket(s)
might be possible, if informations of many diﬀerent sources are considered. The
combination of structure based methods with experimental data, but also including
a detailed literature search, leads to an optimal result. The detailed knowledge
about the target, about the drugs acting on the target, the knowledge about the
potency and the limitations of methods reveal new insights in the drug–target
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interactions.
The present study included primarily structure based methods of the in-silico
part of the cooperation within the SFB35. Finally, here should be discussed the
limitations of the present work, but also some improvements, which have not been
known in the beginning.
Homology modelling can be improved by using multiple alignment and multi-
ple structures. This includes also snapshots from long range MD simulations of a
stable transporter. The indication of stable water molecules in the S1 site during
inhibitor binding could be included by analysing the binding pocket with regard
to putative water binding pockets.
Once a validated homology model was selected, a MD simulations might be
performed to test the stability of the model. As seen in several simulations, helical
regions of TMDs 1, 3, 8 and EL4 were removed. Assessing the model by this
method in an early stage, helps to avoid such artefacts.
Docking experiments were performed by avoiding bias from scoring functions.
Having this in mind, a relatively complicated protocol was created, that needs
manual intervention after several steps. An advantage of such a protocol is the
validation through the experimentator by comparing with the intermediate re-
sults with the up-to-date literature data. Important ﬁndings, such as the crucial
interaction of ligands with D98 in SERT, can be implemented into the protocol.
This is only possible if the target and the ligands are known in detail. Having
a database of ligands, where the binding mode should be discovered, a faster and
more unbiased protocol has to be established. Therefore, several docking programs
and scoring functions should be assessed with respect to the known experimental
data.
In case of SERT, it is known that it binds preferentially amines, that are
protonated at physiological pH. The analysis of related proteins might help to
understand the binding of ligands to the target of the research focus. As an
example, a docking pose of tiagabine in GAT1 has been published. Regarding the
homology of GAT1 and SERT and further regarding the chemical/pharmacophore
and geometrical similarity between tiagabine and imipramine, the binding mode
might be similar in both cases.
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Molecular dynamics simulation is a very powerful technique, that is appli-
cable in each step of a structure based study. Here it was used to validate the
docking poses with regard to the stability. But more important, the use of explicit
water molecules during the simulations revealed the hypothesis of water mediated
interactions between SERT and inhibitors. A future directive is the correlation
of experimental data, where binding energies are measured, with the simulations,
such as binding free energy calculations. Out of the scope of the study were the
steered MD simulations. Applying this method might reveal energy barriers when
comparing the binding of highly active with low aﬃnity compounds.
It is important to simulate a membrane protein in its native environment. The
membrane created for the study was used to ensure a hydrophobic environment
of the transporter and especially to avoid water access into the binding site over
the TMDs. The natural composition of the bilayer within lipid rafts is more
complex, than using only one single lipid. For functional studies on NSS, the near
native membrane composition should be considered as well as the di- or tetrameric
organisation of the transporter and the concentration gradient between the intra-
and the extracellular medium.
Pharmacophore modelling was successfully used to screen a database of drug-
like molecules and to obtain newly identiﬁed compounds binding to SERT with
aﬃnities lower than cyproheptadine. During the evaluation of the model, known
inactives have not been included prior the screen. This is a known limitation of
the last chapter of the present study.
To extend the pharmacophore model, a more diverse set of ligands should have
been used. A consensus model using the information of known active ligands might
increase the quality of the model. But this is only the case, if the binding mode
on the target is similar.
Experimental approaches can be proposed at the end of the this work. Start-
ing from the ligand, as proof of concept chemical modiﬁcations on imipramine in
pose 3 and subsequent binding experiments on SERT-WT might be considered to
verify the binding hypothesis. Within the cooperation, cyproheptadine and deslo-
ratadine were chosen as representatives of the TCAs. But compared to imipramine
or trimipramine, the distance between the central atom of the seven–membered
ring and the terminal nitrogen is shortened, due to double bonded piperidine ring.
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Figure 6.2: Putative mutation sites.
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ADHD attention deﬁcit and hyperactivity disorder




cAMP cyclic adenosine mono phosphate
CG conjugated gradient








GABA γ-amino butyric acid
HBP halogene binding pocket







MDMA methylene dioxy methamphetamine
MD (molecular dynamics)





OCT organic cation transporter
PDB Protein Data Bank
PMAT plasmamembrane monamine transporter
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
RMSD root mean sqare deviation
RTR R-trimipramine





SFB35 Spezialforschungsbereich Nummer 35
SLC solute carrier
SNRI selective norepinephrine reuptake inhibitors
SSRI selective serotonin reuptake inhibitors
STR S-trimipramine
TMD transmembrane domain
TCDB transporter classiﬁcation database
VMAT vesicular monoamine transporter
VSC Vienna Scientiﬁc Cluster





The sequences were downloaded from reference 290 in .fasta ﬁle format. The
alignment of SERT, DAT and NET including LeuT based on reference 3 and was














































































































Following, the alignment of the TMDs aligning the substrate translocation pathway
is depicted. Mutations are marked as green arrows. Important residues in function






↑ ↑ ↑ ↑
AF A
TM3 S1 S2



































































3 # Homology modeling by the automodel class
from modeller import * # Load standard Modeller classes
from modeller.automodel import * # Load the automodel class
log.verbose () # request verbose output
8 env = environ () # create a new MODELLER environment to build this model in
# directories for input atom files
env.io.atom_files_directory = ["/home/solanum /00 _Pharmazie /00 _aktuell /10 _Modelling/hSERT_2A65+na+leu"]
env.io.hetatm = env.io.water = True
13
class MyModel (automodel):
def special_restraints (self , aln):
rsr = self.restraints
at = self.atoms
18 # A disulfide between residues with UID 200 and 209 but abs. position 122 and 131:
def special_patches(self , aln):
self.patch(residue_type=’DISU’, residues =(self.residues[’122:A’], self.residues[’131:A’]))
# rsr.add(secondary_structure.alpha(self.residue_range (’612:B’, ’633:B ’)))
23
a = MyModel(env ,
alnfile = ’ali_SERT+leut_mod -in-EL4+na’, # alignment filename
knowns = ’2A65+na+leu.pdb’, # codes of the templates
sequence = ’hSERT ’, # code of the target
28 assess_methods =( assess.DOPE , assess.GA341))
a.starting_model= 1 # index of the first model
a.ending_model = 250 # index of the last model
#a.ending_model = 1 # index of the last model
# (determines how many models to calculate)
33
file = open(’/home/solanum /00 _Pharmazie /00 _aktuell /10 _Modelling/hSERT_2A65+na+leu/2a65+na_output+leu’, ’w’)
sys.stdout=file
# Very thorough VTFM optimization:





43 # Thorough MD optimization:
a.md_level = refine.very_slow
#a.md_level = refine.fast
# Repeat the whole cycle 2 times and do not stop unless obj.func. > 1E6
48 a.repeat_optimization = 2
a.max_molpdf = 1e6
a.make() # do the actual homology modeling
53 # Get a list of all successfully built models from a.outputs
ok_models = filter(lambda x: x[’failure ’] is None , a.outputs)
# Rank the models by DOPE score
key = ’DOPE␣score ’
58 ok_models.sort(lambda a,b: cmp(a[key], b[key]))
# Get top model
m = ok_models [0]




1 ### MODEL SCORING ###
# create subdirs in the modelling dir and move the created files there
NAME=hSERT
mkdir mod_V mod_D pdbs procheck dfire
6 mv $NAME.V* mod_V
mv $NAME.D* mod_D
mv $NAME.*pdb pdbs
# extract top 10 structures by
11 # DOPE
grep ^$NAME *_output | tr -s "␣" | cut -d "␣" -f 1,3 | tr "␣" "." | sort -t "." -k 4n -k 5nr | head >
top10_DOPE
for i in $(cat top10_DOPE | cut -d "." -f 1-3);
do
cp pdbs/$i procheck /;
16 done
# molPDF
grep ^$NAME *_output | tr -s "␣" | cut -d "␣" -f 1,2 | tr "␣" "." | sort -t "." -k 4n -k 5n | head >
top10_PDF
for i in $(cat top10_PDF | cut -d "." -f 1-3);
21 do
cp pdbs/$i procheck /;
done
# dDFIRE
26 # only total energy is considered (first numerical column)
# output is a textfile with the scores
for i in $(ls pdbs/$NAME.B99990*pdb); do dfire $i; done | tee dfire /2A65+na_dfire -scores
# search for the top10 -scored models and copy to procheck -dir
31 cat dfire/2A65+na_dfire -scores \
| cut -d "/" -f 2 \
| cut -d "␣" -f 1,2 \
| tr ":" "␣" \
| tr -s "␣" \
36 | tr "␣" "." \
| sort -t "." -k 4n -k 5nr \
| head > top10_DFIRE
for i in $(cat top10_DFIRE | cut -d "." -f 1-3);
do





# run procheck for each structure
for i in $(ls *.pdb);
do
DIR=$(echo "$i" | cut -d "." -f 2 | cut -c 7-);






# extract the line with the percentages from the .sum -output file of procheck
# for each scoring function and write the output
for i in $(cat ../ top10_DOPE | cut -d "." -f 1-3); do \
NAME=$(basename $i .pdb); printf "$i\t"; grep -w "Ramachandran" $(find . -name $NAME.sum); \
241
61 done > ram_DOPE
for i in $(cat ../ top10_PDF | cut -d "." -f 1-3); do \
NAME=$(basename $i .pdb); printf "$i\t"; grep -w "Ramachandran" $(find . -name $NAME.sum); \
done > ram_PDF
66
for i in $(cat ../ top10_DFIRE | cut -d "." -f 1-3 | cut -d ":" -f 1); \
do NAME=$(basename $i .pdb); printf "$i\t"; grep -w "Ramachandran" $(find . -name $NAME.sum); \
done > ram_DFIRE
71 # paste important information into one file
paste ../ top10_DOPE ram_DOPE > ../ top10_DOPE+ram
paste ../ top10_PDF ram_PDF > ../ top10_PDF+ram
paste ../ top10_DFIRE ram_DFIRE > ../ top10_DFIRE+ram
76 cp -rp pdbs pdbs_prochecked
cd pdbs_prochecked
for i in $(ls *.pdb);
do







# sort models by precentage of residues in allowed regions
# since bash is not able to sort floating point numbers , a workaround was needed.
for i in $(ls -d */); do cd $i; printf "$(ls␣*.sum)\t"; grep -w "Ramachandran" hDAT*.sum; cd ..; done > rams
91 cat rams \
| tr "%" "\0" \
| tr "\t" "␣" \
| tr -s "␣" \
| cut -d "␣" -f 1,5 \
96 | tr "␣" "." \
| sort -t "." -k 4 -nr -k 5 -nr \
| head > rams_sorted
Model Selection




# finally , copy the selected models into one directory
mkdir "$TEMPLATE"_selected -models
for i in $(find procheck/ -name "*pdb"); do cp $i "$TEMPLATE"_selected -models; done
cd "$TEMPLATE"_selected -models
9 # create a file with all scoring values and add the filename as ’HEADER ’
echo "model␣PDF␣DOPE␣GA341␣DFIRE␣core␣allow␣gener␣disall" > "$MODEL"_"$TEMPLATE"_selected -models_scores.csv
# extract col -names from procheck
### grep -w "Ramachandran" $(find ../ procheck/ -name "$(basename $i .pdb).sum") | cut -d ":" -f 2 | tr -s " "
| cut -d " " -f 3,5,7,9
for i in $(ls *pdb);
14 do
# add as HEADER the filename for proper import into MOE
sed -i "1␣i␣HEADER␣␣␣␣$i" $i
# extract modeller scores
grep ^$i ../"$TEMPLATE"_output | tr -s "␣" > modeller.tmp
19 # extract dfire scores
grep $i ../ dfire/"$TEMPLATE"_dfire -scores | cut -d "/" -f 2 | tr ":" "\0" | cut -d "␣" -f 2 > dfire.tmp
# extract the values from ramachandran plot reported by procheck
grep -w "Ramachandran" $(find ../ procheck/ -name "$(basename␣$i␣.pdb).sum") | cut -d ":" -f 2 | tr -s "␣"
| cut -d "␣" -f 2,4,6,8 | tr "%" "␣" | tr -s "␣" > procheck.tmp
# add the scores to the final scores -file































// Protocol of Minimisation adapted from "Patny et. al, Proteins , 2006" by









vdw : ’800R3’ ,
vdw_cutoff : 10.00 ,
ele : ’GB’ ,
ele_cutoff : 15.00 ,
49 d_in : 4.00 , // changed from 1
d_out : 80.00 ,
T : 310.00 , // changed from 300
ionC : 0.10 ,
pH : 7.40 , // changed from 7.00




59 // read system
local atoms = Atoms [];
// definition of the atom types
64 // Hydrogens
local mask_H = aElement atoms == ’H’;
local H_atoms = atoms|mask_H;
// heavy atoms
69 local mask_Heavy = not mask_H;
pr mask_Heavy;
local Heavy_atoms = atoms|mask_Heavy;
// backbone
74 local mask_backbone = aBackbone atoms;
local backbone_atoms = atoms|mask_backbone;
// sidechains
local mask_sidechain = not mask_backbone;







// 1. MM der Wasserstoffe
local tether_vector = 1000* mask_Heavy;
Minimize tether_vector;
94
// 2. MM der Seitenketten
tether_vector = 1000* mask_backbone;
Minimize tether_vector;
99
// 3. MM der Seitenketten inclusive tethered Backbone (Kraft auf Backbone: 100)




// 4. MM der Seitenketen inclusive tethered Backbone (Kraft auf Backbone: 50)
tether_vector = 50 * mask_backbone;
Minimize tether_vector;
109
// 5. MM der Seitenketen inclusive tethered Backbone (Kraft auf Backbone: 25)
tether_vector = 25 * mask_backbone;
Minimize tether_vector;
114
// 6. MM der Seitenketen inclusive tethered Backbone (Kraft auf Backbone: 10)
tether_vector = 10 * mask_backbone;
Minimize tether_vector;
119
// 7. MM der Seitenketen inclusive tethered Backbone (Kraft auf Backbone: 5)






1 // Creation of a conformational database of the ligand
// by running a short MD simulation in vacuum.
3 // The script depends on several MOE functions , indicated in the header
#svl










18 local function ligmd_confdb []
// Read in database key of the ligands
local ligdb = dbv_DefaultView [];
local ents = db_Entries ligdb;
23 local lig , name , mol;
local scsdb , name_scsdb , scsmol;
local mddb , name_mddb , newmol , t;
local name_findb;
28 local i = 0;
while i <> length ents loop
i=i+1;
Close [force :1];
// load ligand into MOE window
33 lig(i) = cat db_ReadFields [ligdb ,ents(i),’mol’];
mol = mol_Create lig(i);
// set name of the output databases
name = fbase (cat lig(i))(1);
name_mddb = tok_cat [name , ’_2000.mdb’];
38 name_scsdb = tok_cat [name , ’_stochconfs.mdb’];
name_findb = tok_cat [name , ’_100_export.mdb’];
// stochastic search for the initial minimum conformation

























scsdb = db_Open name_scsdb;
// load the minimum conformation into MOE window
scsmol = cat db_ReadFields[scsdb , (db_Entries scsdb)(1), ’mol’];
68 mol = mol_Create scsmol;
// MD -simulation of the selected conformation














DynamicsInit [name_mddb , opt_md ];
t(i) = Dynamics [name_mddb , 10, 2000, 101, opt_md ];
// energy minimisation of the obtained snapshots
local opt_dbmin = [
88 esel : 0,
dst_field : ’mol_min ’,
gtest : 0.001,
rebuild : ’minimize ’,
keep_chirality : 1,




db_Minimize [ name_mddb , ’mol’, opt_dbmin ];
98 write [’Energieminimierung␣fuer␣{}␣erledigt ...’, name ];
// calculation of the RMSD to the initial conformation after superposition
Close [force :1];
mddb = dbv_Open [name_mddb , 0];
newmol = cat db_ReadFields [mddb , (db_Entries mddb)(1), ’mol_min ’];
103 mol = mol_Create newmol;
local atoms = Atoms mol;
aSetSelected [atoms , 1];
local selected = aSelected atoms;
aSetSelected [atoms , 0];
























// calculation of the potential energy ’E’
133 QuaSAR_DescriptorMDB [mddb , ’mol_min ’, ’E’];
// run ’Diverse Subset ’ based on RMSD and E
local confexport = 100;














db_DiverseSubset[mddb , ’mol_min ’, opt_divsub_desc ];
// export 100 conformations selected
local sortmask=db_Sort [mddb , ’$DIVPRIO ’, 0];
local entries = db_Entries mddb;
153 local finfields = [’mol_min ’, ’E’, ’RMSD’, ’$DIVPRIO ’];
local exportentries = entries | db_ReadColumn [mddb , ’$DIVPRIO ’] <= confexport;





1 // calculates a squared RMSD -matrix and exports directly to and ASCII file
2
#svl




12 load ’/home/solanum/scripts/mol_rmsd.svl’; // from SVL -exchange
local matrix =[];
if isnull db then
db = dbv_DefaultView [];
17 endif
local entries = db_Entries db;
db_EnsureField [db ,’index_matrix ’,’int’];
22 local matrix_datei;
matrix_datei = fopenw [tok_cat [fbase db_Filename db, ’_matrix.csv’]];
local i=1, first_line;
first_line(i) = ’index_matrix ’;
27







37 for n=1, length first_line , 1 loop
local format = rep["{};", length first_line(n)];
format = cat format;
format = drop [format ,-1];
format = append [format ,"\n"];
42 format = token format;
fwrite cat [matrix_datei , format , first_line(n)];
endloop
local anzahl=length entries;
47 local field = 0;
local x=1, y=0;
while db_NextEntry [db,field] loop
field = db_NextEntry [db ,field];
52 // load reference pose
// create columns
x=x+1;
57 local mol_ref = cat db_ReadFields [db,field ,’mol’];
local spaltenkopf = twrite [’RMSD_{n:}’, x-1];
// print status
62 print [spaltenkopf , "von", anzahl ];
local entry = 0;
matrix (1) = spaltenkopf;
y=0;
67
while db_NextEntry [db,entry] loop
246
entry = db_NextEntry [db ,entry];
// load actual pose
72 // write RMSD into row
local mol_target = cat db_ReadFields [db,entry ,’mol’];
local rms = mol_RMSD [mol_ref , mol_target ];





matrix = tr matrix;
for j=1, length matrix , 1 loop
format = rep["{};", length matrix(j)];
87 format = cat format;
format = drop [format ,-1];
format = append [format ,"\n"];
format = token format;





Clustering for Removal of Duplicates
1 # This script applies clustering on the previously obtained RMSD -matrix.
# It calculates the cluster at a defined _niveau_ and delivers the cluster centroids.
3 # All files located in the defined _path_ will be considered.
# The output consists of .csv -files with information about
# - amount of cluster
# - clustersize
# - centroids
8 # additional informations are located in the defined _directory of the logfiles_
#
# Starting the script within R:
# source ("/path/to/R_clustering_centroids.R")
# Starting from bash
13 # R --file=/path/to/script.R
# Problem: the ’height ’ component of ’tree ’ is not sorted (in ascending order); consider applying as.hclust
first
# Solution: http://tolstoy.newcastle.edu.au/R/e4/help/08/05/12735. html
# or: http://www.mail -archive.com/r-help@r -project.org/msg21360.html
18
# if the package is not installed: type install.packages () and select ...
23 library(clv)
### Definition of the niveau , where the cluster -tree should be cut
### corresponds to the maximal distance within a cluster in Angstrom ,
### if the clustering algorithm is set to ’complete -linkage ’
28
niveau =1
### Definition of the paths ###
path <- "/home/solanum/00_Pharmazie/DOCK_model_actives/"
33
### INITIAL CLUSTERING AFTER DOCKING (NIVEAU =1) ###
matrixfiles <- "2_matrix/"
clusterfiles <- "3_cluster/"
38 centroidfiles <- "4_centroids/"
logfiles <- "clusterlogs/"
### CLUSTERING AFTER MINIMISATION (NIVEAU =4) ###








53 #logfiles <- "/"
247
### Zuweisung der Pfade in Variablen
58 pathmatrixfiles <- gsub("␣", "", paste(path ,matrixfiles ))
pathclusterfiles <- gsub("␣","",paste(path ,clusterfiles))
pathcentroidfiles <- gsub("␣","",paste(path ,centroidfiles))
pathlogfiles <- gsub("␣","",paste(path ,logfiles))
63 ### Laden der Dateien
files <- list.files(pathmatrixfiles , pattern="_matrix.csv")
print(files)
68 ### Entleeren der Variablen
rm(clust_cent)
rm(alles)
73 ende = length(files)
anzahl = 1
for ( anzahl in 1 : ende )
78 {
### Einlesen der Matrix , Berechnung und Ausgabe der Cluster
matrixfile=gsub ("␣", "", paste (pathmatrixfiles , files[anzahl ]))




outputcluster = cutree(cluster , h=niveau)
88 clusterfile = gsub ("_matrix.csv","_cluster.csv", files[anzahl ])
clusterpath = gsub("␣","",paste (pathclusterfiles ,clusterfile))
write.table(outputcluster , clusterpath , quote=FALSE , sep=";", col.names="index_matrix;Cluster")
### Berechnung und Ausgabe der Centroid -Matrix
93
temp_centroids=cls.attrib(inputmatrix , outputcluster )
centroidmatrix=t(temp_centroids$cluster.center)
centroidmatrixfile = gsub ("_cluster.csv","_centroidmatrix.csv", clusterfile)
centroidmatrixpath = gsub("␣","",paste (pathlogfiles ,centroidmatrixfile))
98 write.table(centroidmatrix , centroidmatrixpath , quote=FALSE , sep=";", col.names=TRUE , row.names=FALSE)
### Fusionieren der Cluster und der Centroidmatrix
clust=read.table(clusterpath , sep=";", header=T)
103 temp=read.csv(clusterpath)
write.table(temp ,clusterpath , quote=FALSE , sep=";", col.names="index_matrix;ID;cluster")
cent=read.table(centroidmatrixpath , sep=";", header=T)
clust_cent=cbind(clust ,cent)
clustercentroidpath = gsub ("_centroidmatrix.csv","_clusters_and_centers.csv", centroidmatrixpath)
108 write.table(clust_cent , clustercentroidpath , quote=FALSE , sep=";", col.names=TRUE , row.names=FALSE)
### Berechnung und Ausgabe der Cluster -Informationen
clusterinfo = cls.scatt.diss.mx(inputmatrix , outputcluster)
113 clusterstats = cbind(t(clusterinfo$intracls.complete),t(clusterinfo$intracls.average),clusterinfo$cluster.
size)
clusterdistancepath = gsub ("_centroidmatrix.csv","_cluster_dists.csv", centroidmatrixpath)
write.table("complete;average;size", clusterdistancepath , quote=FALSE , col.names=FALSE , row.names=FALSE)
write.table(clusterstats , clusterdistancepath , append=TRUE , quote=FALSE , sep=";", col.names=FALSE , row.
names=FALSE)





### Extrahieren und Ausgabe der Centroide
i=1




if (i==1) { fin=cbind(tmp[1,]) }
133 else { fin=cbind(fin ,tmp[1,]) }
i=i+1
}
centroidpath = gsub ("_centroidmatrix.csv","_centroids _tmp.csv", centroidmatrixpath)
138 write.table("index_matrix;Cluster;dist_to_centroid", centroidpath , quote=FALSE , row.names=FALSE , col.names
=FALSE)
write.table(t(fin),centroidpath , append=TRUE , quote=FALSE , sep=";", col.names=FALSE , row.names=FALSE)
cent_export=read.table(centroidpath , sep=";", header=T)
cent_dists=read.table(clusterdistancepath , sep=";", header=T)
248
143 finalcentroidfile = gsub ("_matrix.csv","_centroids.csv", files[anzahl ])
finalcentroidpath = gsub("␣","",paste (pathcentroidfiles ,finalcentroidfile))
finalcentroids=cbind(cent_export ,cent_dists)




cluststatfullpath = gsub ("_centroidmatrix.csv","_clust_stats.csv",centroidmatrixpath)
write.table(clust_stat_head , cluststatfullpath , quote=FALSE , sep=";", col.names=FALSE , row.names=FALSE)
153 write.table(clust_stat_data , cluststatfullpath , append=TRUE , quote=FALSE , sep=";", col.names=FALSE , row.
names=FALSE)




1 // The .csv -files obtained by clustering with R are imported into .mdb -files
// Both files , the .csv -files with the centroids (* _centroids.csv) and
// the initial database (dock_ *.mdb) out of the docking are merged
// to a new database (* _merged.mdb), containing only the centroids of the first clustering
6 #svl




// =============================== don’t forget to =====================================
16
if isnull pfad then
pfad = ’/Users/solanum/docking/DOCK_test ’;
endif
local dock = ’/1_dock ’;
21 local cluster = ’/3 _cluster ’;
local centroids = ’/4 _centroids ’;
local merge = ’/5 _merge ’;
// ========================== select the correct paths =================================
26
// attaches a ’slash’ (/) onto the filename
local dockpfad = tok_cat [dock , ’/’];
local clusterpfad = tok_cat [cluster , ’/’];
local centroidspfad = tok_cat [centroids , ’/’];
31 local mergepfad = tok_cat [merge , ’/’];
// defines the fields to be created in the database
local felder_clust = [’Cluster ’];
local felder_cent = [’Cluster ’,’dist_to_centroid ’,’complete ’,’average ’,’size’];
36 local felder_dock = [];
// reads the files
local dockfiles = flist tok_cat [pfad , dockpfad ];
local clusterfiles = flist tok_cat [pfad , clusterpfad ];
41 local centroidfiles = flist tok_cat [pfad , centroidspfad ];
// check , if the number of files is ident (for safety purposes )
if length dockfiles == length centroidfiles then
local anzahl = length centroidfiles;
46 else
write [’ERROR!␣\n’];











61 // print status
write[’\n###␣file␣{}␣of␣{}␣###\n’, i, anzahl ];
// ================ import centroids ===========================
66 // creating centroid database
local cent_csv = tok_cat[fbase centroidfiles(i),’.mdb’];
249
local cent_mdb = db_Open[cent_csv ,’create ’];
// print status
71 write[’\n#####␣processing␣{}\n’, ftail cent_csv ];
// importing centroids into MOE database file
db_ImportASCII[
ascii_file : centroidfiles(i),
76 db_file : cent_csv ,
delimiter : ’;’,
quotes : 0,
names : [’index_matrix ’,’Cluster ’,’dist_to_centroid ’,’complete ’,’average ’,’size’],
types : [’int’, ’int’,’float’,’float’,’float’,’int’],




86 local cent_db_merged = tok_cat[fbase ftail cent_csv ,’_merge.mdb’];
local pfad_cent_merged = tok_cat[pfad , mergepfad ];
local cent_merged = tok_cat[pfad_cent_merged ,cent_db_merged ];
local cent_merged_db = db_Open[cent_merged ,’create ’];
91 local db = db_Open[dockfiles(i), ’read’];
felder_dock = (db_Fields db)(1) | not freq [( db_Fields db)(1),’index_matrix ’];
write[’\n#####␣processing␣{}\n’, ftail cent_merged ];
96 // merge the centroid poses of the clustering the docking poses
db_Merge[
db1 : cent_csv ,
db2 : dockfiles(i),
db3 : cent_merged_db ,
101 key1 : ’index_matrix ’,
key2 : ’index_matrix ’,
import1 : felder_cent ,
import2 : felder_dock ,
opt : ’shared_only ’,




111 local clust_csv = tok_cat[fbase clusterfiles(i), ’.mdb’];
local clust_mdb = db_Open[clust_csv ,’create ’];
write[’\n#####␣processing␣{}\n’, ftail clust_csv ];
116 // ================ import cluster ===========================
// importing cluster into MOE database file
db_ImportASCII[
ascii_file : clusterfiles(i),
121 db_file : clust_csv ,
delimiter : ’;’,
quotes : 0,
names : [’index_matrix ’,’ID’,’Cluster ’],
types : [’int’, ’char’, ’int’],




131 local clust_db_merged = tok_cat[fbase ftail clust_csv ,’_merge.mdb’];
local pfad_clust_merged = tok_cat[pfad , clusterpfad ];
local clust_merged = tok_cat[pfad_clust_merged ,clust_db_merged ];
local clust_merged_db = db_Open[clust_merged ,’create ’];
136 write [’\n#####␣processing␣{}\n’, ftail clust_merged ];
// merge the docking poses with the information of the clustering (which pose is in which cluster ?)
db_Merge[
db1 : clust_csv ,
141 db2 : dockfiles(i),
db3 : clust_merged_db ,
key1 : ’index_matrix ’,
key2 : ’index_matrix ’,
import1 : felder_clust ,
146 import2 : felder_dock ,

















1 // This script minimises docking poses within the binding pocket
// using the LigX function.
// It depends on several MOE functions , defined in the header
6 #svl
#set main ’ligxmin_batch ’





16 function ligxmin_batch [pfad , protein]
load ’/Users/solanum/docking/scripts/rmsdmatrix_to_ascii_min.svl’;




pfad = ’/Users/solanum/docking/DOCK_test ’;
local enriched = ’/6_plif/’;
26 local mindock = ’/7 _minimize/’;
local auswertung = ’/8 _auswertung/’;
protein = ’/Users/solanum/docking/DOCK_test/model_7 -209+ prot3d_site0_postdock.moe’;
// /////////////////////////////////////////
31
local enrichedpfad = tok_cat [pfad , enriched ];
local mindockpfad = tok_cat [pfad , mindock ];
local auswertungspfad = tok_cat [pfad , auswertung ];
local inputdbs = flist enrichedpfad;
36 local anzahl = length inputdbs;




local namenewdb = tok_cat[’min_’,ftail inputdbs(i)];
local pfadnewdb = tok_cat[mindockpfad , namenewdb ];














local entries = db_Entries newdb;
db_EnsureField [newdb , ’mol_min ’, ’molecule ’];
61 db_EnsureField [newdb , ’rec_min ’, ’molecule ’];
db_EnsureField [newdb , ’complex_min ’, ’molecule ’];
print length entries;
local j=1;
66 for length entries loop
Close[force :1];
ReadMOE protein;
71 mol_Create cat db_ReadFields [newdb , entries(j), ’mol’];
print [j, "von", length entries ];
_ligX_min [];
76
db_Write [newdb , entries(j), tag [’complex_min ’, [( mol_Extract Atoms []) ]]];
db_Write [newdb , entries(j), tag [’mol_min ’, [( mol_Extract _Atoms ’$$ligand ’)]]];
251
db_Write [newdb , entries(j), tag [’rec_min ’, [( mol_Extract _Atoms ’$$receptor ’)]]];
81 j=j+1;
endloop
86 print asctime [];
write [’\nligXmin␣␣erledigt ...’];
// db_rescore_flex [pfadnewdb ,[]];




//write [’\nExport der RMSD -Matrix erledigt ... ’];
i=i+1;
db_Close newdb;






# bilayer is equilibrated. next steps: embedding , #
# solvating , minimizing , equilibration , runmd #
############################################################
5







LIG=$(cat $LIGANDFILE | tr -s "␣" | cut -d "␣" -f 4 | uniq);
15 cp -rfvp ../../ popc.itp .;




echo "keep␣2" > index;
echo "q" >> index;
make_ndx -f ../../ bilayer_equil -npt.gro -o bilayer_equil -npt.ndx < index;
25 X=$(sed ’$!d’ ../../ bilayer_equil -npt.gro | tr -s "␣" | sed ’s/^\ //g’ | cut -d "␣" -f 1);
Y=$(sed ’$!d’ ../../ bilayer_equil -npt.gro | tr -s "␣" | sed ’s/^\ //g’ | cut -d "␣" -f 2);
Z=9.00000;




grep -w "ATOM" $PROTEINFILE > complex.pdb;
grep "NA.*NA" $PROTEINFILE >> complex.pdb;
35 grep "CL.*CL" $PROTEINFILE >> complex.pdb;
grep -w "HETATM" $LIGANDFILE >> complex.pdb;
# convert complex into gro
grep -w "ATOM" complex.pdb | \
40 grep -wv "NA.*NA" | \
grep -wv "CL.*CL" | \
grep -wv "$LIG" | \
grep -wv "SOL" > complex_protein;
grep -w "NA.*NA" complex.pdb > complex_ions;
45 grep -w "CL.*CL" complex.pdb >> complex_ions;
cat complex_protein complex_ions > complex_protein+ions.pdb;
pdb2gmx -f complex_protein+ions.pdb -o complex_protein+ions.gro -p embed.top -ff gromos53a6 -water spc -
ignh;
252
grep -w "$LIG" complex.pdb > complex_ligand.pdb;
editconf -f complex_ligand.pdb -o complex_ligand.gro;
50 echo "$LIG␣␣␣␣␣1" >> embed.top;
sed ’1,2d’ complex_protein+ions.gro | sed ’$d’ > complex;
sed ’1,2d’ complex_ligand.gro | sed ’$d ’ >> complex;
echo "GROMACS_embedding_protein_into_membrane" > complex.gro;
55 printf "$(cat␣complex␣|␣wc␣-l)\n" >> complex.gro;
cat complex >> complex.gro;
sed ’$!d’ complex_protein+ions.gro >> complex.gro;
##############################################
60 # solvating and select waters prior embedding
##############################################
editconf -f complex.gro -o complex+box.gro -d 1 -c -resnr 0;
genbox -cp complex+box.gro -cs spc216.gro -o complex+box+sol.gro;
65 PFAD=$(pwd)
echo "#␣This␣.tcl␣script␣is␣used␣to␣extract␣water␣molecules␣within␣6A␣of␣the␣ligand" > keep_water.tcl;
echo "set␣RADIUS␣6" >> keep_water.tcl;
echo "set␣LIGAND␣$LIG" >> keep_water.tcl;
echo "mol␣new␣{$PFAD/complex+box+sol.gro}␣type␣{gro}" >> keep_water.tcl;
70 echo "set␣ID␣0" >> keep_water.tcl;
echo "set␣SOL_index␣[atomselect␣top␣\"water within \$RADIUS of resname $LIG\"]" >> keep_water.tcl;
echo "set␣SOL_resid␣[\ $SOL_index␣get␣residue]" >> keep_water.tcl;
echo "set␣SOL_selected␣[lsort␣-integer␣-increasing␣-unique␣\$SOL_resid]" >> keep_water.tcl;
echo "set␣SOL␣[atomselect␣top␣\"resid \$SOL_selected\"]" >> keep_water.tcl;
75 echo "\$SOL␣writepdb␣$PFAD/complex_sol -selected.pdb" >> keep_water.tcl;
echo "quit" >> keep_water.tcl;
if test $(uname) = Darwin;
then /Applications/VMD\ 1.9. app/Contents/vmd/vmd_MACOSXX86 -dispdev text -e keep_water.tcl
80 elif test $(uname) = Linux;
then vmd -dispdev text -e keep_water.tcl;
fi;
cp ../../ hoh.itp .;
85 grep -w "SOL" complex_sol -selected.pdb | sed ’s/SOL/HOH/’ > complex_waters.pdb;
editconf -f complex_waters.pdb -o complex_waters.gro;
sed ’1,2d’ complex+box.gro | sed ’$d ’ > complex_solv
sed ’1,2d’ complex_waters.gro | sed ’$d ’ >> complex_solv
90 echo "GROMACS_embedding_protein_into_membrane" > complex_solv.gro;
printf "$(cat␣complex_solv␣|␣wc␣-l)\n" >> complex_solv .gro;
cat complex_solv >> complex_solv.gro;
sed ’$!d’ complex+box+sol.gro >> complex_solv.gro;
95 #####################




100 echo ’; ============================================================== ;’ > embed.top;
echo ’; Include forcefield parameters , lipid topology added ’ >> embed.top;
if test $(uname) = Darwin;
then HOMEDIR=Users;
elif test $(uname) = Linux;
105 then HOMEDIR=home;
fi;
echo "#include␣\"/$HOMEDIR/solanum /00 _Pharmazie/md1/ gromos53a6_lipid.ff/forcefield.itp\"" >> embed.top;
echo ’; ============================================================== ;’ >> embed.top;
echo ’; Include protein chain topologies ’ >> embed.top;
110 echo ’#include "./ Protein_chain_A.itp"’ >> embed.top;
echo ’#include "./ Ion_chain_B.itp"’ >> embed.top;
echo ’; ============================================================== ;’ >> embed.top;
echo ’; Include other topologies ’ >> embed.top;
echo ’#include "./ popc.itp"’ >> embed.top;
115 echo "#include␣\"./$LIG.itp\"" >> embed.top;
echo ’; ============================================================== ;’ >> embed.top;
echo ’; Include topology for previously added water in site ’ >> embed.top;
echo ’#include "./hoh.itp"’ >> embed.top;
echo ’#ifdef POSRES ’ >> embed.top;
120 echo ’; Position restraint for each water oxygen ’ >> embed.top;
echo ’[ position_restraints ]’ >> embed.top;
echo ’; i funct fcx fcy fcz ’ >> embed.top;
echo ’ 1 1 1000 1000 1000’ >> embed.top;
echo ’#endif ’ >> embed.top;
125 echo ’; ============================================================== ;’ >> embed.top;
echo ’; Include water topology and position restraints ’ >> embed.top;
echo ’#include "gromos53a6.ff/spc.itp"’ >> embed.top;
echo ’#ifdef POSRES_WATER ’ >> embed.top;
echo ’; Position restraint for each water oxygen ’ >> embed.top;
130 echo ’[ position_restraints ]’ >> embed.top;
echo ’; i funct fcx fcy fcz ’ >> embed.top;
echo ’ 1 1 1000 1000 1000’ >> embed.top;
echo ’#endif ’ >> embed.top;
echo ’; ============================================================== ;’ >> embed.top;
135 echo ’; Include topology for ions ’ >> embed.top;
echo ’#include "gromos53a6.ff/ions.itp"’ >> embed.top;
echo ’; ============================================================== ;’ >> embed.top;
echo ’[ system ]’ >> embed.top;
253
echo ’; Name ’ >> embed.top;
140 echo ’Protein -ligand -complex into membrane ’ >> embed.top;
echo ’; ============================================================== ;’ >> embed.top;
echo ’[ molecules ]’ >> embed.top;
echo ’; Compound #mols ’ >> embed.top;
echo ’Protein_chain_A 1’ >> embed.top;
145 echo ’Ion_chain_B 1’ >> embed.top;
echo "$LIG␣␣␣␣␣1" >> embed.top;
printf "HOH␣␣␣␣$(($(grep␣HOH␣complex_solv.gro␣|␣wc␣-l)/3))\n" >> embed.top;
########################
150 # orient complex in box
########################
# the orientation in Z-axis is not centered in the bilayer as reported on opm
X=$(sed ’$!d’ bilayer.gro | tr -s "␣" | sed ’s/^\ //g’ | cut -d "␣" -f 1);
Y=$(sed ’$!d’ bilayer.gro | tr -s "␣" | sed ’s/^\ //g’ | cut -d "␣" -f 2);
155 Z=$(sed ’$!d’ bilayer.gro | tr -s "␣" | sed ’s/^\ //g’ | cut -d "␣" -f 3);
x=$(echo "scale =5;␣$X/2" | bc);
y=$(echo "scale =5;␣$Y/2" | bc);
z=$(echo "scale =5;␣$Z/2 -0.45" | bc);
editconf -f complex_solv.gro -box $X $Y $Z -center $x $y $z -rotate 90 0 0 -o complex_placed.gro;
160
###########################
# fuse complex and bilayer
###########################
sed ’1,2d’ complex_placed.gro | sed ’$d ’ > bilayer+complex
165 sed ’1,2d’ bilayer.gro | sed ’$d ’ >> bilayer+complex
echo "GROMACS_embedding_protein_into_membrane" > bilayer+complex.gro;
printf "$(cat␣bilayer+complex␣|␣wc␣-l)\n" >> bilayer+complex.gro;
cat bilayer+complex >> bilayer+complex.gro;
sed ’$!d’ bilayer.gro >> bilayer+complex.gro;
170
echo "1|12|15|23" > index;
echo "q" >> index;
make_ndx -f bilayer+complex.gro -o embed.ndx < index;
175 grep ^POP embed.top;
if test $? -eq 0;
then mv embed.top embed.tmp; sed ’/^POP/d’ embed.tmp > embed.top; rm -f embed.tmp;
fi;





grompp -f ../ embed.mdp -po embedding.mdp -c bilayer+complex.gro -p embed.top -o embed.tpr -n embed.ndx;
185
echo 26 16 | \
g_membed -f embed.tpr \
-n embed.ndx \
-xyinit 0.1 \











# add ions , minimize system ######################################
##################################################################
if test -f embed.gro;




11 LIGANDFILE=$(basename $PROTEINFILE .pdb)_UA.pdb;
LIG=$(cat $LIGANDFILE | tr -s "␣" | cut -d "␣" -f 4 | uniq)
##################################################################
##################################################################
16 ### add ions
### minimization of the system (SD 100, 100, 500, 500, 500, 100)








mv ../../ _vdwradii.dat_ vdwradii.dat;
26 genbox -cp embed.gro -cs spc216.gro -o embed+sol.gro -p embed.top;
mv vdwradii.dat ../../ _vdwradii.dat_;
###################
# create final gro
31 ###################
sed ’1,2d’ embed+sol.gro | sed ’$d’ | grep -v IMI | grep -v HOH | grep -v POP | grep -v SOL > system;
grep IMI embed+sol.gro >> system;
grep POP embed+sol.gro >> system;
grep HOH embed+sol.gro | sed ’s/HOH/SOL/’ >> system;
36 grep SOL embed+sol.gro >> system;
sed ’1,2!d’ embed+sol.gro > embed+sol_fin.gro;
cat system >> embed+sol_fin.gro;





sed ’/^POP/d’ embed.top | sed ’/^HOH/d’ | sed ’/^SOL/d’ > system.top;
46 printf "POP␣␣␣␣$(($(grep␣POP␣embed+sol_fin.gro␣|␣wc␣-l)/52))\n" >> system.top;








56 echo "23" | genion -s system.tpr -g system.log -o system.gro -p system.top -nn $CHARGE;
#############################################
# create index files and position restraints
#############################################
61 # protein
echo "keep␣1" > index;
echo "q" >> index;
make_ndx -f system.gro -o protein.ndx < index;
genrestr -f system.gro -n protein.ndx -o posre_Protein_chain_A.itp -fc 1000 1000 1000;
66
# backbone
echo "keep␣4" > index;
echo "q" >> index;
make_ndx -f system.gro -o BB.ndx < index;
71 genrestr -f system.gro -n BB.ndx -o posre -BB.itp -fc 1000 1000 1000;
grep posre -BB.itp Protein_chain_A.itp > /dev/null;
if test $? -ne 0;




echo "keep␣9" > index;
echo "q" >> index;
make_ndx -f system.gro -o SC.ndx < index;
81 genrestr -f system.gro -n SC.ndx -o posre -SC.itp -fc 1000 1000 1000;
grep posre -SC.itp Protein_chain_A.itp > /dev/null;
if test $? -ne 0;




echo "keep␣15" > index;
echo "q" >> index;
make_ndx -f system.gro -o LIG.ndx < index;
91 echo ";␣position␣restraints␣for␣the␣ligand␣$LIG" > posre_Ligand.itp;
echo ’[ position_restraints ]’ >> posre_Ligand.itp;
for ((i=1; i<=30; i++)); do printf "%4i␣␣␣␣1␣␣␣␣1000␣␣␣␣1000␣␣␣␣1000\n" $i >> posre_Ligand.itp; done;
cat ../../ $LIG.itp > $LIG.itp
grep "posre_Ligand.itp" $LIG.itp > /dev/null;
96 if test $? -ne 0;
then printf "\n#ifdef␣POSRES\n#include␣\"posre_Ligand .itp\"\n#endif\n\n" >> $LIG.itp;
fi;
# membrane
101 echo "keep␣16" > index;
echo "q" >> index;
make_ndx -f system.gro -o POP.ndx < index;
POPMOLS=$(($(grep POP system.gro | wc -l)/52));
echo ’; position restraints for POP of bilayer ’ > posre_Membrane.itp;
106 echo ’[ position_restraints ]’ >> posre_Membrane.itp;
for ((i=1; i<= $POPMOLS; i++)); do for ((j=1; j<=52; j++)); do printf "%4i␣␣␣␣1␣␣␣␣1000␣␣␣␣1000␣␣␣␣1000\n" $j;
done; done >> posre_Membrane.itp;
cat ../../ popc.itp > popc.itp
grep "posre_Membrane.itp" popc.itp > /dev/null;
if test $? -ne 0;






echo "1|15" > index
echo "23|12" >> index
echo "q" >> index





# WATER: posres , posres -pop
126 grompp -f ../ min_water_SD -100. mdp -c system.gro -p system.top -po minwater.mdp -o system_minSOL.tpr;
mdrun -s system_minSOL.tpr -deffnm system_minSOL -o -x -c -e -g -v;
# POP: posres , posres -water
grompp -f ../ min_membrane_SD -500. mdp -c system_minSOL.gro -p system.top -po minpop.mdp -o system_minSOLPOP.
tpr;
131 mdrun -s system_minSOLPOP.tpr -deffnm system_minSOLPOP -o -x -c -e -g -v;
# SC+LIG: posres -bb, posres -water
grompp -f ../ min_sc+lig_SD -500. mdp -c system_minSOLPOP.gro -p system.top -po minsclig.mdp -o
system_minSOLPOPSCLIG.tpr;
mdrun -s system_minSOLPOPSCLIG.tpr -deffnm system_minSOLPOPSCLIG -o -x -c -e -g -v;
136
# BB: posres -water
grompp -f ../ min_bb_SD -500. mdp -c system_minSOLPOPSCLIG .gro -p system.top -po minbb.mdp -o
system_minSOLPOPSCLIGBB.tpr;




grompp -f ../ watequil_10ps.mdp -c system_minSOLPOPSCLIGBB.gro -n system.ndx -p system.top -po eqsol.mdp -o
system_mineqSOL.tpr;
mdrun -s system_mineqSOL.tpr -deffnm system_mineqSOL -o -x -c -e -g -v;
146
##################################################
# add more water , equilibrate and minimize system
##################################################
mv ../../ _vdwradii.dat_ vdwradii.dat;
151 genbox -cp system_mineqSOL.gro -cs spc216.gro -o system_fin.gro -p system.top;
mv vdwradii.dat ../../ _vdwradii.dat_;
editconf -f system_fin.gro -resnr 79 -o system_fin.gro
156 echo "1|15" > index
echo "23|12" >> index
echo "q" >> index
make_ndx -f system_fin.gro -o system.ndx < index
161 grompp -f ../ watequil_10ps.mdp -c system_fin.gro -n system.ndx -p system.top -po eqsol.mdp -o system_fin_min.
tpr;
mdrun -s system_fin_min.tpr -deffnm system_fin_min -o -x -c -e -g -v;
grompp -f ../ min_system_SD -100 -c system_fin_min -n system.ndx -p system.top -po eqsol.mdp -o
system_fin_minimized.tpr;







# add ions , minimize system , equilibrate system , run production #
#################################################################




10 PROTEINFILE =1_SERT -WT_Imipramine.pdb;
LIGANDFILE=$(basename $PROTEINFILE .pdb)_UA.pdb;
LIG=$(cat $LIGANDFILE | tr -s "␣" | cut -d "␣" -f 4 | uniq)
##################################################################
15 ##################################################################
### equilibration of the system
### - water 10ps
### - membrane 100ps





echo "1" > index
25 echo "q" >> index
make_ndx -f system_fin_minimized.gro -o protein.ndx < index
for i in 500 250 100;
do
30 genrestr -f system_fin_minimized.gro -n protein.ndx -o posre_Protein$i.itp -fc $i $i $i < index;
grep posre -Protein$i.itp Protein_chain_A.itp > /dev/null;
if test $? -ne 0;
then printf "\n#ifdef␣POSRES$i\n#include␣\"posre_Protein$i.itp\"\n#endif\n\n" >> Protein_chain_A.itp;
fi;
35 done
## position restraints for protein
#genrestr -f system_fin_minimized.gro -n protein.ndx -o posre_Protein500.itp -fc 500 500 500 < index;
#grep posre -Protein500.itp Protein_chain_A.itp > /dev/null;
40 #if test $? -ne 0;
#then printf "\n#ifdef POSRES500\n#include \" posre_Protein500.itp\"\n#endif\n\n" >> Protein_chain_A.itp;
#fi;
#
#genrestr -f system_fin_minimized.gro -n protein.ndx -o posre_Protein250.itp -fc 250 250 250 < index;
45 #grep posre -Protein100.itp Protein_chain_A.itp > /dev/null;
#if test $? -ne 0;
#then printf "\n#ifdef POSRES100\n#include \" posre_Protein250.itp\"\n#endif\n\n" >> Protein_chain_A.itp;
#fi;
#
50 #genrestr -f system_fin_minimized.gro -n protein.ndx -o posre_Protein100.itp -fc 100 100 100 < index;
#grep posre -Protein50.itp Protein_chain_A.itp > /dev/null;
#if test $? -ne 0;




sed ’s/1000.*1000.*1000/500 500 500/g’ posre_Ion_chain_B.itp > posre_Ion500.itp;
grep posre_Ion500.itp Ion_chain_B.itp > /dev/null;
if test $? -ne 0;
60 then printf "\n#ifdef␣POSRES500\n#include␣\"posre_Ion500.itp\"\n#endif\n\n" >> Ion_chain_B.itp;
fi;
sed ’s/1000.*1000.*1000/250 250 250/g’ posre_Ion_chain_B.itp > posre_Ion250.itp;
grep posre_Ion250.itp Ion_chain_B.itp > /dev/null;
65 if test $? -ne 0;
then printf "\n#ifdef␣POSRES250\n#include␣\"posre_Ion250.itp\"\n#endif\n\n" >> Ion_chain_B.itp;
fi;
sed ’s/1000.*1000.*1000/100 100 100/g’ posre_Ion_chain_B.itp > posre_Ion100.itp;
70 grep posre_Ion100.itp Ion_chain_B.itp > /dev/null;
if test $? -ne 0;
then printf "\n#ifdef␣POSRES100\n#include␣\"posre_Ion100.itp\"\n#endif\n\n" >> Ion_chain_B.itp;
fi;
75 # ligand
sed ’s/1000.*1000.*1000/ 500 500 500/g’ posre_Ligand.itp > posre_Ligand500.itp;
grep posre_Ligand500.itp $LIG.itp > /dev/null;
if test $? -ne 0;
then printf "\n#ifdef␣POSRES500\n#include␣\"posre_Ligand500.itp\"\n#endif\n\n" >> $LIG.itp;
80 fi;
sed ’s/1000.*1000.*1000/ 250 250 250/g’ posre_Ligand.itp > posre_Ligand250.itp;
grep posre_Ligand250.itp $LIG.itp > /dev/null;
if test $? -ne 0;
85 then printf "\n#ifdef␣POSRES250\n#include␣\"posre_Ligand250.itp\"\n#endif\n\n" >> $LIG.itp;
fi;
sed ’s/1000.*1000.*1000/ 100 100 100/g’ posre_Ligand.itp > posre_Ligand100.itp;
grep posre_Ligand100.itp $LIG.itp > /dev/null;
90 if test $? -ne 0;
then printf "\n#ifdef␣POSRES100\n#include␣\"posre_Ligand100.itp\"\n#endif\n\n" >> $LIG.itp;
fi;
echo "1|15" > index
95 echo "23|12" >> index
echo "q" >> index
make_ndx -f system_fin_minimized.gro -o system_minimized.ndx < index
##################################################################
100 ##################################################################
# EQUILIBRATION PART 1 - WATER
grompp -f ../ watequil_50ps.mdp -c system_fin_minimized.gro -p system.top -po eqsol.mdp -n system_minimized.
ndx -o system_eqSOL.tpr;
mdrun -s system_eqSOL.tpr -deffnm system_eqSOL -o -x -c -e -g -v;
105 # EQUILIBRATION PART 2 - POP
grompp -f ../ memequil_200ps.mdp -c system_eqSOL.gro -t system_eqSOL.trr -n system_minimized.ndx -p system.top
-po eqpop.mdp -o system_eqSOLPOP.tpr;
mdrun -s system_eqSOLPOP.tpr -deffnm system_eqSOLPOP -o -x -c -e -g -v;
# EQUILIBRATION PART 3 - COMPLEX -DPOSRES500
110 grompp -f ../ sysequil500_250ps.mdp -c system_eqSOLPOP.gro -t system_eqSOLPOP.trr -n system_minimized.ndx -p
system.top -po eqpop.mdp -o system_eqSOLPOP500.tpr;
257
mdrun -s system_eqSOLPOP500.tpr -deffnm system_eqSOLPOP500 -o -x -c -e -g -v;
# EQUILIBRATION PART 4 - COMPLEX -DPOSRES250
grompp -f ../ sysequil250_250ps.mdp -c system_eqSOLPOP500.gro -t system_eqSOLPOP500.trr -n system_minimized.
ndx -p system.top -po eqpop.mdp -o system_eqSOLPOP250.tpr;
115 mdrun -s system_eqSOLPOP250.tpr -deffnm system_eqSOLPOP250 -o -x -c -e -g -v;
# EQUILIBRATION PART 5 - COMPLEX -DPOSRES100
grompp -f ../ sysequil100_250ps.mdp -c system_eqSOLPOP250.gro -t system_eqSOLPOP250.trr -n system_minimized.
ndx -p system.top -po eqpop.mdp -o system_eqSOLPOP100.tpr;
mdrun -s system_eqSOLPOP100.tpr -deffnm system_eqSOLPOP100 -o -x -c -e -g -v;
Production
1 #!/bin/bash
#$ -N imi -wt -1




#$ -l h_rt =07:00:00
mpirun -m $TMPDIR/machines -np $NSLOTS /home/lv70165/rweiss/bin/gromacs -4.5.4/ bin/mdrun_mpi -s
system_mdrun_10ns.tpr -deffnm system_mdrun_10ns -o -x -c -e -g -v &> sysrun10ns.log
MD Analysis
Deviations
1 # This script calculates deviations.
# RMSD from backbone , ligand and selected residues
# RMSF from sidechain , Calpha and Cbeta
# It has to be started in the directory of the trajectory files
5
#check if the number of arguments is correct:
if [ $# -ne 3 ]; then
echo "Input␣arguments␣are␣not␣correct."
echo "The␣ligand␣should␣be␣provided␣three -letter -code␣(eg.␣IMI)";








RESIDUES=$(echo $RESIDUES | sed ’s/_/ /g’)
FILE=$3
20

















# make index -files for residue -sidechains
for i in $RESIDUES;
do
echo "8␣&␣r␣$i" > index
45 echo "keep␣26" >> index
echo "name␣0␣SC" >> index
echo "splitres␣0" >> index
258
echo "keep␣1" >> index
echo "q" >> index
50 make_ndx -f $FILE.tpr -o "$i"SC.ndx < index
done
# make index -files for residues
for i in $RESIDUES;
55 do
echo "1␣&␣r␣$i" > index
echo "keep␣26" >> index
echo "name␣0␣SC" >> index
echo "splitres␣0" >> index
60 echo "keep␣1" >> index
echo "q" >> index
make_ndx -f $FILE.tpr -o "$i"RES.ndx < index
done
65
#make index -files for parts of the system
# 0 system
echo "keep␣0" > index
echo "q" >> index
70 make_ndx -f $FILE.tpr -o system.ndx < index
# 1 protein
echo "keep␣1" > index
echo "q" >> index
75 make_ndx -f $FILE.tpr -o protein.ndx < index
# 4 backbone
echo "keep␣4" > index
echo "q" >> index
80 make_ndx -f $FILE.tpr -o backbone.ndx < index
# 9 sidechain
echo "keep␣9" > index
echo "q" >> index
85 make_ndx -f $FILE.tpr -o sidechain.ndx < index
# 3 Calpha
echo "keep␣3" > index
echo "q" >> index
90 make_ndx -f $FILE.tpr -o Calpha.ndx < index
# 6&!5; keep 26 Cbeta
echo "6␣&␣!␣5" > index
echo "keep␣26" >> index
95 echo "q" >> index
make_ndx -f $FILE.tpr -o Cbeta.ndx < index
# 15 ligand
echo "keep␣15" > index
100 echo "q" >> index
make_ndx -f $FILE.tpr -o ligand.ndx < index
# 16 membrane
echo "keep␣16" > index
105 echo "q" >> index
make_ndx -f $FILE.tpr -o membrane.ndx < index
# 23 water
echo "keep␣23" > index
110 echo "q" >> index




for i in backbone ligand
do
echo $i
120 g_rms -s $FILE.tpr -f $FILE.xtc -n $i.ndx -o rmsd/rmsd_$i.xvg -nice 0
done
for i in $RESIDUES
do





for i in sidechain Calpha Cbeta
do
echo $i







1 # This script calculates distances between selected residue atoms and the ligand.
# It has to be started in the directory of the trajectory files and
# requires the execution of ’calc_deviations.sh’
5 #check if the number of arguments is correct:
if [ $# -ne 3 ]; then
echo "Input␣arguments␣are␣not␣correct."
echo "The␣ligand␣should␣be␣provided␣three -letter -code␣(eg.␣IMI_N19)";
echo "The␣needed␣residue␣atom␣has␣to␣be␣provided␣with␣’_’␣in␣between␣(eg.␣95_OH)";
10 echo "The␣prefix␣of␣the␣trajectory␣file␣should␣be␣provided␣(eg.␣system_mdrun)";




LIGATM=$(echo $LIG | cut -d "_" -f 2)
LIG=$(echo $LIG | cut -d "_" -f 1)
RES=$2
RESATM=$(echo $RES | cut -d "_" -f 2)
20 RES=$(echo $RES | cut -d "_" -f 1)
FILE=$3









# - make index -files of lig -n+ and r95 -oh/hh (shell script extracts data from the .gro -structure file)
35
#RES -Atom
INDEX=$(grep -w "$RES.* $RESATM" $FILE.gro | tr -s "␣" | cut -d "␣" -f 4)
echo "[␣"$RES"_"$RESATM"␣]" > "$LIG$LIGATM"_"$RES$RESATM".ndx
echo "$INDEX" >> "$LIG$LIGATM"_"$RES$RESATM".ndx
40
#LIG -Nitrogen
INDEX=$(grep "$LIG.* $LIGATM" $FILE.gro | tr -s "␣" | cut -d "␣" -f 4)
echo "[␣$LIG_$LIGATM␣]" >> "$LIG$LIGATM"_"$RES$RESATM".ndx
echo "$INDEX" >> "$LIG$LIGATM"_"$RES$RESATM".ndx
45
if test ! -d dists; then
mkdir dists;
fi






1 # This script searches for residues within a defined radius of the ligand
# over the trajectory.
# It has to be started in the directory of the trajectory files
#check if the number of arguments is correct:
6 if [ $# -ne 2 ]; then
echo "Input␣arguments␣are␣not␣correct."





if test $(uname) = Darwin;
then HOMEDIR=Users;



















g_select -f ../ $FILE.xtc -s ../ $FILE.tpr -oi lig -prot_oi.dat -resnr index -select "group␣Protein␣and␣within␣
0.45␣of␣resname␣$LIG" -nice 0
cat lig -prot_oi.dat | tr -s "␣" | grep -v ^\# > lig -prot_oi.dat.tr
41
R --file=/ $HOMEDIR/solanum /00 _Pharmazie/scripts/extract_protein_lig.R
############################################################################
# the following is done within R
46 # sort -n uniq_residues.out > uniq_residues_sort.out
###########################
# check sorting floats !!! #
# sort -nr -k 2 -t ";" uniq_residues.out > uniq_residues_sort_occurrence.out
###########################
51 # grep ^$NAME *_output | tr -s " " | cut -d " " -f 1,2 | tr " " "." | sort -t "." -k 4n -k 5n
############################################################################
if [ -f residue_numbers.tmp ]; then rm -f residue_numbers.tmp; fi;
56 for i in $(cut -d ";" -f 1 uniq_residues_sort.out);
do
grep -w ".*\␣$i\␣" ../ $FILE.gro >> residue_numbers.tmp;
done;
61 cat residue_numbers.tmp | tr -s "␣" | cut -d "␣" -f 1-4 > 1.tmp
cat uniq_residues_sort.out > 2.tmp
paste -d "␣" 1.tmp 2.tmp | tr "␣" "\t" > protein -ligand -interactions.dat
cat protein -ligand -interactions.dat | cut -f 2 | uniq > protein -ligand -interactions_residues.dat
66 if [ -f residue_numbers.tmp ]; then rm -f residue_numbers.tmp; fi;
for i in $(cut -d ";" -f 1 uniq_residues_sort_occurrence.out);
do
grep -w ".*\␣$i\␣" ../ $FILE.gro >> residue_numbers.tmp;
done;
71
cat residue_numbers.tmp | tr -s "␣" | cut -d "␣" -f 1-4 > 1.tmp
cat uniq_residues_sort_occurrence.out > 2.tmp
paste -d "␣" 1.tmp 2.tmp | tr "␣" "\t" > protein -ligand -interactions_occurrence.dat
76 rm *.tmp
############################################################################
# check sorting floats !!! - done with the output of the R-script#
# sort -nr -k 2 -t ";" protein -ligand -interactions.dat > protein -ligand -interactions_sortoccur.dat
81 ############################################################################
for i in $(cat protein -ligand -interactions_residues.dat); do grep $i protein -ligand -interactions.dat | sort -
nr -k 2 -t ";" | head -n 1; done | sort -nr -k 2 -t ";" > protein -ligand -interactions_residues_mostpop.
dat
# export most populated atom numbers
86 cat protein -ligand -interactions_residues_mostpop.dat | cut -f 5 | sort -n -t ";" -k 2 | cut -d ";" -f
1 > atom_nums.tmp
# read the first line of the interactions -table (containing the atom numbers)
COLUMN =($(head -n 1 near_residues_numbers.csv))
# extract the column numbers of the needed atom names
if [ -f col_nums.tmp ]; then rm -f col_nums.tmp; fi
91 for ATNUM in $(cat atom_nums.tmp)
do
n=0
for COL in ${COLUMN[@]}
do
96 if [ $COL == $ATNUM ]; then





# search for the columns extracted and export the occurrency of interactions
# write timestep into a file
cut -d "␣" -f 1 near_residues_numbers.csv > timestep.tmp
# write the needed columns into temporary files and
106 # replace the value != 0 with the number of the column
n=1
261
for i in $(cat col_nums.tmp)
do
echo "$(head␣-n␣$n␣atom_nums.tmp␣|␣tail␣-n␣1)" > column.tmp
111 for j in $(cut -d "␣" -f $i near_residues_numbers.csv | tail -n +2)
do
if [ $j -ne 0 ]; then
echo "$n" >> column.tmp
else
116 echo "$j" >> column.tmp
fi
done
# paste the new data into one file
if [ $n -eq 1 ]; then
121 cat column.tmp > all_columns.tmp
else















1 # This script extracts stable water molecules , calculates distances between them and
# parts of the ligand and parts of some residues.
# It has to be started in the directory of the trajectory files
4
#check if the number of arguments is correct:
if [ $# -ne 2 ]; then
echo "Input␣arguments␣are␣not␣correct.";







if test $(uname) = Darwin;
then HOMEDIR=Users;




LIG=$(echo $LIGATM | cut -d "_" -f 1)
24 ATM=$(echo $LIGATM | cut -d "_" -f 2)
FILE=$2









echo "[␣$LIGATM␣]" > $LIGATM.ndx
39 grep -w "$ATM" $FILE.gro | tr -s "␣" | cut -d "␣" -f 4 >> $LIGATM.ndx
mkdir $LIGATM -water
g_select -f $FILE.xtc -s $FILE.tpr -oi $LIGATM -water/lig - water_oi.dat -resnr index -select "resname␣SOL␣and␣
name␣OW␣and␣within␣0.45␣of␣resname␣$LIG␣and␣name␣$ATM" -nice 0
44 cd $LIGATM -water
# replace tabs by space




# read the table and process , so that the following output will be obtained
# creates following files
# - lig -water_ou.dat.tr.out # contains the filled tables with atom indices per time step
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54 # - uniq_waters.out # contains waters within the radius and the occurrency
# - near waters.out # contains a binary data matrix indicating occurence at time step
R --file=/ $HOMEDIR/solanum /00 _Pharmazie/scripts/extract_waters_lig.R
tail -n +2 near_waters_number.csv | cut -d "␣" -f 1,3- > near_waters_number.out
59
# echo "[ uniq_waters ]" > uniq_waters.ndx;
# for i in $(cat uniq_waters.out | cut -d ";" -f 1 | sort -n); do printf "$i " >> uniq_waters.ndx; done;
# printf "\n" >> uniq_waters.ndx;
64 # retain water molecules occurring more than 10 percent over the trajectory
if [ -f frequent_waters.out ]; then rm -f frequent_waters.out; fi;
for i in $(cat uniq_waters_sort_occurrence.out);
do
INDEX=$(printf "$i" | cut -d ";" -f 1);
69 OCCURRENCE=$(printf "$i" | cut -d ";" -f 2 | cut -d "." -f 1);
if [ $OCCURRENCE -ge 10 ]; then




74 #paste -d " " frequent_waters.out uniq_waters_sort_occurrence.out | sed ’s/;/ /g’ > frequent_waters+
occurrence.out
echo "[␣frequent_waters␣]" > frequent_waters.ndx;
for i in $(cut -d "W" -f 2 frequent_waters.out);
do
79 printf "$i␣" >> frequent_waters.ndx;
done;
printf "\n" >> frequent_waters.ndx;
84 if [ -f frequent_waters_resid.out ]; then rm -f frequent_waters_resid.out; fi;
for i in $(cut -d "S" -f 1 frequent_waters.out);
do
printf "$i␣" >> frequent_waters_resid.out;
done;
















#input=read.table(inputtable ,header=FALSE , sep=" ", fill=TRUE)
13 ncol=max(count.fields(inputtable))
input=read.csv(inputtable ,header=FALSE ,sep="␣",fill=TRUE ,col.names=paste("V",seq_len(ncol +1),sep=""))
ncols=length(input)
# find unique entries in the columns
18 ##############################################
# Alle Wassernummern in einen Vector schreiben








28 # anzahl=anzahl +1
# i=i+1
}




for ( j in 1 : length(uniqs_pre) )
{


















# das Konvertieren der NAs zu 0
# aus den Schleifen nehmen
58 # nur 1mal
for (spalten in 4 : ncols)
{
for (zeilen in 1 : nrows)
{

















#print(c(" Wasser",wasser ,uniqs[wasser ]))
83
for ( spalten in 4 : ncols )
{



























uniqs=cbind(uniqs ,sprintf("%.2f",round(occurrence*100, digits =2)))
#write.table(input ,outputtable ,sep=";", quote=FALSE ,col.names=FALSE ,row.names=FALSE)




118 write.table(export ,"uniq_waters_sort.out",quote=FALSE ,sep=";",col.names=FALSE ,row.names=FALSE)
temp=read.table("uniq_waters.out",sep=";")
uniqs_sort=temp[order(temp[,2], decreasing=TRUE),]
123 export=cbind(uniqs_sort[,1], sprintf("%.2f",uniqs_sort [,2]))
write.table(export ,"uniq_waters_sort_occurrence.out",quote=FALSE ,sep=";",col.names=FALSE ,row.names=FALSE)
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Stable Water Molecules
1 # search for waters with more than 0.25 occurrence over the trajectory
for DIR in IMI RTR STR CYP DES
do
5 cd $DIR





# remove all old files containting information of stable waters:
# necessary , if the script is executed more than once
15 find . -name "*OW*.ndx" | xargs rm -f
find . -name "*DIST_OW*" | xargs rm -f
find . -name "dist*OW*.xvg" | xargs rm -f
find . -name "stable_waters*" | xargs rm -f
20 echo "all␣previous␣data␣present␣in␣$SUBDIR␣are␣deleted"
DIRNAME=$(ls -d 13_prod *)
cd $DIRNAME
25 if [ -f all_waters ]; then rm -f all_waters; fi;
for i in $(find . -name "uniq_waters_sort_occurrence.out"); do cat $i >> all_waters; done
cat all_waters | sort -t ";" -n -k 2 -r > all_waters_sort
CUTOFF =10
30 WATERS =100
until [ $WATERS -le 6 ] || [ $CUTOFF -ge 75 ];
do
if [ -f stable_waters ]; then rm -f stable_waters; fi;
for i in $(cat all_waters_sort);
35 do
INDEX=$(printf "$i" | cut -d ";" -f 1);
OCCURRENCE=$(printf "$i" | cut -d ";" -f 2 | cut -d "." -f 1);
if [ $OCCURRENCE -ge $CUTOFF ]; then
grep $i all_waters_sort >> stable_waters;
40 fi;
done;
cat stable_waters | cut -d ";" -f 1 | sort -n | uniq > stable_waters_index.dat





50 if [ -f stable_waters_gro.dat ]; then rm -f stable_waters_gro; fi;
for INDEX in $(cat stable_waters_index.dat)
do





echo "[␣frequent_waters␣]" > stable_waters.ndx;
for i in $(cut -d "W" -f 2 stable_waters_gro.dat);
60 do
printf "$i␣" >> stable_waters.ndx;
done;
printf "\n" >> stable_waters.ndx;
65 if [ -f stable_waters_resid.dat ]; then rm -f stable_waters_resid; fi;
if [ -f stable_waters_vmd.dat ]; then rm -f stable_waters_vmd.dat; fi;
for i in $(cut -d "S" -f 1 stable_waters_gro.dat);
do
printf "$i␣" >> stable_waters_vmd.dat;










Distance to Water Molecules
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1 # calculate distances between atoms and stable waters
# this script follows recalc_stable_waters.sh




if [ $# -ne 2 ]; then
9 echo "Input␣arguments␣are␣not␣correct."









#for DIR in CYP DES IMI RTR STR
#do
24 cd $DIR #
for SUBDIR in $(ls -d *SERT -WT* *SERT -I172A*)
do
cd $SUBDIR ##
DIRNAME=$(ls -d 13_prod *)
29
echo "entered␣in␣$DIR/$SUBDIR"
# check , if previous script was executed







# calculate distances in equilibration dirs
cd 12 _equilibration ###
for EQDIR in SOL SOLPOP SOLPOP500 SOLPOP250 SOLPOP100
do
44 cd $EQDIR ####
cp ../../ $DIRNAME/stable_waters_index.dat .
FILE=$(basename $(ls *xtc) .xtc)
for RESIDUES in $LIGATOM 95_OH 98_CG 176_OH
do





54 cd .. ##
# calculate distances in production dir
cd $DIRNAME ###
FILE=$(basename $(ls system_mdrun_10ns.xtc) .xtc)
59 for RESIDUES in $LIGATOM 95_OH 98_CG 176_OH
do
bash $SCRIPTPATH/calc_water -dist.sh $RESIDUES $FILE
echo "calculating␣water␣distances␣of␣production␣run␣between␣$RESIDUES"
done







1 # This script calculates Hbonds.
# Hbonds between:
# - the Ligand and the Protein ,
4 # - the Ligand and Water (stable ones included) and
# - selected residues and water water
# It uses the function g_hbonds and the vmd -built in Hbond analysis tool
# It has to be started in the directory of the trajectory files , and depends
# on the scripts calc_water*sh
9
#check if the number of arguments is correct:
if [ $# -ne 3 ]; then
echo "Input␣arguments␣are␣not␣correct."
echo "The␣ligand␣should␣be␣provided␣three -letter -code␣(eg.␣IMI)";
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RESIDUES=$(echo $RESIDUES | sed ’s/_/ /g’)
FILE=$3
24
if test $(uname) = Darwin;
then HOMEDIR=Users;
elif test $(uname) = Linux;
then HOMEDIR=home;
29 fi;












cp /home/data1/solanum/ZZ_newdata/simulations.orig /01 _simulations.orig/redo/recalc_hbonds.tcl .
printf "$LIG" > calc_hbonds_ligname
49 printf "$RESIDUES" > calc_hbonds_resid
printf "$FILE" > filename
# the copy -step is necessary , since I couldn ’t solve the problem of
# giving arguments to a .tcl script ...
54 if test $(uname) = Darwin;
then /Applications/VMD\ 1.9. app/Contents/vmd/vmd_MACOSXX86 -dispdev text -e recalc_hbonds.tcl
elif test $(uname) = Linux;





for i in $(ls "$PRE"lig -protein* "$PRE"lig -water* "$PRE"protein -water -* "$PRE"r*-water* "$PRE"water -water -*)
64 do
echo $i
if test ! -f $i;
then touch NOT_EXISTING_"$i";
else
69 tail -n +2 $i > hbond -detail.tmp
cat hbond -detail.tmp | tr -s "␣" | cut -d "␣" -f 1 > donor.tmp
cat hbond -detail.tmp | tr -s "␣" | cut -d "␣" -f 3 > acceptor.tmp
cat hbond -detail.tmp | tr -s "␣" | cut -d "␣" -f 5 > occurrence.tmp
74 paste occurrence.tmp donor.tmp acceptor.tmp > modified_hbonds.tmp
head -n +1 $i > frequent_$i
head -n +1 modified_hbonds.tmp >> frequent_$i
tail -n +2 modified_hbonds.tmp > sorted_hbonds.tmp









Hydrogen Bonds within VMD
1 #!/usr/local/bin/vmd
3 # start this script with:




#load data of the present system
#the resid and the resname have to be stored in files!
267
#at the moment, no argument can be given to the script...
set RESIDFILE [ open "calc_hbonds_resid" r]
13 set RESID [read $RESIDFILE]
set LIGNAMEFILE [ open "calc_hbonds_ligname" r]
set LIGNAME [read $LIGNAMEFILE]
set FILEFILE [ open "filename" ]
set FILE [ read $FILEFILE ]
18
#load stable waters
#the resids are stored in a space separated file
set stable_file [ open "../stable_waters_vmd.dat" r]
#set stable_content [read $stable_file]
23 set STABLE [read $stable_file]
#set STABLE [split $stable_content "\n"]
# load sytem and trajectory
28 mol new ../$FILE.gro type gro first 0 last -1 step 1 filebonds 1 autobonds 1 waitfor all
mol addfile ../$FILE.xtc type xtc first 0 last -1 step 1 filebonds 1 autobonds 1 waitfor all
# select parts
set LIG [atomselect top "resname␣$LIGNAME"]
33 set WATER [atomselect top {water}]
set RES [atomselect top "resid␣$RESID"]





foreach {i} $RESID {
43 puts "$i"
set RES [atomselect top "resid␣$i"]
# calculate hydrogen bonds between residues and water
hbonds -sel1 $RES -sel2 $WATER -writefile yes -upsel yes -dist 3.5 -ang 30 -plot no -log hbonds_r$i-water.log
-outfile hbonds-count_r$i-water.dat -DA both -type all -detailout hbonds-detail_r$i-water.dat
48
}
# calculate hydrogen bonds between ligand and water
hbonds -sel1 $LIG -sel2 $WATER -writefile yes -upsel yes -dist 3.5 -ang 30 -plot no -log hbonds_lig-water.log
-outfile hbonds-count_lig-water.dat -DA both -type all -detailout hbonds-detail_lig-water.dat
53 # # calculate hydrogen bonds between ligand and protein
# hbonds -sel1 $LIG -sel2 $PROTEIN -writefile yes -upsel yes -dist 3.5 -ang 30 -plot no -log
hbonds_lig-protein.log -outfile hbonds-count_lig-protein.dat -DA both -type all -detailout
hbonds-detail_lig-protein.dat
foreach {i} $STABLE {
puts "$i"
58 set WAT [atomselect top "resid␣$i"]
puts "$WAT"
hbonds -sel1 $LIG -sel2 $WAT -writefile yes -upsel yes -dist 3.5 -ang 30 -plot no -log
hbonds_lig-water-$i.log -outfile hbonds-count_lig-water-$i.dat -DA both -type all -detailout
hbonds-detail_lig-water-$i.dat
hbonds -sel1 $RES -sel2 $WAT -writefile yes -upsel yes -dist 3.5 -ang 30 -plot no -log
hbonds_r$RESID-water-$i.log -outfile hbonds-count_r$RESID-water-$i.dat -DA both -type all
-detailout hbonds-detail_r$RESID-water-$i.dat
# hbonds -sel1 $PROTEIN -sel2 $WAT -writefile yes -upsel yes -dist 3.5 -ang 30 -plot no -log
hbonds_protein-water-$i.log -outfile hbonds-count_protein-water-$i.dat -DA both -type all -detailout
hbonds-detail_protein-water-$i.dat
63 # hbonds -sel1 $WATER -sel2 $WAT -writefile yes -upsel yes -dist 3.5 -ang 30 -plot no -log







1 ; final topology of Imipramine
; created manually using parameters of
3 ; ATB -entry _JDY (http :// compbio.biosci.uq.edu.au/atb)
; GAUSSIAN09
; PDB -entry 2Q72 (http ://www.rcsb.org)
; according to the GROMOS 53A6 forcefield
8 [ moleculetype ]
; Name nrexcl
IMI 3
13 [ atoms ]
; USED =
; NT 14.00670 ; 7 terminal nitrogen (NH2)
; NL 14.00670 ; 8 terminal nitrogen (NH3)
; C 12.01100 ; 12 bare carbon
18 ; CH2 14.02700 ; 15 aliphatic or sugar CH2 -group
; CH3 15.03500 ; 16 aliphatic CH3 -group
; CH2r 14.02700 ; 18 CH2 -group in a ring
; HC 1.00800 ; 20 hydrogen bound to carbon
; H 1.00800 ; 21 hydrogen not bound to carbon
23 ; nr type resnr resid atom cgnr charge mass total_charge code
1 C 607 IMI C1 1 -0.140 12.0110 ; 12
2 HC 607 IMI H1 1 0.140 1.0080 ; 0.000 ; 20
3 C 607 IMI C2 2 -0.140 12.0110 ; 12
4 HC 607 IMI H2 2 0.140 1.0080 ; 0.000 ; 20
28 5 C 607 IMI C3 3 -0.140 12.0110 ; 12
6 HC 607 IMI H3 3 0.140 1.0080 ; 0.000 ; 20
7 C 607 IMI C4 4 -0.140 12.0110 ; 12
8 HC 607 IMI H4 4 0.140 1.0080 ; 0.000 ; 20
9 C 607 IMI C5 5 0.000 12.0110 ; 12
33 10 CH2r 607 IMI C6 5 0.000 14.0270 ; 0.000 ; 18
11 CH2r 607 IMI C7 6 0.000 14.0270 ; 18
12 C 607 IMI C8 6 0.000 12.0110 ; 0.000 ; 12
13 C 607 IMI C9 7 -0.140 12.0110 ; 12
14 HC 607 IMI H9 7 0.140 1.0080 ; 0.000 ; 20
38 15 C 607 IMI C10 8 -0.140 12.0110 ; 12
16 HC 607 IMI H10 8 0.140 1.0080 ; 0.000 ; 20
17 C 607 IMI C11 9 -0.140 12.0110 ; 12
18 HC 607 IMI H11 9 0.140 1.0080 ; 0.000 ; 20
19 C 607 IMI C12 10 -0.140 12.0110 ; 12
43 20 HC 607 IMI H12 10 0.140 1.0080 ; 0.000 ; 20
21 C 607 IMI C13 11 0.050 12.0110 ; 12
22 NT 607 IMI N14 11 -0.200 14.0067 ; 7
23 C 607 IMI C15 11 0.050 12.0110 ; 12
24 CH2 607 IMI C16 11 0.100 14.0270 ; 0.000 ; 15
48 25 CH2 607 IMI C17 12 0.000 14.0270 ; 0.000 ; 15
26 CH2 607 IMI C18 13 0.200 14.0270 ; 15
27 NL 607 IMI N19 13 0.152 14.0067 ; 8
28 H 607 IMI H19 13 0.248 1.0080 ; 21
29 CH3 607 IMI C20 13 0.200 15.0350 ; 16
53 30 CH3 607 IMI C21 13 0.200 15.0350 ; 1.000 ; 16
; total charge of the molecule: 1.000
[ bonds ]
; USED =
58 ; #define gb_2 0.1000 1.8700e+07; H - N (all) 895;
; #define gb_3 0.1090 1.2300e+07; HC - C 700;
; #define gb_16 0.1390 1.0800e+07; C, CR1 - CH2 , C, CR1 (6-ring) 1000;
; #define gb_18 0.1430 8.1800e+06; CHn - OA 800;
; #define gb_21 0.1470 8.7100e+06; CHn - N, NT , NL , NZ , NE 900;
63 ; #define gb_26 0.1520 5.4300e+06; CHn - CHn (sugar) 600;
; #define gb_27 0.1530 7.1500e+06; C, CHn - C,CHn 800;
; 0.1430 8.1800e+06 18 CHn - OA ;-> fits best the measured length
; 0.1520 5.4300e+06 26 CHn - CHn (Sugar) ;-> fits best the measured length
; ai aj funct code c0 c1
68 1 2 2 gb_3 ; 0.1090 1.2300e+07
1 3 2 gb_16 ; 0.1390 1.0800e+07
1 23 2 gb_16 ; 0.1390 1.0800e+07
3 4 2 gb_3 ; 0.1090 1.2300e+07
3 5 2 gb_16 ; 0.1390 1.0800e+07
73 5 6 2 gb_3 ; 0.1090 1.2300e+07
5 7 2 gb_16 ; 0.1390 1.0800e+07
7 8 2 gb_3 ; 0.1090 1.2300e+07
7 9 2 gb_16 ; 0.1390 1.0800e+07
9 10 2 gb_26 ; 0.1520 5.4300e+06
78 9 23 2 gb_16 ; 0.1390 1.0800e+07
10 11 2 gb_27 ; 0.1530 7.1500e+06
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11 12 2 gb_26 ; 0.1520 5.4300e+06
12 13 2 gb_16 ; 0.1390 1.0800e+07
12 21 2 gb_16 ; 0.1390 1.0800e+07
83 13 14 2 gb_3 ; 0.1090 1.2300e+07
13 15 2 gb_16 ; 0.1390 1.0800e+07
15 16 2 gb_3 ; 0.1090 1.2300e+07
15 17 2 gb_16 ; 0.1390 1.0800e+07
17 18 2 gb_3 ; 0.1090 1.2300e+07
88 17 19 2 gb_16 ; 0.1390 1.0800e+07
19 20 2 gb_3 ; 0.1090 1.2300e+07
19 21 2 gb_16 ; 0.1390 1.0800e+07
21 22 2 gb_18 ; 0.1430 8.1800e+06
22 23 2 gb_18 ; 0.1430 8.1800e+06
93 22 24 2 gb_21 ; 0.1470 8.7100e+06
24 25 2 gb_27 ; 0.1530 7.1500e+06
25 26 2 gb_27 ; 0.1530 7.1500e+06
26 27 2 gb_21 ; 0.1470 8.7100e+06
27 28 2 gb_2 ; 0.1000 1.8700e+07
98 27 29 2 gb_21 ; 0.1470 8.7100e+06
27 30 2 gb_21 ; 0.1470 8.7100e+06
[ angles ]
; USED =
103 ; #define ga_11 109.50 425.00; H - NL - C, CHn / H - NT - CHn 90;
; #define ga_15 111.00 530.00; CHn - CHn - C, CHn , OA, NR, NT, NL 110;
; #define ga_22 117.00 635.00; CH3 - N - C, CHn - C - OM 120;
; #define ga_25 120.00 505.00; H - N - CH3 , H, HC - 6-ring , H - NT - CHn 90;
; #define ga_27 120.00 560.00; N, C, CR1 (6-ring , no H) 100;
108 ; #define ga_30 121.00 685.00; O - C - CHn , C / CH3 - N - CHn 120;
; #define ga_31 122.00 700.00; CH1 , CH2 - N - C 120;
; #define ga_33 124.00 730.00; O - C - OA, N, NT , NL / C - NE - CH2 120;
; 117.00 635.00 22 CH3 - N - C, CHn - C - OM -> fits best the measured angle
; ai aj ak funct code angle fc
113 2 1 3 2 ga_25 ; 120.00 505.00
2 1 23 2 ga_25 ; 120.00 505.00
3 1 23 2 ga_27 ; 120.00 560.00
1 3 4 2 ga_25 ; 120.00 505.00
1 3 5 2 ga_27 ; 120.00 560.00
118 4 3 5 2 ga_25 ; 120.00 505.00
3 5 6 2 ga_25 ; 120.00 505.00
3 5 7 2 ga_27 ; 120.00 560.00
6 5 7 2 ga_25 ; 120.00 505.00
5 7 8 2 ga_25 ; 120.00 505.00
123 5 7 9 2 ga_27 ; 120.00 560.00
8 7 9 2 ga_25 ; 120.00 505.00
7 9 10 2 ga_27 ; 120.00 560.00
7 9 23 2 ga_27 ; 120.00 560.00
10 9 23 2 ga_27 ; 120.00 560.00
128 9 10 11 2 ga_15 ; 111.00 530.00
10 11 12 2 ga_15 ; 111.00 530.00
11 12 13 2 ga_27 ; 120.00 560.00
11 12 21 2 ga_27 ; 120.00 560.00
13 12 21 2 ga_27 ; 120.00 560.00
133 12 13 14 2 ga_25 ; 120.00 505.00
12 13 15 2 ga_27 ; 120.00 560.00
14 13 15 2 ga_25 ; 120.00 505.00
13 15 16 2 ga_25 ; 120.00 505.00
13 15 17 2 ga_27 ; 120.00 560.00
138 16 15 17 2 ga_25 ; 120.00 505.00
15 17 18 2 ga_25 ; 120.00 505.00
15 17 19 2 ga_27 ; 120.00 560.00
18 17 19 2 ga_25 ; 120.00 505.00
17 19 20 2 ga_25 ; 120.00 505.00
143 17 19 21 2 ga_27 ; 120.00 560.00
20 19 21 2 ga_25 ; 120.00 505.00
19 21 12 2 ga_27 ; 120.00 560.00
19 21 22 2 ga_27 ; 120.00 560.00
12 21 22 2 ga_27 ; 120.00 560.00
148 21 22 23 2 ga_27 ; 120.00 560.00
21 22 24 2 ga_22 ; 117.00 635.00
23 22 24 2 ga_22 ; 117.00 635.00
1 23 22 2 ga_27 ; 120.00 560.00
1 23 9 2 ga_27 ; 120.00 560.00
153 9 23 22 2 ga_27 ; 120.00 560.00
22 24 25 2 ga_15 ; 111.00 530.00
24 25 26 2 ga_15 ; 111.00 530.00
25 26 27 2 ga_15 ; 111.00 530.00
26 27 28 2 ga_11 ; 109.50 425.00
158 26 27 29 2 ga_30 ; 131.00 685.00
26 27 30 2 ga_30 ; 131.00 685.00
28 27 29 2 ga_11 ; 109.50 425.00
28 27 30 2 ga_11 ; 109.50 425.00
29 27 30 2 ga_30 ; 131.00 685.00
163
[ dihedrals ]
; GROMOS improper dihedrals
#define gi_1 0.0 167.42309; planar groups 40;
; USED =
168 ; 1: fc=0.051 , ang=0.0, planar
; ai aj ak al funct code angle fc
; ring 1
270
23 1 3 5 2 gi_1 ; 0.00 167.36
1 3 5 7 2 gi_1 ; 0.00 167.36
173 3 5 7 9 2 gi_1 ; 0.00 167.36
5 7 9 23 2 gi_1 ; 0.00 167.36
7 9 23 1 2 gi_1 ; 0.00 167.36
9 23 1 3 2 gi_1 ; 0.00 167.36
; H/R on ring 1
178 1 2 3 23 2 gi_1 ; 0.00 167.36
3 4 5 1 2 gi_1 ; 0.00 167.36
5 6 3 7 2 gi_1 ; 0.00 167.36
7 8 5 9 2 gi_1 ; 0.00 167.36
9 10 7 23 2 gi_1 ; 0.00 167.36
183 23 22 1 9 2 gi_1 ; 0.00 167.36
; ring 2
21 12 13 15 2 gi_1 ; 0.00 167.36
12 13 15 17 2 gi_1 ; 0.00 167.36
13 15 17 19 2 gi_1 ; 0.00 167.36
188 15 17 19 21 2 gi_1 ; 0.00 167.36
17 19 21 12 2 gi_1 ; 0.00 167.36
19 21 12 13 2 gi_1 ; 0.00 167.36
; H/R on ring 2
13 14 12 15 2 gi_1 ; 0.00 167.36
193 15 16 13 17 2 gi_1 ; 0.00 167.36
17 18 15 19 2 gi_1 ; 0.00 167.36
19 20 17 21 2 gi_1 ; 0.00 167.36
12 11 13 21 2 gi_1 ; 0.00 167.36
21 22 12 19 2 gi_1 ; 0.00 167.36
198 ; central N
22 24 21 23 2 gi_1 ; 0.00 167.36
[ dihedrals ]
; USED =
203 ; #define gd_29 0.000 3.77 3; -C,CHn ,SI- 0.9;
; #define gd_34 0.000 5.92 3; -CHn ,SI-CHn - 1.4;
; #define gd_40 0.000 1.0 6; -CHn -C,NR(ring), CR1 - 0.24;
; #define gd_41 0.000 3.77 6; -CHn -NT- 0.9;
; ai aj ak al funct code ph0 cp mult
208 7 9 10 11 1 gd_40 ; 0.00 1.00 6 added
9 10 11 12 1 gd_29 ; 0.00 3.77 3 gromos 45a6 - 14
10 11 12 13 1 gd_40 ; 0.00 1.00 6 atb
21 22 24 25 1 gd_40 ; 0.00 1.00 6 gromos 45a6 - 20
22 24 25 26 1 gd_34 ; 0.00 5.92 3 gromos 45a6 - 17
213 23 22 24 25 1 gd_40 ; 0.00 1.00 6 atb
24 25 26 27 1 gd_34 ; 0.00 5.92 3 gromos 45a6 - 17
25 26 27 29 1 gd_41 ; 0.00 3.77 6 atb
25 26 27 30 1 gd_41 ; 0.00 3.77 6 added
218 [ pairs ] ; allow rotation














233 25 28 1
25 29 1
25 30 1
[ exclusions ] ; manually

















































1 [ moleculetype ]
; Name nrexcl
POP 3
5 [ atoms ]
; nr type resnr residu atom cgnr charge mass
1 LC3 1 POP C1 0 0.4000 15.0350 ; qtot :0.36
2 LC3 1 POP C2 0 0.4000 15.0350 ; qtot :0.72
3 LC3 1 POP C3 0 0.4000 15.0350 ; qtot :1.08
10 4 LNL 1 POP N4 0 -0.5000 14.0067 ; qtot :0.76
5 LH2 1 POP C5 0 0.3000 14.0270 ; qtot :1.0
6 LC2 1 POP C6 1 0.4000 14.0270 ; qtot :1.0
7 LOS 1 POP O7 1 -0.800 15.9994 ; qtot :0.54
8 LP 1 POP P8 1 1.700 30.9738 ; qtot :2.3
15 9 LOM 1 POP O9 1 -0.800 15.9994 ; qtot :1.5
10 LOM 1 POP O10 1 -0.800 15.9994 ; qtot :0.7
11 LOS 1 POP O11 1 -0.700 15.9994 ; qtot:0
12 LC2 1 POP C12 2 0.400 14.0270 ; qtot :0.08
13 LH1 1 POP C13 2 0.300 13.0190 ; qtot :0.52
20 14 LOS 1 POP O14 2 -0.700 15.9994 ; qtot : -0.14
15 LC 1 POP C15 2 0.7000 12.0110 ; qtot :0.56
16 LO 1 POP O16 2 -0.700 15.9994 ; qtot :0.0
17 LP2 1 POP C17 3 0.0 14.0270 ; qtot:
18 LP2 1 POP C18 4 0 14.0270 ; qtot:
25 19 LP2 1 POP C19 5 0 14.0270 ; qtot:
20 LP2 1 POP C20 6 0 14.0270 ; qtot:
21 LP2 1 POP C21 7 0 14.0270 ; qtot:
22 LP2 1 POP C22 8 0 14.0270 ; qtot:
23 LP2 1 POP C23 9 0 14.0270 ; qtot:
30 24 LH1 1 POP C24 10 0 13.0190 ; qtot:
25 LH1 1 POP C25 11 0 13.0190 ; qtot:
26 LP2 1 POP C26 12 0 14.0270 ; qtot:
27 LP2 1 POP C27 13 0 14.0270 ; qtot:
28 LP2 1 POP C28 14 0 14.0270 ; qtot:
35 29 LP2 1 POP C29 15 0 14.0270 ; qtot:
30 LP2 1 POP C30 16 0 14.0270 ; qtot:
31 LP2 1 POP C31 17 0 14.0270 ; qtot:
32 LC2 1 POP C32 18 0.50 14.0270 ; qtot:
33 LOS 1 POP O33 18 -0.70 15.9994 ; qtot:
40 34 LC 1 POP C34 18 0.800 12.0110 ; qtot:
35 LO 1 POP O35 18 -0.60 15.9994 ; qtot:
36 LP2 1 POP C36 19 0 14.0270 ; qtot:
37 LP2 1 POP C37 20 0 14.0270 ; qtot:
38 LP2 1 POP C38 21 0 14.0270 ; qtot:
45 39 LP2 1 POP C39 22 0 14.0270 ; qtot:
40 LP2 1 POP C40 23 0 14.0270 ; qtot:
41 LP2 1 POP C41 24 0 14.0270 ; qtot:
42 LP2 1 POP C42 25 0 14.0270 ; qtot:
43 LP2 1 POP C43 26 0 14.0270 ; qtot:
50 44 LP2 1 POP C44 27 0 14.0270 ; qtot:
45 LP2 1 POP C45 28 0 14.0270 ; qtot:
46 LP2 1 POP C46 29 0 14.0270 ; qtot:
47 LP2 1 POP C47 30 0 14.0270 ; qtot:
48 LP2 1 POP C48 31 0 14.0270 ; qtot:
55 49 LP2 1 POP C49 32 0 14.0270 ; qtot:
50 LP3 1 POP C50 33 0 15.0350 ; qtot:
51 LP2 1 POP CA1 34 0 14.0270 ; tail2
52 LP3 1 POP CA2 35 0 15.0350; tail2
60 [ bonds ]
; ai aj funct
272
4 5 1 0.14700E+00 0.37660E+06
5 6 1 0.15300E+00 0.33470E+06
6 7 1 0.14300E+00 0.25100E+06
65 7 8 1 0.16100E+00 0.25100E+06
8 9 1 0.14800E+00 0.37660E+06
8 10 1 0.14800E+00 0.37660E+06
8 11 1 0.16100E+00 0.25100E+06
11 12 1 0.14300E+00 0.25100E+06
70 12 13 1 0.15300E+00 0.33470E+06
13 14 1 0.14350E+00 0.25100E+06
13 32 1 0.15300E+00 0.33470E+06
14 15 1 0.13600E+00 0.37660E+06
15 16 1 0.12300E+00 0.50210E+06
75 15 17 1 0.15300E+00 0.33470E+06
17 18 1 0.15300E+00 0.33470E+06
18 19 1 0.15300E+00 0.33470E+06
19 20 1 0.15300E+00 0.33470E+06
20 21 1 0.15300E+00 0.33470E+06
80 21 22 1 0.15300E+00 0.33470E+06
22 23 1 0.15300E+00 0.33470E+06
23 24 1 0.15300E+00 0.33470E+06
24 25 1 0.13900E+00 0.41840E+06
25 26 1 0.15300E+00 0.33470E+06
85 26 27 1 0.15300E+00 0.33470E+06
27 28 1 0.15300E+00 0.33470E+06
28 29 1 0.15300E+00 0.33470E+06
29 30 1 0.15300E+00 0.33470E+06
30 31 1 0.15300E+00 0.33470E+06
90 31 51 1 0.15300E+00 0.33470E+06
51 52 1 0.15300E+00 0.33470E+06
32 33 1 0.14300E+00 0.25100E+06
33 34 1 0.13600E+00 0.37660E+06
34 35 1 0.12300E+00 0.50210E+06
95 34 36 1 0.15300E+00 0.33470E+06
36 37 1 0.15300E+00 0.33470E+06
37 38 1 0.15300E+00 0.33470E+06
38 39 1 0.15300E+00 0.33470E+06
39 40 1 0.15300E+00 0.33470E+06
100 40 41 1 0.15300E+00 0.33470E+06
41 42 1 0.15300E+00 0.33470E+06
42 43 1 0.15300E+00 0.33470E+06
43 44 1 0.15300E+00 0.33470E+06
44 45 1 0.15300E+00 0.33470E+06
105 45 46 1 0.15300E+00 0.33470E+06
46 47 1 0.15300E+00 0.33470E+06
47 48 1 0.15300E+00 0.33470E+06
48 49 1 0.15300E+00 0.33470E+06
49 50 1 0.15300E+00 0.33470E+06
110 1 4 1 0.14700E+00 0.37450E+06
2 4 1 0.14700E+00 0.37450E+06
3 4 1 0.14700E+00 0.37450E+06
[ pairs ]

























140 22 25 1 ; pair around double bond




145 34 38 1
35 37 1
[ angles ]
; ai aj ak funct
150 4 5 6 1 0.10950E+03 0.46020E+03
5 6 7 1 0.10950E+03 0.46020E+03
6 7 8 1 0.12000E+03 0.39750E+03
273
7 8 9 1 0.10960E+03 0.39750E+03
7 8 10 1 0.10960E+03 0.39750E+03
155 7 8 11 1 0.10300E+03 0.39750E+03
8 11 12 1 0.12000E+03 0.39750E+03
9 8 10 1 0.12000E+03 0.58580E+03
9 8 11 1 0.10960E+03 0.39750E+03
10 8 11 1 0.10960E+03 0.39750E+03
160 11 12 13 1 0.11100E+03 0.46020E+03
12 13 14 1 0.10950E+03 0.46020E+03
12 13 32 1 0.10950E+03 0.46020E+03
13 14 15 1 0.12000E+03 0.41840E+03
13 32 33 1 0.11100E+03 0.46020E+03
165 14 13 32 1 0.10950E+03 0.46020E+03
14 15 16 1 0.12400E+03 0.50210E+03
14 15 17 1 0.11500E+03 0.50210E+03
15 17 18 1 0.11100E+03 0.46020E+03
16 15 17 1 0.12100E+03 0.50210E+03
170 17 18 19 1 0.11100E+03 0.46020E+03
18 19 20 1 0.11100E+03 0.46020E+03
19 20 21 1 0.11100E+03 0.46020E+03
20 21 22 1 0.11100E+03 0.46020E+03
21 22 23 1 0.11100E+03 0.46020E+03
175 22 23 24 1 0.11100E+03 0.46020E+03
23 24 25 1 120.000 502.080 ; cis thingies
24 25 26 1 120.000 502.080 ; cis thingies
25 26 27 1 0.11100E+03 0.46020E+03
26 27 28 1 0.11100E+03 0.46020E+03
180 27 28 29 1 0.11100E+03 0.46020E+03
28 29 30 1 0.11100E+03 0.46020E+03
29 30 31 1 0.11100E+03 0.46020E+03
30 31 51 1 0.11100E+03 0.46020E+03
31 51 52 1 0.11100E+03 0.46020E+03
185 32 33 34 1 0.12000E+03 0.41840E+03
33 34 35 1 0.12400E+03 0.50210E+03
33 34 36 1 0.11500E+03 0.50210E+03
34 36 37 1 0.11100E+03 0.46020E+03
35 34 36 1 0.12100E+03 0.50210E+03
190 36 37 38 1 0.11100E+03 0.46020E+03
37 38 39 1 0.11100E+03 0.46020E+03
38 39 40 1 0.11100E+03 0.46020E+03
39 40 41 1 0.11100E+03 0.46020E+03
40 41 42 1 0.11100E+03 0.46020E+03
195 41 42 43 1 0.11100E+03 0.46020E+03
42 43 44 1 0.11100E+03 0.46020E+03
43 44 45 1 0.11100E+03 0.46020E+03
44 45 46 1 0.11100E+03 0.46020E+03
45 46 47 1 0.11100E+03 0.46020E+03
200 46 47 48 1 0.11100E+03 0.46020E+03
47 48 49 1 0.11100E+03 0.46020E+03
48 49 50 1 0.11100E+03 0.46020E+03
1 4 2 1 0.10950E+03 0.33470E+03
2 4 3 1 0.10950E+03 0.33470E+03
205 3 4 1 1 0.10950E+03 0.33470E+03
1 4 5 1 0.10950E+03 0.37660E+03
2 4 5 1 0.10950E+03 0.37660E+03
3 4 5 1 0.10950E+03 0.37660E+03
210 [ dihedrals ]
; ai aj ak al funct phi0 cp mult
1 4 5 6 1 0.0 3.76 3
4 5 6 7 1 0.0 5.85 3
5 6 7 8 1 0.0 3.76 3
215 6 7 8 11 1 0.0 1.05 3
6 7 8 11 1 0.0 3.14 2
7 8 11 12 1 0.0 1.05 3
7 8 11 12 1 0.0 3.14 2
8 11 12 13 1 0.0 3.76 3
220 11 12 13 14 1 0.0 2.09 2
11 12 13 32 1 0.0 5.85 3
11 12 13 32 1 0.0 0.42 2
12 13 32 33 1 0.0 5.85 3
12 13 32 33 1 0.0 0.42 2
225 12 13 14 15 1 0.0 3.77 3
13 32 33 34 1 0.0 3.76 3
13 14 15 17 1 180.0 16.74 2
14 13 32 33 1 0.0 2.09 2
14 15 17 18 1 0.0 0.42 6
230 15 17 18 19 1 0.0 5.86 3
17 18 19 20 3
18 19 20 21 3
19 20 21 22 3
20 21 22 23 3
235 21 22 23 24 3
22 23 24 25 1 0.000 5.858 3
; 23 24 25 26 1
24 25 26 27 1 0.000 5.858 3
25 26 27 28 3
240 26 27 28 29 3
27 28 29 30 3
28 29 30 31 3
29 30 31 51 3
274
30 31 51 52 3
245 13 32 33 34 1 0.0 3.76 3
32 33 34 36 1 180.0 16.74 2
33 34 36 37 1 0.0 0.42 6
34 36 37 38 1 0.0 5.86 3
36 37 38 39 3
250 37 38 39 40 3
38 39 40 41 3
39 40 41 42 3
40 41 42 43 3
41 42 43 44 3
255 42 43 44 45 3
43 44 45 46 3
44 45 46 47 3
45 46 47 48 3
46 47 48 49 3
260 47 48 49 50 3
[ dihedrals ]
; ai aj ak al funct
13 14 32 12 2 35.264 0.33470E+03
265 15 14 17 16 2 0.00000E+00 0.16740E+03
34 33 36 35 2 0.00000E+00 0.16740E+03
23 24 25 26 2 0.000 167.360
Topology File of the Simulation
1 ; ============================================================== ;
2 ; Include forcefield parameters , lipid topology added
#include "/home/solanum /00 _Pharmazie/md1/gromos53a6_lipid.ff/forcefield.itp"
; ============================================================== ;
; Include protein chain topologies
#include "./ Protein_chain_A.itp"
7 #include "./ Ion_chain_B.itp"
; ============================================================== ;
; Include other topologies
#include "./ popc.itp"
#include "./ IMI.itp"
12 ; ============================================================== ;
; Include topology for previously added water in site
#include "./ hoh.itp"
#ifdef POSRES
; Position restraint for each water oxygen
17 [ position_restraints ]
; i funct fcx fcy fcz
1 1 1000 1000 1000
#endif
; ============================================================== ;
22 ; Include water topology and position restraints
#include "gromos53a6.ff/spc.itp"
#ifdef POSRES_WATER
; Position restraint for each water oxygen
[ position_restraints ]
27 ; i funct fcx fcy fcz
1 1 1000 1000 1000
#endif
; ============================================================== ;





Protein -ligand -complex into membrane in water
















;===== RUN CONTROL ====================================================================
integrator = md
9 tinit = 0









;===== LANGEVIN DYNAMICS OPTIONS ======================================================
bd -fric = 0
ld -seed = 2012
;======================================================================================
24
;===== ENERGY MINIMIZATION OPTIONS ====================================================
emtol = 2000
emstep = 0.01










;===== OUTPUT CONTROL OPTIONS =========================================================
nstxout = 5000
nstvout = 5000










;===== NEIGHBORSEARCHING PARAMETERS ===================================================
nstlist = 5
ns -type = Grid
pbc = xyz





;===== OPTIONS FOR ELECTROSTATICS AND VDW =============================================
;===== Coulomb =====
coulombtype = Cut -off
rcoulomb -switch = 0
69 rcoulomb = 1.4
epsilon_r = 1
epsilon_rf = 1
;===== Van der Waals =====
vdw -type = Cut -off










84 fourier_nz = 0
;======================================================================================
;===== EWALD/PME/PPPM parameters ======================================================










;===== GENERALIZED BORN ELECTROSTATICS ================================================
gb_algorithm = Still





109 gb_obc_beta = 0.8
gb_obc_gamma = 4.85
gb_dielectric_offset = 0.009
sa_algorithm = Ace -approximation
sa_surface_tension = -1
114 ;======================================================================================
;===== OPTIONS FOR WEAK COUPLING ALGORITHMS ===========================================
;===== Temperature coupling =====
119 tcoupl = V-rescale
nsttcouple = -1
nh -chain -length = 10
tc -grps = Protein_Ion_IMI_SOL POP
tau -t = 0.1 0.1
124 ref -t = 300 300




129 tau -p = 1 1 1
compressibility = 5.3e-05 5.3e-05




;===== GENERATE VELOCITIES FOR STARTUP RUN ============================================
gen -vel = yes
139 gen -temp = 300
gen -seed = 173529
;======================================================================================
144 ;===== OPTIONS FOR BONDS ==============================================================
constraints = all -bonds
constraint -algorithm = Lincs
continuation = no
Shake -SOR = no
149 shake -tol = 0.0001
lincs -order = 4
lincs -iter = 1
lincs -warnangle = 30
morse = no
154 freezegrps = Protein_Ion_IMI_SOL
freezedim = Y Y Y




















;===== RUN CONTROL ====================================================================
8 integrator = steep
tinit = 0
277
dt = 0.001 [ps]
nsteps = 100
init_step = 0
13 simulation_part = 1
comm -mode = Linear




;===== LANGEVIN DYNAMICS OPTIONS ======================================================
bd -fric = 0
ld -seed = 2012
23 ;======================================================================================
;===== ENERGY MINIMIZATION OPTIONS ====================================================
emtol = 10 ; 1000
28 emstep = 0.01
nbfgscorr = 10
nstcgsteep = 100 ; 1000
niter = 50 ; 20
fcstep = 0
33 ;======================================================================================
;===== TEST PARTICLE INSERTION OPTIONS ================================================
rtpi = 0.05
38 ;======================================================================================
;===== NEIGHBORSEARCHING PARAMETERS ===================================================
nstlist = 10






;===== OPTIONS FOR ELECTROSTATICS AND VDW =============================================
;===== Coulomb =====
53 coulombtype = PME




58 ;===== Van der Waals =====
vdw -type = Switch
rvdw -switch = 1.0
rvdw = 1.4
DispCorr = No
63 ;===== Tables =====













78 epsilon_surface = 0
optimize_fft = no
;======================================================================================
83 ;===== IMPLICIT SOLVENT ALGORITHM =====================================================
implicit_solvent = No
;======================================================================================














103 ;===== GENERATE VELOCITIES FOR STARTUP RUN ============================================
gen -vel = yes
gen -temp = 310
gen -seed = 173529
;======================================================================================
108
;===== OPTIONS FOR BONDS ==============================================================
constraints = none
constraint -algorithm = Lincs
113 continuation = no
Shake -SOR = no
shake -tol = 0.0001
lincs -order = 4
lincs -iter = 1
118 lincs -warnangle = 30
morse = no
;======================================================================================

















;===== RUN CONTROL ====================================================================
integrator = md
tinit = 0




comm -mode = Linear
15 nstcomm = 5
comm -grps =
;======================================================================================
20 ;===== LANGEVIN DYNAMICS OPTIONS ======================================================
bd -fric = 0
ld -seed = 2012
;======================================================================================
25





















xtc -precision = 500
279
50 xtc -grps = Protein_IMI POP SOL_Ion
energygrps = Protein_IMI POP SOL_Ion
;======================================================================================
55 ;===== NEIGHBORSEARCHING PARAMETERS ===================================================
nstlist = 5 ; 10
ns -type = Grid
pbc = xyz
periodic_molecules = no
60 rlist = 1.2
rlistlong = 1.6
;======================================================================================
65 ;===== OPTIONS FOR ELECTROSTATICS AND VDW =============================================
;===== Coulomb =====
coulombtype = PME
rcoulomb -switch = 0.8
rcoulomb = 1.2
70 epsilon_r = 1
epsilon_rf = 1
;===== Van der Waals =====
vdw -type = Switch
rvdw -switch = 1.0
75 rvdw = 1.4
DispCorr = No
;===== Tables =====
table -extension = 1
energygrp_table =






;===== EWALD/PME/PPPM parameters ======================================================
pme_order = 4










;===== GENERALIZED BORN ELECTROSTATICS ================================================
gb_algorithm = Still
nstgbradii = 1





110 gb_obc_gamma = 4.85
gb_dielectric_offset = 0.009




;===== OPTIONS FOR WEAK COUPLING ALGORITHMS ===========================================
;===== Temperature coupling =====
tcoupl = Nose -Hoover
120 nsttcouple = 2
nh -chain -length = 10
tc -grps = Protein_IMI POP SOL_Ion
tau -t = 0.5 0.5 0.5
ref -t = 310 310 310
125 ;===== Pressure coupling =====
Pcoupl = Parrinello -Rahman
Pcoupltype = semiisotropic
nstpcouple = -1
tau -p = 0.5
130 compressibility = 4.5e-5 4.5e-5





;===== GENERATE VELOCITIES FOR STARTUP RUN ============================================
gen -vel = no
gen -temp = 310
140 gen -seed = 173529
280
;======================================================================================
;===== OPTIONS FOR BONDS ==============================================================
145 constraints = Hbonds
constraint -algorithm = Lincs
continuation = yes
Shake -SOR = no
shake -tol = 0.0001
150 lincs -order = 4
lincs -iter = 1



















Der Serotonin Transporter ist ein neuronales Membranprotein, zuständig für die
Wiederaufnahme von während eines Aktionspotentiales in den synaptischen Spalt
freigesetztem Serotonin. Dieser ist gemeinsam mit dem Dopamin Transporter und
dem Noradrenalin Transporter zugehörig zur Familie des SLC6 Gens, bzw. der
Familie der neuronalen Monoamin oder Neurotransmitter:Natrium Transporter.
Diese integralen Membranproteine nutzen einen existierenden Natriumgradienten
als Energiequelle für den Transport der Neurotransmitter Serotonin, Dopamin und
Noradrenalin gegen den Konzentrationsgradienten in die freisetzende Nervenzelle.
Sie spielen eine entscheidende Rolle in der Homöostase dieser wichtigen Transmit-
ter und sind aus diesem Grund in verschiedene Erkrankungen des Nervensystems
involviert, wie zum Beispiel der Depression. Die Neurotransmittertransporter sind
wichtige Angriﬀspunkte der Pharmakotherapie dieser Krankheit. Auch illegale
Drogen, wie Kokain oder Amphetamine, zeigen ihre Wirkungen durch die Beein-
ﬂussung der Wiederaufnahme der genannten Neurotransmitter.1
Bis zum Zeitpunkt, wurde noch keiner der humanen Transporter kristallisiert.
Die Kirstallstruktur eines bakteriellen Leucinransporters, homolog in Struktur
und Funktion zu den Neurotransmittertransportern, konnte bisher in drei un-
terschiedlichen Konformationen aufgeklärt werden.2,84,186 Die Sequenzidentität
zwischen dem Leucin- und dem Serotonin beträgt ungefähr 20 % über die gesamte
Sequenz und 45 % in der Bindungstasche.3 Die genauen molekularen Mecha-
nismen der Transporterhemmung und des Substrattransports sind Gegenstand
intensiver Forschungen. Um detailierte Einsichten in die molekularen Protein–
Ligand–Interaktionen zwischen trizyklischen Antidepressiva und dem Serotonin-
transporter zu erhalten, wurden in der vorliegenden Studie rechnergestützte Meth-
oden mit pharmakologischen Experimenten kombiniert. Diese wurde im Rah-
men des Spezialforschungsbereichs 35 (SFB35 — Transmembranäre Transporter in
Gesundheit und Krankheit) in Kooperation mit Prof. Michael Freissmuth, Leiter
des Instituts für Pharmakologie der Medizinischen Universität Wien, und Prof.
Harald Sitte, Sprecher des Forschungsprojekts SFB35, durchgeführt.
Zunächst wurde ein Homologiemodell4 des Serotonintransporters basierend auf
den strukturellen Daten des Leucintransporters in der zum Extrazellularraum
282
oﬀenen Konformation2 sowie den angeglichen Primärsequenzen3 erstellt. Dieses
Modell war die Grundlage für die computerunterstützten Bindungsstudien (dock-
ing)5 ausgewählter tricyclischer Antidepressiva. Um eine Verzerrung der ersten
Ergebnisse durch Bewertungsfunktionen (scoring) zu vermeiden, wurde ein Pro-
tokoll erarbeitet, das die Informationen aus den Protein–Ligand–Interaktionen der
erhaltenen Komplexe einerseits und publizierten Daten andererseits mit den ge-
ometrischen Informationen der Atomkoordinaten, die über hierarchisch–agglomeratives
Gruppieren (clustering) reduziert wurden, kombiniert. Das Auswahlverfahren der
durch die Bindungsstudien erhaltenen Komplexe wurde letztendlich durch die
Ergebnisse der experimentellen Daten unterstützt. Diese Zusammenarbeit kon-
nte einen neuen Bindungsmodus von Imipramin im Serotonintransporter zeigen.6
Um diese Bindungshypothese zu stützen, aber auch diese zu veriﬁzieren wurden
weitere Methoden angewendet. Parallel zu den Punktmutationen am Serotonin-
transporter wurden Moleküldynamiksimulationen7 an den ausgewählten Protein–
Ligand–Komplexen durchgeführt, um die molekularen Mechanismen zu studieren.
Diese sehr rechenintensiven Simulationen wurden amWiener Wissenschafts Großrech-
ner (Vienna Scientiﬁc Cluster — VSC, www.vsc.ac.at) durchgeführt. Die da-
raufhin erhaltenen Daten sind bezüglich Stabilität des Liganden, speziﬁschen Dis-
tanzen und Wasserstoﬀbrücken und deren Neztwerken untersucht worden. Die
Auswertung erfolgte halbautomatisch durch die Erstellung von kleinen Program-
men (scripts). Es konnte gezeigt werden, dass es während der Bindung von In-
hibitoren am Serotonintransporter zu Interaktionen mit Wassermolekülen kommen
kann.
Diese Informationen ﬂossen neben den Informationen der getesteten Wirk-
stoﬀe und des erhaltenen Komplexes von Imipramin im Serotonintransporter in
den letzten Teil der Studie ein: dem Pharmakophormodell.8 Dieses Modell di-
ente als Grundlage für das elektronische Sichten (screening) einer Datenbank mit
zu Arzneistoﬀen ähnlicher und verfügbarer Substanzen. Aus dieser Datenbank
wurden 13 Substanzen ausgewählt und zum Zweck der experimentellen Überprü-
fung erworben (www.lifechemicals.com). Am Institut für Pharmakologie wur-
den die Substanzen pharmakologisch am Serotonintransporter getestet. 4 der 13
Substanzen zeigten eine Wirkung im nieder µ-molaren Bereich, was auf potenziell
neue, am Serotonintransporter wirksame Substanzen hindeutet.
283
B.2 Publications
‘Mutational Analysis of the High-Affinity Zinc Binding Site Validates
a Refined Human Dopamine Transporter Homology Model’
Stockner T, Montgomery TR, Kudlacek O, Weissensteiner R, Ecker GF, Freiss-
muth M, Sitte HH
PLoS Computational Biology, 2012, accepted
‘The high-affinity Binding Site for Tricyclic Antidepressants resides
in the outer Vestibule of the Serotonin Transporter’
Sarker S, Weissensteiner R, Steiner I, Sitte HH, Ecker GF, Freissmuth M and Sucic
S
Molecular Pharmacology, 2010, 78(6):1026-35
‘The N Terminus of Monoamine Transporters is a Lever required
for the Action of Amphetamines’
Sucic S, Dallinger S, Zdrazil B, Weissensteiner R, Jørgensen TN, Holy M, Kud-
lacek O, Seidel S, Cha JH, Gether U, Newman AH, Ecker GF, Freissmuth M, Sitte
HH
Journal of Biological Chemistry, 2010, 285(14):10924-38
‘Towards an understanding of the Psychostimulant Action of Am-
phetamine and Cocaine’
Weissensteiner R, Steinkellner T, Jurik A, Bulling S, Sandtner W, Kudlacek O,
Freissmuth M, Ecker GF and Sitte HH
In: SENSORY PERCEPTION, Mind andMatter, Eds.: Barth F.G., Giamperi-
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B.3 Posters
‘An in-silico study to elucidate Protein Ligand Interactions between
Selected Inhibitors and Neurotransmitter:Sodium Symporter’
presented at the annual SFB-Symposium in Vienna, September 2010
‘The high–affinity Binding Site for Tricyclic Antidepressants resides
in the outer Vestibule of the human Serotonin Transporter’
presented at the annual SFB-Symposium in Vienna
‘How do Tricyclic Antidepressants bind to the Serotonin Trans-
porter?’
presented at the DK+ project in Vienna, October 2010
‘Insights into Molecular Interactions between the Serotonin Trans-
porter and Tricyclic Antidepressants’
presented at the EWDD in Siena, May 2011
‘Molecular Dynamics Simulations propose a Structural Water in-
volved in Binding of Imipramine to SERT’
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René Weissensteiner – Curriculum Vitae
Personal Data
Name Mag. René Weissensteiner





Birth 02.11.1978, St. Pölten, Lower Austria
Nationality Austrian
Familiy Status married since 20.09.2009
with Mag.a Martina Tamara Weissensteiner
Children Sophie Katharina Gall (∗ 08.10.2006 † 12.02.2008)
Lorenz Maximilian Weissensteiner (∗ 17.11.2008)
Magdalena Lucia Weissensteiner (∗ 28.02.2011)
not yet deﬁned (≈ May/June 2013)
Education
12/2008– PhD at the Department of Medicinal Chemistry, University of Vienna
Research Focus: “In-silico studies on neurotransmitter:sodium symporter”
wihtin the project ‘SFB35 - Transmembrane Transporters in Health and Disease’
Pharmacoinformatics Research Group Vienna
supervised by Univ.-Prof. Dr. Gerhard F. Ecker
10/1999–11/2008 Study of Pharmacy at University of Vienna
Diploma Thesis: “Molecular Modelling Studies for Analysing Interactions of Sub-
strates and Inhibitors of the Serotonin Transporter”
Department of Medicinal Chemistry, Emerging Focus Pharmacoinformatics
supervised by Univ.-Prof. Dr. Gerhard F. Ecker
Award for the best diploma thesis in the ﬁeld Medicinal Chemistry at the
21st Meeting of the Austrian Pharmaceutical Society in Vienna, April 2009
01/1995–06/1999 Commercial Highschool, St. Pölten
Final Exam: 11.06.1999
Work Experience
08/2012– Aspirantenjahr, Apotheke zur Heiligen Dreifaltigkeit, Neulengbach, Lower Austria
03/2011–08/2011 Arzneistoﬀanalytik (Teaching Assistant), University of Vienna
10/2010–01/2011 Arzneistoﬀanalytik (Teaching Assistant), University of Vienna
03/2009–08/2009 Arzneistoﬀanalytik (Teaching Assistant), University of Vienna
10/2008–01/2009 Arznemittelanalytik und Wirkstoﬀentwicklung (Tutor), University of Vienna
10/2006–09/2007 Paternity leave
11/2002–01/2004 Internships in various Pharmacies
10/2000–09/2001 Civilian Service at ‘Emmausgemeinschaft St. Pölten’
11/1998–01/2003 Work during the holidays
315
Publications
Articles 06/2012 ‘Mutational Analysis of the High-Aﬃnity Zinc Binding Site Validates
a Reﬁned Human Dopamine Transporter Homology Model’
Stockner T, Montgomery TR, Kudlacek O, Weissensteiner R, Ecker GF,
Freissmuth M, Sitte HH
PLoS Computational Biology, 2012, submitted
12/2010 ‘The high-aﬃnity Binding Site for Tricyclic Antidepressants resides in the
outer Vestibule of the Serotonin Transporter’
Sarker S, Weissensteiner R, Steiner I, Sitte HH, Ecker GF, Freissmuth M
and Sucic S
Molecular Pharmacology, 2010, 78(6):1026–35
04/2010 ‘The N–Terminus of Monoamine Transporters is a Lever required for
the Action of Amphetamines’
Sucic S, Dallinger S, Zdrazil B, Weissensteiner R, Jørgensen TN, Holy M,
Kudlacek O, Seidel S, Cha JH, Gether U, Newman AH, Ecker GF, Freiss-
muth M, Sitte HH
Journal of Biological Chemistry, 2010, 285(14):10924–38
Book Chapter 2011 ‘Towards an Understanding of the Psychostimulant Action of Amphetamine
and Cocaine’
Weissensteiner R, Steinkellner T, Jurik A, Bulling S, Sandtner W, Kudlacek
O, Freissmuth M, Ecker GF and Sitte HH
In: SENSORY PERCEPTION, Mind and Matter, Eds.: Barth F.G., Giamperi-
Deutsch P., Klein H.-D. (2011)
Presentations 2010 ‘How do Tricyclic Antidepressants bind to the Serotonin Transporter?’
Youngster meeting of the SFB in Vienna in September 2010
Posters 09/2011 ‘Molecular Dynamics Simulations propose a Structural Water involved in
Binding of Imipramine to SERT’
presented at the annual SFB-Symposium in Vienna
05/2011 ‘Insights into Molecular Interactions between the Serotonin Transporter and
Tricyclic Antidepressants’ presented at the EWDD in Siena
09/2010 ‘The high–aﬃnity Binding Site for Tricyclic Antidepressants resides in the
Outer Vestibule of the human Serotonin Transporter’
presented at the annual SFB-Symposium in Vienna
09/2009 ‘An in-silico study to elucidate Protein Ligand Interactions between selected
Inhibitors and Neurotransmitter:Sodium Symporter’
presented at the annual SFB-Symposium in Vienna
06/2009 ‘Docking of Substrates and Inhibitors into new Models of Neurotransmit-
ter:Sodium Symporter’
presented at the JMMC in Budapest
04/2009 ‘Docking of Multiple Ligands into a new Homology Model of the Serotonin
Transporter’
presented at the meeting of the OePHG in Vienna
09/2008 ‘Molecular Modelling Studies for Analysing Diﬀerences in Interaction be-
tween Substrates and Inhibitors of the Serotonin Transporter’
presented at the annual SFB-Symposium in Vienna
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Skills
Languages German (native), English (ﬂuent), basics in Spanish und French
Computer Operating systems: Linux, Mac OSX, Windows, Systemadministration
Software: MOE, Discovery Studio, Schrödinger
MODELLER, GOLD, VMD, gromacs, namd, acemd
LATEX, TikZ, “Oﬃce”–packages, R, xmgrace, gnuplot
programs for editing photos (GIMP, Photoshop, ImageMagick), music (Logic,
Cubase) and videos (Premiere, mplayer)
Programming languages: basics in C++, Java und Python
Scripting languages: bash, R, SVL; basics in tcl, html and php
Sparetime Activities
Music playing drumset since 04/1993 in various groups, teaching since 10/2007
playing guitar since 10/1996
Digital Media Creation and editing of photos (snapshots, panoramas),
music (techno unplugged and other own stuﬀ) and videos (timelapse from thou-
sands of photos)
Sports Cycling (main means of transport within a radius of 20 km),
hiking (if there is time), somtimes swimming (in summer), rarely snowboarding
(in winter)
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